<?xml version="1.0" encoding="UTF-8"?>
<root>
    <row>
        <App_ID>2027468</App_ID>
        <Date_Announced>2024-02-09T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Abdullah Mamun</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 NHMRC-Global Alliance for Chronic Diseases</Sub_Type>
        <Grant_Title>Preventing non-communicable diseases (PreventNCD) among Indigenous children and youth in major cities of Australia</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,544,970.90</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander diet and nutrition | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health promotion | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </Fields_of_Research>
        <Res_KW1>aboriginal health</Res_KW1>
        <Res_KW2>early detection</Res_KW2>
        <Res_KW3>chronic diseases</Res_KW3>
        <Res_KW4>community intervention</Res_KW4>
        <Res_KW5>primary care</Res_KW5>
        <Plain_Description>The aim of this implementation research project is to build a partnership between our multidisciplinary research team and urban Aboriginal Community Controlled Health Services (ACCHS) in two state capital cities of Australia (Brisbane and Darwin) to co-develop and deliver a best-evidence behavioural change intervention program that is embedded into the ACCHS’s existing service delivery model of care to prevent the emergence of NCD risks among urban Indigenous children and youth in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2027938</App_ID>
        <Date_Announced>2024-02-09T00:00:00</Date_Announced>
        <CIA_Name>Prof Amanda Thrift</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2023 NHMRC-Global Alliance for Chronic Diseases</Sub_Type>
        <Grant_Title>Co-designing a multi-level intervention for improving continuum of care for NCDs in three diverse cities in Nepal</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,240,497.71</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | primary health care | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>community health care</Res_KW1>
        <Res_KW2>chronic illness prevention</Res_KW2>
        <Res_KW3>health care worker education</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>equity</Res_KW5>
        <Plain_Description>To address the current fragmentation of primary and community health care systems, we will co-design a multi-level intervention to determine what works, and in what dose, frequency and duration to prevent, diagnose and manage risk factors for non-communicable diseases (NCDs). Community health workers will be trained to provide lifestyle counselling and monitoring of people with NCDs, and track and refer them for appropriate care. We will assess both clinical and implementation outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032344</App_ID>
        <Date_Announced>2024-04-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Elif Ekinci</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Ensuring the Quality and Safety of Telehealth</Sub_Type>
        <Grant_Title>Advancing Quality and Safe Virtual Diabetes Care in Emergency Settings (VIRDI)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$915,823.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>diabetes</Res_KW1>
        <Res_KW2>telemedicine</Res_KW2>
        <Res_KW3>emergency medicine</Res_KW3>
        <Res_KW4>indigenous health</Res_KW4>
        <Res_KW5>rural and remote health services</Res_KW5>
        <Plain_Description>Diabetes–the fastest-growing chronic condition in Australia–impacts every part of our health system. Indigenous Australians, rural/remote communities and people from culturally and linguistically diverse backgrounds are disproportionately impacted by diabetes. Our research will address the gap in access to urgent diabetes care, developing a roadmap for culturally safe virtual specialist support accessible to all Australians experiencing a diabetes-related emergency regardless of geography.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032615</App_ID>
        <Date_Announced>2024-04-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Della Forster</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Ensuring the Quality and Safety of Telehealth</Sub_Type>
        <Grant_Title>Does offering a combination of video health and face-to-face visits for antenatal care result in improved patient experience and is it as safe as standard (face-to-face) care? A co-designed non-inferiority randomised controlled trial</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$999,585.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | midwifery | clinical midwifery | health sciences | health services and systems | health services and systems not elsewhere classified | biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>maternal and child health</Res_KW1>
        <Res_KW2>pregnancy</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>midwifery</Res_KW4>
        <Res_KW5>consumer preferences</Res_KW5>
        <Plain_Description>Telehealth in pregnancy (where women have some pregnancy appointments with their midwife or doctor by video call instead of face-to-face) has become common in Australia since the COVID-19 pandemic. We will carefully evaluate the use of some telehealth for pregnancy care in a large study to make sure it is safe for pregnant women and their babies, understand the cost implications, and importantly, understand what women think of telehealth and how it affects their experiences and access to care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032671</App_ID>
        <Date_Announced>2024-04-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Sarah Larkins</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Ensuring the Quality and Safety of Telehealth</Sub_Type>
        <Grant_Title>Leveraging NQ telehealth experience for contextually-informed process guidelines to optimise health service access, quality and safety in rural and remote Australia </Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$997,376.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | digital health | health sciences | health services and systems | rural and remote health services | health sciences | health services and systems | health systems | </Fields_of_Research>
        <Res_KW1>telemedicine</Res_KW1>
        <Res_KW2>quality improvement</Res_KW2>
        <Res_KW3>health service accessibility</Res_KW3>
        <Res_KW4>cultural perceptions</Res_KW4>
        <Res_KW5>rural and remote health services</Res_KW5>
        <Plain_Description>Use of telehealth in north Queensland has evolved early and rapidly in response to the health service needs of a culturally diverse population spread over a large area. This project maps knowledge about existing telehealth usage, examines strategies for safe and high quality use, including cultural acceptability and co-develops guidelines for health care providers and consumers for the optimal usage of telehealth across north Queensland. This is likely to be applicable across other RRR areas.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032726</App_ID>
        <Date_Announced>2024-04-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Meredith Makeham</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Ensuring the Quality and Safety of Telehealth</Sub_Type>
        <Grant_Title>The general practice and residential aged care study of telehealth augmented holistic care – exploring safety, quality, acceptability and sustainability: "The GRACE-Telehealth Study”</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$999,969.95</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | patient safety | health sciences | health services and systems | digital health | health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>aged care</Res_KW1>
        <Res_KW2>general practice</Res_KW2>
        <Res_KW3>telemedicine</Res_KW3>
        <Res_KW4>patient safety</Res_KW4>
        <Res_KW5>quality of care</Res_KW5>
        <Plain_Description>The GRACE-Telehealth study will provide high quality new evidence on the safety, quality, acceptability and sustainability of using telehealth for people living in residential aged care homes (RACHs). It will evaluate telehealth from the perspective of residents, carers, RACHs and GPs, producing decision support for clinicians to choose when telehealth is appropriate and how to use it, and health economic guidance to improve RACH telehealth adoption and resident's access to health services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032739</App_ID>
        <Date_Announced>2024-04-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Karnon</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Ensuring the Quality and Safety of Telehealth</Sub_Type>
        <Grant_Title>Enabling safe, high quality &amp; high value virtual emergency care in Australia</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$999,945.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>emergency medical service</Res_KW1>
        <Res_KW2>telemedicine</Res_KW2>
        <Res_KW3>clinical epidemiology</Res_KW3>
        <Res_KW4>health economics</Res_KW4>
        <Res_KW5>consumers</Res_KW5>
        <Plain_Description>ED ramping results in delays in access to appropriate health care and distress to patients. Reducing ED ramping by improving the management of patients requiring emergency care is a top priority for the Australian health system. Virtual ED services aim to provide appropriate care for non-life-threatening emergencies in the community. Collaborating with health professionals and consumers, this research aims to inform improvements in the design and application of virtual ED services in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032743</App_ID>
        <Date_Announced>2024-04-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Christine Phillips</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Ensuring the Quality and Safety of Telehealth</Sub_Type>
        <Grant_Title>Enhancing safe telehealth for all in high risk consultations: a multiperspective, mixed-methods study </Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$602,998.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | general practice | </Fields_of_Research>
        <Res_KW1>primary care</Res_KW1>
        <Res_KW2>doctor-patient relationships</Res_KW2>
        <Res_KW3>doctor-patient interaction</Res_KW3>
        <Res_KW4>informed decision making</Res_KW4>
        <Res_KW5>patient safety</Res_KW5>
        <Plain_Description>This project explores ways to improve the safety of telehealth consultations in primary care, including people with limited English proficiency, through the study of simulated consultations for high-risk medications, using mixed method research. The results of the project will be translated into decision aids for clinicians and consumers addressing medication safety and promotion of shared decision-making, with a particular focus on people with limited English proficiency.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2025089</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Dr Peter Arrow</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>The use of Silver Fluoride and Teledentistry to manage and prevent childhood dental decay among Aboriginal children in remote communities</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,499,986.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | dentistry | dentistry not elsewhere classified  | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | </Fields_of_Research>
        <Res_KW1>oral health</Res_KW1>
        <Res_KW2>access to dental care</Res_KW2>
        <Res_KW3>dental caries</Res_KW3>
        <Res_KW4>dental treatments</Res_KW4>
        <Res_KW5>indigenous health</Res_KW5>
        <Plain_Description>Access to dental treatment by those living in remote communities is limited to times when an oral health professional team visits the community. We aim to improve access to care by testing the feasibility of using the skills of an Aboriginal Health Worker (AHW), supported through the use of teledentistry to assess dental decay, and to apply a bactericidal and remineralising solution to decay-affected teeth of children in remote communities to stop the decay and stop new decay forming.</Plain_Description>
        <Heading18>Access to dental treatment by those living in remote communities is limited to times when an oral health professional team visits the community. We aim to improve access to care by testing the feasibility of using the skills of an Aboriginal Health Worker (AHW), supported through the use of teledentistry to assess dental decay, and to apply a bactericidal and remineralising solution to decay-affected teeth of children in remote communities to stop the decay and stop new decay forming.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2027453</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Prof Deborah Schofield</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Translation of precision medicine into clinics for genetic blindness: from diagnosis to clinical management and therapies</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,496,743.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>economics | applied economics | health economics  | economics | econometrics | economic models and forecasting | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>health economics</Res_KW1>
        <Res_KW2>health policy</Res_KW2>
        <Res_KW3>retinal dystrophy</Res_KW3>
        <Res_KW4>blindness</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Inherited retinal diseases (IRDs) lead to incurable blindness. They have a profound effect on patients and their families. Targeted therapies now hold the promise of preventing progression of blindness and vision improvement for some forms of IRD. The aims of this project are to determine the cost and quality of life impacts of IRDs, and develop a model to assess the cost effectiveness of routine genomic sequencing and the impact of targeted therapeutic options and reproductive planning in IRDs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2029534</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Prof Carol Maher</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Levelling the Playing Field: A Scalable Community-wide Strategy to Improve Equity in Access to a Universal Children's Sports Voucher Program </Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$853,319.85</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | community child health  | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>community child health</Res_KW1>
        <Res_KW2>community intervention</Res_KW2>
        <Res_KW3>controlled trial</Res_KW3>
        <Res_KW4>health services</Res_KW4>
        <Res_KW5>wellbeing</Res_KW5>
        <Plain_Description>The SA government’s $100 Sports Voucher scheme aims to help children participate in sports, due to sport's many health, wellbeing and emotional benefits. However, disadvantaged children, who have the most to benefit, are least likely to access it. We will work with stakeholders to evaluate a community-wide strategy to increase Sports Voucher uptake and sports particpation.  In future, the program may be scaled up to other disadvantaged communities across SA and nationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2030649</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jane Davies</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>A co-designed approach to reducing the burden of liver disease in First Nations populations in northern Australia: Hep B PAST Plus</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,498,670.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>hepatitis b virus</Res_KW1>
        <Res_KW2>aboriginal health</Res_KW2>
        <Res_KW3>hepatocellular carcinoma</Res_KW3>
        <Res_KW4>fatty liver disease</Res_KW4>
        <Res_KW5>liver</Res_KW5>
        <Plain_Description>Liver disease can cause liver cancer and death. It is important that people with liver disease know early so that the condition can be managed appropriately. First Nations people in Australia have higher rates of liver disease, especially in the Northern Territory and Far North Queensland. This project will work with those living with liver disease, the community, and health professionals so that First Nations people living with liver disease can live longer and healthier lives.
</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2030931</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Aideen McInerney-Leo</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Melanoma Population Screening: Using Genomics to Facilitate Risk Stratification  </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,117,222.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | health sciences | public health | preventative health care | human society | policy and administration | health policy | </Fields_of_Research>
        <Res_KW1>population screening</Res_KW1>
        <Res_KW2>melanoma</Res_KW2>
        <Res_KW3>risk assessment</Res_KW3>
        <Res_KW4>cancer prevention</Res_KW4>
        <Res_KW5>early detection</Res_KW5>
        <Plain_Description>Melanoma is the third most commonly diagnosed cancer in Australia. Population-wide screening is not feasible, but targeted screening of high-risk individuals is economically viable and improves patient outcomes. We will collaborate with industry and consumers to create personalised risk scores based on genetic and skin damage data. After evaluating impact on consumers, and health economic data, policy experts will determine whether this model meets Australian population screening criteria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2031038</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Prof Paulo Ferreira</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Delivering best-practice community care for low back pain through an effective national help line</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,497,427.95</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health and community services | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>low back pain</Res_KW1>
        <Res_KW2>musculoskeletal disorders</Res_KW2>
        <Res_KW3>access to health care</Res_KW3>
        <Res_KW4>health care delivery</Res_KW4>
        <Res_KW5>health care utilisation</Res_KW5>
        <Plain_Description>MSK Australia is Australia’s leading musculoskeletal consumers group. This project will upgrade and evaluate MSK Australia’s existing national Help Line to bridge the gap in community-based support services for patients with low back pain across Australia. If successful, the upgraded Help Line will improve patients’ self-management, and reduce preventable general practitioner and Emergency Department presentations for low back pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032058</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Prof Penelope Hasking</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>COMPAS-S: Checking on mental health - Providing alternatives to suicide for students</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,012,085.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | clinical and health psychology | counselling psychology | </Fields_of_Research>
        <Res_KW1>suicide prevention</Res_KW1>
        <Res_KW2>preventive screening</Res_KW2>
        <Res_KW3>anxiety</Res_KW3>
        <Res_KW4>depression</Res_KW4>
        <Res_KW5>longitudinal study</Res_KW5>
        <Plain_Description>Every year, nearly 250,000 Australian university students report suicidal thoughts and behaviours, but are reluctant to seek support. We have developed a novel screening tool that accurately identifies students at increased suicide risk, and proactively reach out to offer safety planning and support. Our initial work shows this is associated with a 41.7% reduction in suicidal behaviour one year later. In this project, we will extend this program to support university students across the country.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032073</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Prof Ruth Hubbard</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Derivation, Validation and Implementation of a Digital Frailty Index for Acute Care Settings in Queensland</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,499,780.15</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | health informatics and information systems | </Fields_of_Research>
        <Res_KW1>frailty</Res_KW1>
        <Res_KW2>hospitals</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>geriatric assessment</Res_KW4>
        <Res_KW5>health informatics</Res_KW5>
        <Plain_Description>Currently people who are frail when they go into hospital do not get the right care leading to longer hospital stays and poorer outcomes. Our research team and partners Qld Health, COTA Qld, and IHACPA will test if using data from an electronic medical record can identify how frail a person is when they are first admitted. This electronic data will generate a ‘frailty index’ which could be used by patients, carers, and clinical staff to improve hospital care in Qld hospitals, and Australia-wide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032115</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Prof Sally Brinkman</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Self Regulation RCT in Primary Schools - Understanding the Mechanism and Impact on Wellbeing and Equity</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$920,935.40</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | education | specialist studies in education | teacher and student wellbeing | psychology | cognitive and computational psychology | learning, motivation and emotion | </Fields_of_Research>
        <Res_KW1>curriculum-based learning</Res_KW1>
        <Res_KW2>randomised controlled trial (rct)</Res_KW2>
        <Res_KW3>wellbeing</Res_KW3>
        <Res_KW4>equity</Res_KW4>
        <Res_KW5>social and behavioural research</Res_KW5>
        <Plain_Description>Self-Regulated Learning is a way for people to take charge of their own learning by setting goals, planning, monitoring, evaluating, and adjusting their strategies. It's important because it can predict how well someone will do in school and in life. A study in Germany showed that a simple and inexpensive program helped young students with self regulation. In South Australia we will see if a modified version of the program can have similar positive effects on student success and wellbeing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032120</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Prof Debra Rickwood</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Novel outcome measures for online youth mental health services</Grant_Title>
        <Admin_Institution>University of Canberra</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,272,265.05</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical and health psychology not elsewhere classified | information and computing sciences | human-centred computing | affective computing | </Fields_of_Research>
        <Res_KW1>clinical outcome</Res_KW1>
        <Res_KW2>mental health services</Res_KW2>
        <Res_KW3>youth</Res_KW3>
        <Res_KW4>computer-based decision support</Res_KW4>
        <Res_KW5>internet service delivery</Res_KW5>
        <Plain_Description>Outcome measures for online youth mental health services are urgently needed. This research partnership with headspace online youth mental health services will define, design, and test real-time, unobtrusive measures of change in client outcomes and clinician actions derived by machine learning algorithms during online chat -based services. These measures will be built into a clinical support tool for online clinicians, and provide outcome data for measuring service effectiveness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032173</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Dr Rachel Toovey</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Linking young people with disability to participation through cycling: Implementation and evaluation of the co-designed CycLink program</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,444,460.77</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | health sciences | health services and systems | people with disability | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>disability</Res_KW1>
        <Res_KW2>child</Res_KW2>
        <Res_KW3>physical activity</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>allied health</Res_KW5>
        <Plain_Description>Children with disability have fewer opportunities to participate in their local communities, harming their health across the lifespan. Cycling is a popular activity in Australia, yet barriers to inclusive community participation exist. Reducing barriers to participation requires accessible supports and collaboration across sectors. We will work in partnership to implement and evaluate a co-designed cycling program to improve participation of children with disability in their local community.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032346</App_ID>
        <Date_Announced>2024-04-29T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Michelle Barakat-Johnson</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Improving patient outcomes and reducing the hidden burden of chronic wounds: a digitally enabled Wound Model of Care (The ENABLE Study)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,496,699.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | health systems | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>health service utilisation</Res_KW1>
        <Res_KW2>wound healing</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>cost-effectiveness</Res_KW4>
        <Res_KW5>quality of life</Res_KW5>
        <Plain_Description>The cost of chronic wound care to individual Australians and the health care system is untenable. Our aim is to co-develop implementation strategies and then test, evaluate and disseminate an evidence-based, cost-effective digitally enabled model of care involving virtual access to wound specialists and a digital wound application for people with chronic wounds and their clinicians. Our vision is that every person with a chronic wound has access to timely and appropriate specialist wound care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032961</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Johanna Westbrook</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Optimising and leveraging technology to improve medication safety </Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health informatics and information systems | health sciences | nursing | aged care nursing | health sciences | health services and systems | patient safety | </Fields_of_Research>
        <Res_KW1>health informatics</Res_KW1>
        <Res_KW2>aged care</Res_KW2>
        <Res_KW3>patient safety</Res_KW3>
        <Res_KW4>medications</Res_KW4>
        <Res_KW5>evaluation studies</Res_KW5>
        <Plain_Description>Despite multimillion dollar investments in IT systems to improve medication safety, medication errors continue to cause harm and death in hospitals and residential aged care. My team has pioneered new ways to identify how and why such large scale IT systems are falling short; and innovative solutions to improve their effectiveness. This project aims to expand and scale up our groundbreaking work to ensure costly IT systems can be optimised to reduce medication errors to save lives and money.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032970</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Michelle Kennedy (nee Bovill)</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Upholding our rights to self-determination in tobacco control policy and practice: Indigenous-led solutions to preventable death and disease caused by tobacco</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,598,610.62</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health promotion | </Fields_of_Research>
        <Res_KW1>smoking cessation</Res_KW1>
        <Res_KW2>behavioural intervention</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>public health</Res_KW4>
        <Res_KW5>tobacco control</Res_KW5>
        <Plain_Description>While most Aboriginal and Torres Strait Islander people who smoke want to quit, they are less likely to be offered information about smoking cessation or receive culturally appropriate cessation support. As an Aboriginal tobacco control expert, my program of research will advance knowledge about effective tobacco cessation strategies for Aboriginal and Torres Strait Islander people by privileging Indigenous knowledge and voices.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032980</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Tegan Cruwys</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Effective community solutions to prevent and treat loneliness</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | social and personality psychology | social psychology | health sciences | public health | social determinants of health | </Fields_of_Research>
        <Res_KW1>social identity</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>community intervention</Res_KW3>
        <Res_KW4>social determinants of health</Res_KW4>
        <Res_KW5>mechanism of action</Res_KW5>
        <Plain_Description>Loneliness is one of the strongest predictors of poor health. However, we have few effective strategies to treat or prevent loneliness. This project will tackle this problem, capitalising on my expertise as one of the world's foremost loneliness experts, who has already achieved breakthroughs by developing the first program to achieve large improvements in loneliness. This project will involve 3 streams: experimental lab work, studies of prevention in the community, and a large treatment trial.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032982</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Misty Jenkins</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>A precision medicine approach to the development of innovative Immunotherapies for Brain Cancer </Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | other biological sciences | other biological sciences not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy</Res_KW1>
        <Res_KW2>molecular biology</Res_KW2>
        <Res_KW3>cd8 t cells</Res_KW3>
        <Res_KW4>cell therapy</Res_KW4>
        <Res_KW5>brain</Res_KW5>
        <Plain_Description>Brain cancer defies current treatments, with a dismal 5% 5-year survival rate for glioblastoma and almost no survivors among child brainstem tumour patients. Our research targets three crucial areas: discovering new therapeutic targets, improving CAR T cell immunotherapy safety, and studying the brain tumour environment. Using advanced technologies, we aim to fast-track innovative treatments from the lab to clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032983</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Wallace</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Lost Voices: Improving Outcomes for Older Australians with Communication Disability through Identification, Inclusion and Improved Quality of Care. </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | allied health and rehabilitation science not elsewhere classified | </Fields_of_Research>
        <Res_KW1>communication</Res_KW1>
        <Res_KW2>aged care</Res_KW2>
        <Res_KW3>stroke</Res_KW3>
        <Res_KW4>quality of care</Res_KW4>
        <Res_KW5>aphasia</Res_KW5>
        <Plain_Description>Almost 1 million older Australians live with a communication disorder that affects their ability to understand and to be understood. My research aims to improve care and outcomes for these people through better identification of communication needs, training and resources that support inclusion, and quality assessment that drives quality improvement. I will work in partnership with community, industry, and Government to co-design solutions that ensure all older Australians have a voice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033008</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Benjamin Hogan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Mechanisms to promote lymphatic vessel growth in tissue repair and disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,124,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | </Fields_of_Research>
        <Res_KW1>zebrafish</Res_KW1>
        <Res_KW2>regeneration</Res_KW2>
        <Res_KW3>developmental biology</Res_KW3>
        <Res_KW4>developmental genetics</Res_KW4>
        <Res_KW5>cell biology</Res_KW5>
        <Plain_Description>Lymphatic vessels drain tissue fluids and traffic immune cells. Recent studies discovered that promoting lymphatic vessel growth improves outcomes in cardiovascular disease, cancer and lymphoedema. A clinical need exists to be able to promote the formation of functional lymphatic vessel networks in patients. This program will characterise mechanisms and methods to promote robust lymphatic formation. Outcomes will inform future therapeutic approaches in lymphoedema and diverse clinical settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033012</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ivan Poon</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Defining the molecular basis of apoptotic cell disassembly for therapeutic targeting</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>apoptosis</Res_KW1>
        <Res_KW2>chronic inflammation</Res_KW2>
        <Res_KW3>cell biology</Res_KW3>
        <Res_KW4>acute infective illnesses</Res_KW4>
        <Res_KW5>acute inflammation</Res_KW5>
        <Plain_Description>In humans, billions of cells are programmed to die every day in various organs as part of normal turnover and disease progression. During cell death, dying cells can disassemble into smaller fragments, a process that could facilitate their removal, as well as mediate communication with other healthy cells. We aim to understand the machinery that control the disassembly of dying cells and the role of this process during viral infections and inflammatory diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033013</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Rinaldo Bellomo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Research programs and pivotal trials to improve outcomes in critical care medicine. </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care  | </Fields_of_Research>
        <Res_KW1>sepsis</Res_KW1>
        <Res_KW2>shock</Res_KW2>
        <Res_KW3>acute renal failure</Res_KW3>
        <Res_KW4>acute care</Res_KW4>
        <Res_KW5>septic shock</Res_KW5>
        <Plain_Description>One in two Australians will be admitted to intensive care in their life. As global leader in critical care research, I will study our discovery that angiotensin II and sodium ascorbate might save lives. I will combine experimental studies in sepsis and acute kidney injury with pilot and multicentre trials to investigate such treatments. My work will create the background to definitive global practice changing trials to improve clinical decision-making and outcomes for critically ill patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033018</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Angli Xue</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Identifying and characterising gene regulatory networks of autoimmune diseases at single-cell resolution</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genetic immunology  | biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>autoimmune disease</Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>genetic variation</Res_KW3>
        <Res_KW4>control of gene expression</Res_KW4>
        <Res_KW5>complex genetic disease</Res_KW5>
        <Plain_Description>Autoimmune diseases affect over 1 million Australians and pose a high chronic health burden. This group of diseases are highly heritable and the etiology is complex and largely unknown. My research characterises the gene expression patterns in autoimmune diseases and how disease-causal genes interact in the immunologic network. The outcome will facilitate the development of novel treatments and benefit the personalised medicine by tailoring medical care to an individual's unique genetic makeup.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033019</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kelly Williams</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Deciphering the genetic landscape of motor neuron disease towards improved outcomes for patients</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,056,487.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | genetics | neurogenetics | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>neurodegenerative disorders</Res_KW1>
        <Res_KW2>genetics</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>motor neuron disease (mnd)</Res_KW4>
        <Res_KW5>gene mutations</Res_KW5>
        <Plain_Description>Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disease with no cure. Gene discoveries in ALS can become important diagnostic tools, help to understand the biology of disease, and lead to development of therapies. I will use sophisticated genomics and computational analysis methods to uncover gene defects in both hereditary and sporadic ALS. I will also use deep clinical and biological profiling to develop predictive models of disease progression and prognosis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033037</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Kim Good-Jacobson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>A molecular approach to unlocking B cell memory potential</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | </Fields_of_Research>
        <Res_KW1>b cells</Res_KW1>
        <Res_KW2>germinal centre</Res_KW2>
        <Res_KW3>humoral immunology</Res_KW3>
        <Res_KW4>immunologic memory</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>Memory immune cells are the foundation of vaccine success. They are trained to rapidly clear a reinfection before it can do harm. Yet, we don’t know how long-lasting immune memory is formed, or how chronic viral infections disrupt our ability to form protective immune memory. My research aims to close these knowledge gaps to accelerate the development of new treatments that can significantly reduce the devastating effect of chronic infectious diseases on global health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033042</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Anna DeFazio</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Tailoring treatment to improve outcome for ovarian cancer patients</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,687,947.82</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | </Fields_of_Research>
        <Res_KW1>ovarian cancer</Res_KW1>
        <Res_KW2>anti-tumour drugs</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>targeted therapy</Res_KW4>
        <Res_KW5>women's health</Res_KW5>
        <Plain_Description>Most women with ovarian cancer survive less than five years from diagnosis. Targeted treatments have improved outlook for some patients, but there remains a substantial proportion with no targeted treatment options. My research focuses on some of the most difficult to treat forms of ovarian cancer. It will identify drivers of cancer growth and match these to effective new treatment combinations. The goal is to extend the benefits of tailored treatment to all ovarian cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033054</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Lauren Gardner</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Don't Blow It: Harnessing an Effective and Scalable Drug Prevention Model to Curb Youth Vaping</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>smoking intervention</Res_KW1>
        <Res_KW2>school health promotion</Res_KW2>
        <Res_KW3>addiction prevention</Res_KW3>
        <Res_KW4>school-based intervention</Res_KW4>
        <Res_KW5>mental health promotion</Res_KW5>
        <Plain_Description>Adolescent e-cigarette use (‘vaping’) is now a public health emergency. Effective and scalable prevention programs are urgently needed to upskill and empower youth to make informed health decisions. This research capitalises on a successful drug prevention model to generate crucial new knowledge and an innovative solution to youth vaping that can be immediately disseminated into the community. This will reduce vaping and the associated health, economic and societal burden in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033061</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Georgia Chaseling</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Rising temperatures, rising risks: Preventing heat-induced rises in cardiovascular disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | sports medicine | health sciences | sports science and exercise | exercise physiology | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>climate change</Res_KW1>
        <Res_KW2>cardiovascular disease prevention</Res_KW2>
        <Res_KW3>health consumers</Res_KW3>
        <Res_KW4>ageing</Res_KW4>
        <Res_KW5>heat stress</Res_KW5>
        <Plain_Description>Hot weather and heat extremes claim lives, and people with heart disease are at a greater risk. This Investigator Grant will generate new knowledge to understand why people with heart disease are at risk and long-term adaptation plans to mitigate the health challenges posed by hot weather and heat extremes. Incorporating evidence-based heat management strategies and accessible advice into cardiovascular care will meaningfully reduce cardiovascular events during heat extremes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033062</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jacqueline Gould</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Supporting neurodevelopment through targeted nutrition</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | applied and developmental psychology | applied and developmental psychology not elsewhere classified | biomedical and clinical sciences | nutrition and dietetics | public health nutrition | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>paediatric</Res_KW1>
        <Res_KW2>nutrition supplementation</Res_KW2>
        <Res_KW3>neurodevelopment</Res_KW3>
        <Res_KW4>nutrition status</Res_KW4>
        <Res_KW5>child development</Res_KW5>
        <Plain_Description>Appropriate nutrition is the strongest non-genetic determinant of childhood neurodevelopment and IQ.   My program of research will combine the highest levels of evidence to resolve uncertainties about the nutrient requirements for pregnant women and infants born too soon for three nutrients that are integral to neurodevelopment;  1) Omega-3 fat  2) Donor human (breast) milk (instead of infant formula)  3) Iodine  Results will form the evidence base to guide health policy and practices.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033065</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Thomas Cox</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Delving Deeper into the Matrix: Translating new stromal targets into treatments for solid tumours</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Fields_of_Research>
        <Res_KW1>extracellular matrix</Res_KW1>
        <Res_KW2>cancer therapy</Res_KW2>
        <Res_KW3>tumour targeting</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>The extracellular matrix or 'matrix' surrounds all cells and is important in regulating their behaviour. In cancer, the matrix is dramatically altered, typically making tumours more aggressive, as well as affecting drug response. Our lab develops new ways to study the matrix in cancer, uncover and validate exciting new matrix co-targets. Our research program identifies new therapeutic approaches co-targeting the matrix, taking them through pre-clinical validation and into the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033069</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Deborah Burnett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Development of pre-clinical platforms for enhancing antibody quality in vaccine design.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | </Fields_of_Research>
        <Res_KW1>antibody</Res_KW1>
        <Res_KW2>pre-clinical studies</Res_KW2>
        <Res_KW3>vaccines</Res_KW3>
        <Res_KW4>humoral immunity</Res_KW4>
        <Res_KW5>protective immunity</Res_KW5>
        <Plain_Description>My work aims to develop new platforms for rapid and accurate assessment of the capacity of next-generation vaccines to induce the broadly protective antibodies, which play a pivotal role in immune defence against infectious threats. This research is poised to address significant challenges currently impeding vaccine development. These include the lack of suitable models that mirror human vaccine responses, and the complexities involved in targeting critical of pathogen vulnerability.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033078</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Fabian Kong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Developing a laboratory-based model that mimics oral gonorrhoea infection to find compounds that can be used topically in the mouth (e.g., chewing gum) to prevent infections.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>neisseria gonorrhoeae</Res_KW1>
        <Res_KW2>model</Res_KW2>
        <Res_KW3>drug efficacy</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>Oral gonorrhoea infections are rising &amp; increasingly hard to cure due to drug resistance. Past interventions like condoms and mouthwashes have failed to control it so we must find new strategies. This project will mimic, in a lab, gonorrhoea infection in the human mouth to 1) understand where gonorrhoea grows in the mouth 2) find safe &amp; effective compounds that kill gonorrhoea that can be formulated into a gum, that gay men would use before/after sex to prevent infection and stop transmission.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033081</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Kristy Robledo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Risk prediction models for time to event data: translating clinical trials into practice</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>mathematical sciences | statistics | biostatistics | mathematical sciences | statistics | applied statistics  | biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>risk prediction</Res_KW1>
        <Res_KW2>machine learning</Res_KW2>
        <Res_KW3>prediction</Res_KW3>
        <Res_KW4>survival analysis</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Complex models are available to estimate whether someone will experience an event (like a heart attack, or death) in the future. Recently, new methods to create these models have emerged.   This program will focus on estimating not only if someone will have an event, but when they will have the event. I will be developing and evaluating new methods and applying these to clinical trial datasets. The program will develop a new hub of expertise and develop the next generation of analysts.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033083</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Christine Chaffer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Harnessing plasticity to prevent and treat metastatic and therapy-resistant cancers</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,392,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>plasticity</Res_KW1>
        <Res_KW2>relapse prevention</Res_KW2>
        <Res_KW3>breast cancer metastases</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>novel therapies</Res_KW5>
        <Plain_Description>Every year ~10 million people  worldwide die of cancer. 90% of those deaths arise from advanced-stage cancers that have spread to other sites in the body and have become resistant to anti-cancer therapies. My program zeroes in on these incurable cancers to understand how cancer cells change into therapy-resistant cells. If we can stop those changes, we will uncover new therapies to treat and prevent aggressive cancers from forming.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033087</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Sidonia Eckle</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Understanding a novel immune approach for malaria control and the implications for a vaccine</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>t cell immunity</Res_KW1>
        <Res_KW2>malaria vaccine</Res_KW2>
        <Res_KW3>t cell receptor</Res_KW3>
        <Res_KW4>antigen presentation</Res_KW4>
        <Res_KW5>plasmodium falciparum</Res_KW5>
        <Plain_Description>Malaria remains one of the deadliest infectious diseases worldwide. This research program will unravel the mechanisms by which MAIT cells, a recently identified set of innate-like T cells, contribute to protection from malaria. Thereby, this research program is expected to provide entirely new insights on protective immunity to malaria and substantially advance fundamental knowledge in the emerging MAIT cell field. It will also develop new MAIT cell-based vaccines against malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033089</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Kevin John Selva</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Harnessing mucosal antibodies against respiratory viral infections</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biomedical and clinical sciences | medical microbiology | medical virology  | </Fields_of_Research>
        <Res_KW1>mucosal immunity</Res_KW1>
        <Res_KW2>coronavirus</Res_KW2>
        <Res_KW3>monoclonal antibody</Res_KW3>
        <Res_KW4>fc receptors</Res_KW4>
        <Res_KW5>influenza virus</Res_KW5>
        <Plain_Description>Broad antibody protection could guard against recurring mucosal infections by coronavirus and influenza. However, the antibody types and targeted viral regions driving immunity, particularly at the mucosa, remain unknown. Here, we will identify 1) the antibody features best at protecting against coronavirus and influenza infection, 2) the vaccine platforms most suited to make these antibodies, and 3) if mucosal antibody therapeutics would work against active coronavirus and influenza infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033094</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Tammy Hoffmann</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Harnessing the power of prognostic evidence to transform evidence-based, patient-centred, sustainable healthcare</Grant_Title>
        <Admin_Institution>Bond University Limited</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,878,508.93</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | other health sciences | other health sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>shared clinical decision making</Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>evidence-based clinical practice</Res_KW3>
        <Res_KW4>evidence-based health care</Res_KW4>
        <Res_KW5>guidelines</Res_KW5>
        <Plain_Description>This program will develop interventions to support shared decision making, focusing on common treatments where benefits do not, or hardly, outweigh the harms. It will synthesise prognostic evidence about outcomes with and without treatment. The program will develop co-designed, scalable evidence-based interventions that support clinicians and patients to access this evidence and make informed decisions that maximise patient outcomes, wellbeing, and patient-centred sustainable healthcare.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033097</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Stacey Edwards</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Connecting the noncoding genome to breast cancer development</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,524,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>genetics</Res_KW1>
        <Res_KW2>antisense rna</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>molecular biology</Res_KW4>
        <Res_KW5>transcriptional regulation</Res_KW5>
        <Plain_Description>Breast cancer is a genetic disease, but most research has focused on the 2% of human DNA that contains protein-coding genes. However, the vast majority of DNA outside of these genes (called noncoding DNA) is functional and contains important elements that can promote cancer development. This program will explore how one type of noncoding element, called lncRNAs, promotes breast cancer. A better understanding of lncRNAs in breast cancer will provide new avenues for prevention or treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033103</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Carol Hodgson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Improving the quality of survival after critical illness </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>intensive care</Res_KW1>
        <Res_KW2>physiotherapy</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>respiratory failure</Res_KW4>
        <Res_KW5>outcomes research</Res_KW5>
        <Plain_Description>Patients who are admitted to intensive care (ICU) and require mechanical ventilation for life support account for 63,000 ICU admissions and 8,190 deaths each year in Australia, higher than the national road toll. My research will transform outcomes for these patients by using data within registries and electronic medical records to perform high-impact, low cost clinical trials, generating new knowledge to inform national guidelines and policies and training the next generation of researchers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033108</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Ann-Na Cho</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Harnessing the power of the human Brain Microphysiological System as a model for neuroinflammation, viral infections and pre-clinical therapeutic screening </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | tissue engineering | biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>microglia</Res_KW1>
        <Res_KW2>virology</Res_KW2>
        <Res_KW3>tissue engineering</Res_KW3>
        <Res_KW4>neurovirology</Res_KW4>
        <Res_KW5>disease modelling</Res_KW5>
        <Plain_Description>This stem cell engineering program aims to elucidate a novel neuroinflammation mechanisms associated with virus infection. The anticipated outcome is to provide new neuroscientific findings and lead to an innovative approach to investigating virus infection driven long-term neurological symptoms. Results will be translated to facilitate physician’s decision on diagnosis, monitor virus infection symptoms, optimise treatment through a lab-grown personalised brain model (precision medicine).</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033119</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Chung Kai Chan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Unleashing the power of AI: Supercharging social media campaigns against youth vaping</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | information and computing sciences | artificial intelligence | artificial intelligence not elsewhere classified | </Fields_of_Research>
        <Res_KW1>youth</Res_KW1>
        <Res_KW2>nicotine</Res_KW2>
        <Res_KW3>health promotion</Res_KW3>
        <Res_KW4>smoking</Res_KW4>
        <Res_KW5>mass media</Res_KW5>
        <Plain_Description>The rapid increase in youth vaping demands a fresh approach beyond traditional health-focused campaigns. My research program will harness the power of generative AI to tailor anti-vaping messages to resonate with Australia's diverse youth. We will develop specialized AI models, and produce relevant and diverse campaign materials that will be tested in a trial using generative AI for vaping prevention. This work is expected to revolutionize the design of tailored public health campaigns.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033132</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Melanie Bahlo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Leveraging population cohorts to link common and rare genetic disease mechanisms</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biological sciences | genetics | neurogenetics | biological sciences | other biological sciences | other biological sciences not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>quantitative genetics</Res_KW1>
        <Res_KW2>neurogenetics</Res_KW2>
        <Res_KW3>statistical genetics</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>retinal disease</Res_KW5>
        <Plain_Description>Understanding of what is causing a genetic disease is very important to patients and treating physicians. Identified genes, variants and understanding of how the disease is caused is key to develop diagnostics, to prevent disease, to prognosticate and to develop therapeutics. This project will build on previous work and will focus on neurological and retinal disorders. It will identify new genes and increase understanding of the cause of disease. New tools will also be developed along the way.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033139</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Bruce Campbell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Optimising stroke imaging and reperfusion therapies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>ischaemic stroke</Res_KW1>
        <Res_KW2>brain imaging</Res_KW2>
        <Res_KW3>alternative thrombolytic agents</Res_KW3>
        <Res_KW4>reperfusion</Res_KW4>
        <Res_KW5>perfusion imaging</Res_KW5>
        <Plain_Description>Stroke is a leading cause of death and disability in Australia and globally. I have a strong track record in brain imaging &amp; emergency stroke treatment research that has transformed guidelines and clinical practice globally. My priorities now are to create innovative pre-hospital systems to accelerate emergency treatments, improve the accuracy of brain imaging techniques to guide treatment decision-making and develop improved, widely-applicable strategies to open blocked brain arteries.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033150</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Kim Bennell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Optimising lifestyle care to reduce the burden of knee and hip osteoarthritis</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | health sciences | allied health and rehabilitation science | rehabilitation | biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | </Fields_of_Research>
        <Res_KW1>physiotherapy</Res_KW1>
        <Res_KW2>exercise</Res_KW2>
        <Res_KW3>knee osteoarthritis</Res_KW3>
        <Res_KW4>allied health</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Many Australians live with chronic disabling pain due to knee &amp; hip osteoarthritis. The proposed research will allow us to determine ways to boost the benefits of exercise &amp; to design &amp; evaluate new treatment models that improve access to &amp; optimise lifestyle care. Findings will guide clinical care &amp; provide programs &amp; tools to help people successfully manage their condition. The ultimate aim is that more people with osteoarthritis will receive better lifestyle care to improve outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033152</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Rishi Kotecha</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Improving Outcomes for High-Risk Paediatric Leukaemia</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,483,020.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>acute lymphoblastic leukaemia (all)</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>infant</Res_KW3>
        <Res_KW4>xenografts</Res_KW4>
        <Res_KW5>novel therapeutic agents</Res_KW5>
        <Plain_Description>Modern therapies for children with leukaemia have led to marked improvements in outcome. However, survival rates for certain subtypes remain poor and leukaemia remains a leading cause of disease-related death in children. More effective therapies are desperately needed. My program aims to improve outcomes by developing unique preclinical models to evaluate novel drugs for high-risk paediatric leukaemia and fast-tracking them to the clinic via design and implementation of global clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033153</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Alexander Bryson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Characterizing and correcting epileptic pathology at the microcircuit scale</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | computational neuroscience (incl. mathematical neuroscience and theoretical neuroscience) | </Fields_of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>neurophysiology</Res_KW2>
        <Res_KW3>neuroscience</Res_KW3>
        <Res_KW4>calcium imaging</Res_KW4>
        <Res_KW5>neocortex</Res_KW5>
        <Plain_Description>Epilepsy is a common disorder where abnormal electrical activity (seizures) arise in the brain. Unfortunately, therapies are ineffective for many patients because it is unknown how the brain generates seizures. My project will address this using optical imaging techniques to investigate the mechanisms and treatment of epilepsy in mouse models. These findings will advance our knowledge of epilepsy, enable improved drug discovery, and test a novel form of therapy with translatable potential.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033162</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof James Shine</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Neuroimaging, Neural Models, and Neurobiology: A Fresh Look at Dementia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,449,655.36</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | cognitive and computational psychology | cognition | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>neuroimaging</Res_KW1>
        <Res_KW2>dementia</Res_KW2>
        <Res_KW3>mathematical modelling</Res_KW3>
        <Res_KW4>neurobiology</Res_KW4>
        <Res_KW5>neuropharmacology</Res_KW5>
        <Plain_Description>I will use advanced brain imaging analyses to understand what goes wrong in the brains of people with dementia, in the hope that we can identify affected individuals early in the course of the disease and create new treatments to alleviate their suffering.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033165</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Izanne Roos</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Evidence based use of high-efficacy therapies in multiple sclerosis</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>multiple sclerosis (ms)</Res_KW1>
        <Res_KW2>clinical decision making</Res_KW2>
        <Res_KW3>clinical effectiveness</Res_KW3>
        <Res_KW4>longitudinal cohort study</Res_KW4>
        <Res_KW5>clinical outcome</Res_KW5>
        <Plain_Description>Multiple sclerosis (MS) is a prominent cause of neurological disability. It is therefore essential to select the best treatment strategy that minimises the risk of irreversible long-term disability. MS is however a variable disease, and not all patients require the same strategy to achieve the best long-term outcome. This research stream aims to personalise treatment decisions by studying in who, how, and when, to use the most potent MS therapies to reduce disability while also minimising risk.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033176</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Craig Anderson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Innovative strategies to reduce the global burden of stroke</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | health sciences | epidemiology | major global burdens of disease | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>acute stroke</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>cerebral ischaemia</Res_KW3>
        <Res_KW4>intracerebral haemorrhage</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>Stroke is a major cause of death and disability, worldwide. Some 60,000 Australians are affected by stroke each year. Survivors commonly suffer long-term disability, mood, memory and social problems, and family caregivers are affected. My research focuses on improving the design and conduct of clinical trials in order to develop better approaches to the prevention, treatment and recovery of those affected by stroke, not just in Australia but also in low-resource settings across the world.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033193</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof David Komander</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Mapping and mining the ubiquitin system </Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>ubiquitin</Res_KW1>
        <Res_KW2>molecular basis of disease</Res_KW2>
        <Res_KW3>structural biology</Res_KW3>
        <Res_KW4>biochemistry</Res_KW4>
        <Res_KW5>mass spectrometry</Res_KW5>
        <Plain_Description>The attachment of ubiquitin to proteins furnishes cells with a molecular switchboard to tune a proteins behaviour, regulating its abundance, interactions, and location. Our research focusses on this ‘ubiquitin code’, which we seek to understand, and eventually purposefully (re)write, read, and erase in diseases including cancer, inflammation and neurodegeneration. We are now investigating how and why ubiquitin is attached to sugars and lipids, an exciting new frontier in ubiquitin research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033196</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Claudia Nold</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Developing and Repurposing Therapies: Pioneering Interventional Immunology for Early Life Diseases &amp; Beyond</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>interleukins (il)</Res_KW1>
        <Res_KW2>animal model</Res_KW2>
        <Res_KW3>translational research</Res_KW3>
        <Res_KW4>longitudinal cohort study</Res_KW4>
        <Res_KW5>cytokine regulation</Res_KW5>
        <Plain_Description>Modern intensive care has dramatically improved the survival of preterm infants. Unfortunately, this brings a rise in the incidence of life-threatening diseases that affect the lungs, heart and gut- all involving runaway damaging inflammation. Predicting or treating these diseases is challenging because we do not understand the causes or progression. I will search for biomarkers and investigate candidate drugs that show promise for developing anti-inflammatory therapies for our tiny patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033219</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Catriona Bradshaw</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Transforming the management of treatment refractory sexually transmitted infections (STI) and STI syndromes with precision medicine and genomics   </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>infectious diseases</Res_KW1>
        <Res_KW2>antimicrobial resistance</Res_KW2>
        <Res_KW3>clinical microbiology</Res_KW3>
        <Res_KW4>antimicrobial therapy</Res_KW4>
        <Res_KW5>diagnostic</Res_KW5>
        <Plain_Description>Sexually transmitted infections (STIs) are rising globally and widespread antibiotic misuse is leading to antimicrobial resistance (AMR) impacting on treatment and control. My innovative research programme uses molecular and genomic methods to detect AMR in STIs, develop surveillance for AMR in STIs, and find new causes of genital infections, enabling development of accurate diagnostics and precise treatments, that achieve high cure and reduce antibiotic overuse and AMR in STIs globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033221</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Robyn Williams</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Developing an Aboriginal community led framework to Fetal Alcohol Spectrum Disorder</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | other indigenous data, methodologies and global indigenous studies | other indigenous data, methodologies and global indigenous studies not elsewhere classified | </Fields_of_Research>
        <Res_KW1>fetal alcohol syndrome</Res_KW1>
        <Res_KW2>aboriginal mental health</Res_KW2>
        <Res_KW3>maternal and child health</Res_KW3>
        <Res_KW4>aboriginal child</Res_KW4>
        <Res_KW5>community participation</Res_KW5>
        <Plain_Description>This research involves a codesign of an Aboriginal Community led framework to Fetal Alcohol Spectrum Disorder, that will build competency in clinical and allied health practices in an Aboriginal Medical Service. Aims include the development of the Solid families intervention, early childhood screening, and mental health support. This research framework has the potential to be scaled up for implementation for individuals with this disability across their lifespan in Aboriginal organisations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033228</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Jenny Gunton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Targeting β-cells for diabetes therapy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>islets of langerhans</Res_KW1>
        <Res_KW2>islet transplantation</Res_KW2>
        <Res_KW3>type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</Res_KW3>
        <Res_KW4>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW4>
        <Res_KW5>pancreatic islets</Res_KW5>
        <Plain_Description>Pancreatic ß-cells are the only cells which make and release insulin.  So normal ß-cell mass and function is critical to avoid diabetes.  This project will develop adeno-associated viruses (AAVs) to target ß-cells.  These will be used to a) improve islet transplant outcomes in human islets, b) test ability to prevent type 1 diabetes and c) increase human ß-cell proliferation using mice with human islet transplants.  The studies have potential to completely change our approach to treating human diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033232</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Edith Holloway</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving mental health among Australian adults with diabetes through population-level monitoring </Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$589,520.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health surveillance | health sciences | health services and systems | mental health services | biomedical and clinical sciences | clinical sciences | endocrinology | </Fields_of_Research>
        <Res_KW1>diabetes</Res_KW1>
        <Res_KW2>prospective cohort study</Res_KW2>
        <Res_KW3>mental health</Res_KW3>
        <Res_KW4>monitoring</Res_KW4>
        <Res_KW5>brief intervention</Res_KW5>
        <Plain_Description>1 in 2 people with diabetes have mental health problems. These problems often stay hidden and people with diabetes don’t receive support. We don’t understand what causes mental health problems over time. We also don’t understand when the best time is to help.  Keeping an eye on mental health and providing support to people with diabetes at the right time will help to overcome these problems. This research will address these gaps and improve the mental health of Australian adults with diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033235</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Anthony Rodgers</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Better use of established medicines</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>anti-hypertensive therapy</Res_KW1>
        <Res_KW2>antidepressant therapy</Res_KW2>
        <Res_KW3>high blood pressure</Res_KW3>
        <Res_KW4>cardiovascular disease prevention</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>This Investigator Grant will enable me to lead a research program on better uses of affordable generic medicines. The focus is a new hypertension treatment for which I lead an FDA approval program; and a new use of a generic regarded as a breakthrough treatment for severe depression. The grant will help ensure NMHRC-funded trials are translated into patient benefits; build further research programs addressing major health issues; and help develop our next generation of health researchers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033238</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof John Rasko</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Driving innovation in gene and cell therapy for rare diseases</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>gene therapy</Res_KW1>
        <Res_KW2>cell therapy</Res_KW2>
        <Res_KW3>adeno-associated virus</Res_KW3>
        <Res_KW4>rare diseases</Res_KW4>
        <Res_KW5>gene transfer</Res_KW5>
        <Plain_Description>Gene therapies offer the potential for cures in those suffering with rare diseases. Our research discoveries in gene and cell therapies will transform medicine through improvements in the delivery of gene-based therapeutics using our unique knowledge. In stem cell-based therapies we will develop and apply tools to monitor and analyse how the human body responds following infusion. We will investigate medical, ethical and social aspects of rare disease diagnosis and advocate for cures.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033247</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Ingrid Scheffer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Translational research to transform care in the developmental and epileptic encephalopathies </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | neurogenetics | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>health outcomes</Res_KW2>
        <Res_KW3>neurodevelopmental disorders</Res_KW3>
        <Res_KW4>genetics</Res_KW4>
        <Res_KW5>paediatric</Res_KW5>
        <Plain_Description>I will develop a multifaceted translational research program for patients with Developmental and Epileptic Encephalopathies (DEEs). I will determine the natural history of DEEs, find the cause in the 50% patients currently unsolved and pilot cognitive behavioural therapy with parents and carers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033249</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Grulich</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Achieving HIV elimination and control of related conditions in gay and bisexual men</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | epidemiology | epidemiology not elsewhere classified | biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv)</Res_KW1>
        <Res_KW2>homosexuality</Res_KW2>
        <Res_KW3>chemoprevention</Res_KW3>
        <Res_KW4>human papillomavirus (hpv)</Res_KW4>
        <Res_KW5>cancer prevention</Res_KW5>
        <Plain_Description>New forms of HIV prevention raise the possibility of elimination of HIV transmission. However, the promise has not yet been realized. My research will optimise HIV prevention, investigate new long-acting forms of prevention, and expand prevention in Australia’s neighbours. I will examine whether vaccines can prevent STIs and if screening can prevent anal cancer. My vision is that Australia will be the first country to reach the targets defined as ending AIDS as a public health threat.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033264</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kamala Ley-Thriemer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Optimising radical cure for vivax malaria to accelerate malaria elimination</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,360,416.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>antimalarial</Res_KW2>
        <Res_KW3>malaria control</Res_KW3>
        <Res_KW4>malaria</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>My vision is to contribute to global malaria elimination efforts. I will do this through an international clinical trials program across six countries testing new treatment regimens for vivax malaria. I will also use qualitative methods to design how those new treatment strategies can be implemented and will work directly with national malaria control programs to facilitate that research findings are translated into practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033272</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Kalman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Improving atrial fibrillation outcomes</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,490,815.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>atrial fibrillation</Res_KW1>
        <Res_KW2>treatment evaluation</Res_KW2>
        <Res_KW3>atrial arrhythmias</Res_KW3>
        <Res_KW4>disease mechanisms</Res_KW4>
        <Res_KW5>cardiovascular disease</Res_KW5>
        <Plain_Description>Atrial fibrillation (AF) is the most common heart rhythm disturbance. It is estimated that a quarter of the adult population over the age of 40 will be diagnosed with AF in their lifetime. AF is associated with increased risk of stroke, heart failure and premature death. It is associated with depression and increases the risk of dementia. The proposed randomised studies will provide new approaches to the routine prevention and treatment of AF and of AF-related complications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033277</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Julie Ratcliffe</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>New health economic tools for improving the health and wellbeing of older Australians</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems | biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | </Fields_of_Research>
        <Res_KW1>health economics</Res_KW1>
        <Res_KW2>quality of life</Res_KW2>
        <Res_KW3>quality improvement</Res_KW3>
        <Res_KW4>economic evaluation</Res_KW4>
        <Res_KW5>older people</Res_KW5>
        <Plain_Description>This important and impactful research program will work with key health partners and older patients to develop, validate and implement new health economic measurement tools to assess quality of care and quality of life, supporting a higher quality, efficient and fairer health system for older people. The quality of care experience and quality of life tools will help policy makers and practitioners across health systems world-wide to make better decisions about the care provided to older people.       </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033280</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel King</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Evidence-based interventions for gaming disorder in adolescents and young adults</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>behavioural addictions</Res_KW1>
        <Res_KW2>sedentary behaviour</Res_KW2>
        <Res_KW3>addictive behaviours</Res_KW3>
        <Res_KW4>addiction treatment</Res_KW4>
        <Res_KW5>adolescent health</Res_KW5>
        <Plain_Description>Problem gaming is a major mental health issue that affects more than 300,000 Australians. This research program will better understand the nature and scale of this problem in Australia and develop co-designed interventions to help young people and parents manage and overcome gaming problems. This project will deliver new knowledge and practical tools and resources to reduce and prevent gaming disorder, promoting better health and social outcomes for vulnerable gamers and their families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033294</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Trisha Peel</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Towards Elimination of Avoidable Infections in Surgery</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | clinical sciences | surgery | biomedical and clinical sciences | clinical sciences | anaesthesiology | </Fields_of_Research>
        <Res_KW1>randomised controlled trial (rct)</Res_KW1>
        <Res_KW2>health consumers</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>surgical outcomes research</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>1 in 10 Australians undergo surgery each year. Infections following surgery are a devastating and avoidable complication. These infections have massive impact - and they can be stopped. My investigator grant studies optimal ways to prevent these infections and to better engage surgical patients in their care and as active research partners. My vision is to ensure the best possible outcomes for surgical patients throughout Australia and internationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033297</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Michael Lazarou</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Targeting mitochondrial health in Parkinson's disease through mitophagy</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cell metabolism | biological sciences | biochemistry and cell biology | protein trafficking | biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | </Fields_of_Research>
        <Res_KW1>mitochondria</Res_KW1>
        <Res_KW2>mitochondrial function</Res_KW2>
        <Res_KW3>protein biochemistry</Res_KW3>
        <Res_KW4>autophagy</Res_KW4>
        <Res_KW5>cell biology</Res_KW5>
        <Plain_Description>Mitochondria are essential structures within the cells of our body that generate the energy that sustains life. When mitochondria don’t function properly, it contributes to disease in humans. To better understand of how mitochondria break down and how to fix it, this study will investigate the function of repair pathways that maintain mitochondrial health. The results of this research can be used to identify new points of medical intervention to boost the repair pathways and prevent disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033299</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Eric Chow</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Optimising the use of antibiotics for sexually transmitted infections to improve antimicrobial stewardship</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | biomedical and clinical sciences | clinical sciences | venereology | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>gonorrhoea</Res_KW1>
        <Res_KW2>public health</Res_KW2>
        <Res_KW3>antimicrobial resistance</Res_KW3>
        <Res_KW4>sexually-transmitted infections (sti)</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>Gonorrhoea is a common sexually transmitted infection (STI) with resistance to nearly all the antibiotics used for its treatment globally. The benefits and harms of taking antibiotics to prevent STIs and asymptomatic screening strategies are ambiguous in relation to antibiotic resistance. This research will examine the long-term impact of antibiotic use, trial interventions of reducing screening and co-design resources with clinicians and consumers to decrease antibiotic resistance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033318</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr David Khoury</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Reducing the burden of infectious diseases using translational analytics</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | immunology | immunology not elsewhere classified | mathematical sciences | applied mathematics | biological mathematics  | </Fields_of_Research>
        <Res_KW1>vaccination</Res_KW1>
        <Res_KW2>antimicrobial therapy</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>immune protection</Res_KW4>
        <Res_KW5>biostatistics</Res_KW5>
        <Plain_Description>It is now possible to rapidly collect enormous amounts of data on infectious diseases, such as COVID-19. Thus, the challenge now is – “how do we sensibly integrate data across multiple studies to deliver evidence-based policy for managing infectious diseases?” This project aims to use mathematical and data analytics approaches, in close collaboration with local and international experimentalists and clinicians, to guide efforts to reduce the burden of infectious diseases globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033319</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Louise Maple-Brown</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>A working partnership with Aboriginal and Torres Strait Islander people to address inequities in diabetes and related health conditions</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,739,264.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | health sciences | health services and systems | implementation science and evaluation | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander lifecourse | </Fields_of_Research>
        <Res_KW1>diabetes</Res_KW1>
        <Res_KW2>implementation</Res_KW2>
        <Res_KW3>indigenous health</Res_KW3>
        <Res_KW4>fetal origins of disease</Res_KW4>
        <Res_KW5>maternal and child health</Res_KW5>
        <Plain_Description>First Nations Australians bear a disproportionate burden of type 2 diabetes at all ages. My program of work aims to prevent and slow the progression of type 2 diabetes in First Nations children, through early-life prevention: pre-conception, pregnancy, childhood. I lead a partnership of researchers, health services and policy makers across Australia to improve diabetes-related health outcomes with First Nations communities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033320</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof James Beeson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>New pathways to achieve highly protective and long-lasting malaria vaccines</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | </Fields_of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>young children</Res_KW2>
        <Res_KW3>vaccines</Res_KW3>
        <Res_KW4>adaptive immunity</Res_KW4>
        <Res_KW5>vaccine efficacy</Res_KW5>
        <Plain_Description>This program will advance the development of highly potent and durable malaria vaccines through novel and innovative techniques to identify crucial targets for protective immunity against malaria. We will determine the reasons behind short-lived immunity and develop strategies for new vaccines that offer long-lasting protection with sustained effectiveness. These objectives will be supported by complementary vaccine development and translational activities for new approaches to malaria vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033323</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr John Hart</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Azithromycin and pneumococcal conjugate vaccine for reducing child mortality in high-risk populations</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | community child health  | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>bacterial infection</Res_KW1>
        <Res_KW2>public health</Res_KW2>
        <Res_KW3>pneumococcal disease</Res_KW3>
        <Res_KW4>pneumococcal vaccination</Res_KW4>
        <Res_KW5>bacterial gastroenteritis</Res_KW5>
        <Plain_Description>Child mortality is unacceptably high in many resource-limited settings: 10 to 20 times higher than in high-income countries. I plan to use widely available cheap interventions - a pneumonia vaccine and the antibiotic azithromycin - targeted to children when they are at their most vulnerable, particularly malnourished children, to reduce child deaths. The work will assess if these interventions combined can multiply the benefit, and will progress discussions towards rollout of the interventions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033326</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Evan Healy</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>How does RNA regulate gene repression?</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | genetics | genome structure and regulation | </Fields_of_Research>
        <Res_KW1>epigenetics</Res_KW1>
        <Res_KW2>control of gene expression</Res_KW2>
        <Res_KW3>chromatin</Res_KW3>
        <Res_KW4>chromatin structure</Res_KW4>
        <Res_KW5>gene regulation</Res_KW5>
        <Plain_Description>When the product of certain genes is not needed, these genes are turned off in a process known as gene repression. Genes are switched off by chromatin modifiers, and the activity of these proteins is influenced by RNA. Previously considered a simple messenger molecule, RNA has emerged as a key player during development and in disease. However, our understanding of how RNA regulates gene repression in vertebrates remains rudimentary. This project aims to determine how RNA affects gene repression.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033338</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jaithri Ananthapavan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Transforming resource allocation decision-making for obesity prevention </Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$510,914.41</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>economics | applied economics | health economics  | health sciences | public health | public health not elsewhere classified | health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>health economics</Res_KW1>
        <Res_KW2>preventive health</Res_KW2>
        <Res_KW3>economic evaluation</Res_KW3>
        <Res_KW4>overweight/obesity</Res_KW4>
        <Res_KW5>priority setting</Res_KW5>
        <Plain_Description>Excess body weight is a driver of poor health in Australia, contributes to health inequities, and has a large cost burden on society. Government decision-making on which policies and programs to fund to address this complex issue needs to consider the costs, benefits and equity impacts of potential strategies. This project will work with decision-makers to develop the evidence they need to make informed and consistent decisions to improve the health and wellbeing of all Australians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033340</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ethan Goddard-Borger</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Targeting Glycosylation in Myeloproliferative Diseases</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,392,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | enzymes | biological sciences | biochemistry and cell biology | glycobiology | chemical sciences | medicinal and biomolecular chemistry | proteins and peptides | </Fields_of_Research>
        <Res_KW1>glycobiology</Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>drug discovery</Res_KW3>
        <Res_KW4>protein modification</Res_KW4>
        <Res_KW5>peptides</Res_KW5>
        <Plain_Description>Myelofibrosis, a cancer of the bone marrow, is currently treated with drugs that target the JAK2 protein. Unfortunately, these drugs have many side-effects, are not curative, and there is no back-up for drug resistant cancers. We are addressing these issues using a multi-pronged approach to understand and target a new biochemical pathway implicated in myelofibrosis. This funding will provide the insights and proof-of-concept data required to drive the development of new drugs for this cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033358</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Huacheng Zhang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Artificial Ion Channels for Advancing Neural Signalling and Treating Neurological Diseases </Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | neural engineering | biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | </Fields_of_Research>
        <Res_KW1>ion channels</Res_KW1>
        <Res_KW2>ion transport</Res_KW2>
        <Res_KW3>neural development</Res_KW3>
        <Res_KW4>artificial neural networks</Res_KW4>
        <Res_KW5>neural regulation</Res_KW5>
        <Plain_Description>This project pioneers multifunctional artificial ion channels to replicate biological ion channels' selective and stimuli-gated ion transport properties, aiming to construct advanced neural devices for managing conditions of neurological disorders like Parkinson's disease, chronic pain, anxiety, and depression. Expected outcomes include new knowledge to enhance our understanding of signal transmission, devices to mimic neuron functions, and tailored therapies for various neurological diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033366</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Geoffrey Faulkner</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Mobile DNA decides neuronal fate in the normal and degenerative human brain</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>transposons</Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>somatic mutation</Res_KW4>
        <Res_KW5>neurodegenerative disorders</Res_KW5>
        <Plain_Description>The brain is a complex and dynamic organ tasked with interpreting and responding to the world around us. My team has shown that various aspects of mobile DNA, or 'jumping gene', activity can alter brain development and DNA content. This research program will examine why mobile DNA activity appears to be restricted to certain brain cell types, how this phenomenon turns genes on and off, and whether blocking mobile DNA activity in neurodegenerative diseases reduces brain cell death.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033380</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jessica Kasza</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Developing, translating and implementing biostatistical expertise in stepped wedge cluster randomised trials</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>mathematical sciences | statistics | biostatistics | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>biostatistics</Res_KW1>
        <Res_KW2>randomised controlled trial (rct)</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>controlled trial</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>This program will develop novel cluster randomised trial designs to test new interventions in health that will be flexible and robust to the interruptions and delays commonly faced by these trials. Such issues can invalidate trial conclusions. Drawing on my expertise and international network, I will develop new, robust and flexible designs, leading a hub of researchers who are connected with trialists. The hub's statistical work will inform and be informed by cluster randomised trial practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033400</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Tashjian</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Neural perturbations in anxiety across development</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | applied and developmental psychology | child and adolescent development  | </Fields_of_Research>
        <Res_KW1>psychological disorders</Res_KW1>
        <Res_KW2>psychology</Res_KW2>
        <Res_KW3>anxiety</Res_KW3>
        <Res_KW4>adolescence</Res_KW4>
        <Res_KW5>functional magnetic resonance imaging (fmri)</Res_KW5>
        <Plain_Description>Adolescents are vulnerable to anxiety as a result of ongoing maturation in neural systems used to detect safety. Prevailing therapeutic treatments are ineffective for ~50%. My research proposes distinct anxiety profiles arise during adolescence, characterised by amplified threat detection versus blunted safety recognition. This program will build and computationally assess an integrated brain-based model of anxiety. Findings will contribute to new and more effective treatment approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033412</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Ines Esteves Domingues Pires da Silva</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>NeoPlatform: Neoadjuvant translational research platform to predict, monitor and enhance response to immunotherapy.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$454,385.29</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy</Res_KW1>
        <Res_KW2>prediction</Res_KW2>
        <Res_KW3>drug resistance</Res_KW3>
        <Res_KW4>melanoma</Res_KW4>
        <Res_KW5>monitoring</Res_KW5>
        <Plain_Description>Drugs that stimulate the immune system to fight cancer (immunotherapy) are more effective when given before surgery (neoadjuvant) than after surgery in patients with locoregional melanoma. We will study >200 patients with melanoma treated in the neoadjuvant setting to predict and monitor response, and to identify personalised treatment for patients resistant to immunotherapy. This work is of major significance to the outcome of patients with cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033415</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Natalia Castano Rodriguez</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Identification of a genetic-microbial signature for the prevention and treatment of stomach cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | biomedical and clinical sciences | medical microbiology | medical microbiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>immunogenetics</Res_KW1>
        <Res_KW2>microbial ecology</Res_KW2>
        <Res_KW3>cancer genetics</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>helicobacter pylori</Res_KW5>
        <Plain_Description>Stomach cancer is a major cause of suffering and death globally. While the bacterium Helicobacter pylori is the main risk factor for this cancer, recent evidence suggests that other microbes and genetics also play key roles. We aim to characterise and validate a genetic-microbial signature associated with stomach cancer to identify those at most risk, avoiding the high costs, unintended health consequences and increasing antibiotic resistance rates associated with mass eradication of H. pylori.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033417</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Danilo De Oliveira Silva</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Understanding and reducing the psychological and physical burden of patellofemoral pain in adolescents and young adults</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | health sciences | allied health and rehabilitation science | rehabilitation | biomedical and clinical sciences | clinical sciences | sports medicine | </Fields_of_Research>
        <Res_KW1>knee</Res_KW1>
        <Res_KW2>knee osteoarthritis</Res_KW2>
        <Res_KW3>rehabilitation</Res_KW3>
        <Res_KW4>musculoskeletal disorders</Res_KW4>
        <Res_KW5>physiotherapy</Res_KW5>
        <Plain_Description>This program aims to reduce the psychological and physical suffering caused by chronic knee pain in adolescents and young adults. My proposal is the world’s first in: i) identifying those at highest risk of poor outcomes; ii) discovering features that can be changed to improve treatment; iii) determining the benefits of personalised digital care. Findings will help prevent adolescents and young adults with knee pain from burdening the healthcare system and contribute to a healthier population.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033433</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Han Chow Chua</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Plugging the sodium leak in severe neurodevelopmental disorders</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | basic pharmacology  | </Fields_of_Research>
        <Res_KW1>ion channels</Res_KW1>
        <Res_KW2>de novo mutations</Res_KW2>
        <Res_KW3>neurodevelopmental disorders</Res_KW3>
        <Res_KW4>electrophysiology</Res_KW4>
        <Res_KW5>molecular pharmacology</Res_KW5>
        <Plain_Description>The sodium leak channel, NALCN plays a crucial role in controlling how our neurons communicate. When there are mutations in the NALCN gene in humans, serious health issues including delayed growth, intellectual disabilities, and early death can occur. Unfortunately, our knowledge of how to develop drugs to treat these diseases is limited. My research aims to find new chemicals to fix the problems with NALCN in these diseases, with the goal of improving the health of affected individuals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033440</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Mitchell Stark</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Exploration of the skin molecular ecosystem and early melanoma development</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | molecular evolution | biological sciences | genetics | genomics | biological sciences | other biological sciences | other biological sciences not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>melanoma</Res_KW1>
        <Res_KW2>control of tumour progression</Res_KW2>
        <Res_KW3>skin</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>molecular diagnostics</Res_KW5>
        <Plain_Description>Melanoma can arise from moles or skin without a preexisting mole. We do not currently understand how this happens. This proposal will uncover the mechanism that determines melanoma development. This knowledge has the potential to prevent the excessive excision of benign moles and also improve the early detection of dangerous life-threatening melanoma.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033452</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Ana Traven</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Harnessing disease tolerance and immune protection to treat fungal sepsis</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,524,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | mycology  | </Fields_of_Research>
        <Res_KW1>mycology</Res_KW1>
        <Res_KW2>fungal pathogenesis</Res_KW2>
        <Res_KW3>fungal infection</Res_KW3>
        <Res_KW4>candida albicans</Res_KW4>
        <Res_KW5>macrophages</Res_KW5>
        <Plain_Description>Fungal infections cause 1.5 million deaths world-wide, with limited antifungal treatment options. Therefore, we must think laterally and explore adjunct therapies that can improve infection outcomes. Towards this goal, this project studies how metabolic and nutritional approaches could increase patient survival in fungal infections, which have 20-50% associated mortality. The insight gained could lead to innovative strategies for the treatment of deadly fungal diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033462</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Tuba Gide</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Profiling of immunotherapy resistant tumours to inform treatment selection and drug discovery for patients with advanced cancer</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>cancer immunotherapy</Res_KW1>
        <Res_KW2>metastatic cancer</Res_KW2>
        <Res_KW3>cancer immunology</Res_KW3>
        <Res_KW4>melanoma</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>This proposal will enable the accurate identification of effective immunotherapy combinations for patients with disease resistance to the standard-of-care immunotherapies. The identification of appropriate treatments in real time will allow patients to avoid unnecessary toxicities and limit costs to patients and the healthcare system. The findings of this research will also have major ramifications for clinical trial design and the treatment of patients with a critical unmet need.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033499</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Alicia Oshlack</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Transcriptomics at exquisite resolution</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>cancer genetics</Res_KW2>
        <Res_KW3>transcription</Res_KW3>
        <Res_KW4>sequencing</Res_KW4>
        <Res_KW5>cancer cell biology</Res_KW5>
        <Plain_Description>We now have the technologies to sequence millions of RNA molecules across millions of individual cells. From this we can learn about a variety of diseases including mechanisms that drive cancer and the cells that kill cancer. However these data set are huge and we need robust computational and statistical analysis methods to make sense of this data. This proposal aims to develop computational approaches to analysis that enable deeper understanding of diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033519</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Elise McGlashan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving antidepressant treatment outcomes with personalised circadian medicine</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | psychopharmacology | psychology | biological psychology  | psychophysiology  | </Fields_of_Research>
        <Res_KW1>depression</Res_KW1>
        <Res_KW2>antidepressants</Res_KW2>
        <Res_KW3>circadian rhythms</Res_KW3>
        <Res_KW4>sleep</Res_KW4>
        <Res_KW5>light sensitivity</Res_KW5>
        <Plain_Description>Sleep and ‘body clock’ disruption create vulnerability for depression. We now know that antidepressants affect sleep and the body clock in a way that has the potential to predict treatment outcomes. This program of research will examine the effect of a range of antidepressants on the body clock in both acute (single) and chronic (multiple) doses, and evaluate the effectiveness of circadian measures for predicting antidepressant treatment responses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033530</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Tina Noutsos</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Transforming blood transfusion decision-making and patient blood management for and with Aboriginal and Torres Strait Islander peoples in rural and remote Australia</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$331,285.36</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | </Fields_of_Research>
        <Res_KW1>blood transfusion</Res_KW1>
        <Res_KW2>participatory action research</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>anaemia</Res_KW4>
        <Res_KW5>rural and remote health</Res_KW5>
        <Plain_Description>Blood transfusions can benefit patients in certain settings, such as severe anaemia and major bleeding, but can also cause harm. Most existing research on the benefits and risks of blood transfusion is drawn from metropolitan settings and non-First Nations populations. My research will generate new evidence to guide blood transfusion clinical decision-making for First Nations peoples in rural and remote communities, with a focus on the Northern Territory.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033534</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Raymond Lovett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>The impact of settler-colonial risks on Aboriginal and Torres Strait Islander health and the role of culture as a protective factor</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health policy | health sciences | epidemiology | social epidemiology | </Fields_of_Research>
        <Res_KW1>validation</Res_KW1>
        <Res_KW2>epidemiology</Res_KW2>
        <Res_KW3>risk factors</Res_KW3>
        <Res_KW4>public health</Res_KW4>
        <Res_KW5>indigenous health</Res_KW5>
        <Plain_Description>Almost half the health gap in what contributes to poor health for Indigenous peoples is unexplained. This proposal will analyse, for the first time, large-scale data on settler-colonial risk impacts on Aboriginal and Torres Strait Islander peoples. This proposal will generate new evidence on the ongoing impacts of colonisation, and protective factors of cultural determinants to equip policymakers and communities to shift the dial on Closing the Gap.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033539</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Hannah Wardill</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Harnessing The Gut Microbiota To Predict And Prevent Life-Threatening Complications Of Haematopoietic Stem Cell Transplantation</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,543,893.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | palliative care | biomedical and clinical sciences | oncology and carcinogenesis | chemotherapy | biomedical and clinical sciences | medical biotechnology | medical biotechnology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>supportive care</Res_KW1>
        <Res_KW2>haematopoietic stem cell transplantation</Res_KW2>
        <Res_KW3>quality of life</Res_KW3>
        <Res_KW4>adverse incidents including complications</Res_KW4>
        <Res_KW5>survivorship</Res_KW5>
        <Plain_Description>People with blood cancer are often treated with very high doses of chemotherapy which cause a range of nasty side effects some of which are lethal (e.g. infection). This project aims to PREDICT AND PREVENT these side effects. This will be achieved by: i) developing a simple test to detect certain gut bacteria that are known to cause these side effects, and ii) identifying candidate microbes that can be delivered as a specialised probiotic to prevent side effects from occurring all together.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033543</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jonathan Paul</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Leveraging Uterine-Targeted Nanoparticles for Preventing Preterm Birth</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,592,745.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | </Fields_of_Research>
        <Res_KW1>premature birth</Res_KW1>
        <Res_KW2>drug delivery systems</Res_KW2>
        <Res_KW3>therapeutics</Res_KW3>
        <Res_KW4>myometrium</Res_KW4>
        <Res_KW5>nanotechnology</Res_KW5>
        <Plain_Description>Thousands of babies could be saved each year by preventing spontaneous preterm birth. Current approaches are hampered by a lack of drug specificity. To address this, we first developed uterine-targeted nanocarriers for targeting interventions to the pregnant uterus. We now seek to leverage this platform to achieve the targeted delivery of multiple advanced therapies possessing the capacity to (re)program uterine smooth muscle cells and silence premature contractions to prevent preterm birth.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033554</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Sarah-Jane Dawson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Liquid biopsy multi-omic approaches to optimise precision medicine in cancer </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | </Fields_of_Research>
        <Res_KW1>oncology</Res_KW1>
        <Res_KW2>translational research</Res_KW2>
        <Res_KW3>cancer biology</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Many cancers shed small amounts of DNA (circulating tumour DNA) into the patient’s bloodstream, which exists as a mixture with cell free DNA (cfDNA) fragments released from healthy tissues. Recent technological advances allow levels of circulating DNA to be accurately measured in the blood to understand cancer biology.  My research program will advance the use of innovative liquid biopsy approaches to improve disease monitoring and individualise treatment decisions in cancer management.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033557</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Dawson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Identifying and targeting epigenetic mechanisms of therapeutic resistance in cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>cancer biology</Res_KW1>
        <Res_KW2>clonal diversity</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>experimental haematology</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>The prevailing dogma in personalised cancer medicine suggests that cancer cell behaviour including the emergence of therapy resistance is primarily due to evolving genetic mutations. My research has challenged this doctrine and shown that epigenetic processes contribute substantially to cancer cell fitness and therapy evasion. My future work will study the interaction between genetic and epigenetic processes in mediating resistance to find new strategies to improve outcomes for cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033561</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Gutman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Investigating Interventions and Outcomes in the Obesity-related Heart Failure with Preserved Ejection Fraction Phenotype</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$462,200.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>chronic heart failure (chf)</Res_KW1>
        <Res_KW2>haemodynamics</Res_KW2>
        <Res_KW3>diastolic dysfunction</Res_KW3>
        <Res_KW4>overweight/obesity</Res_KW4>
        <Res_KW5>magnetic resonance imaging (mri)</Res_KW5>
        <Plain_Description>My projects will determine whether weight loss in people living with obesity and heart failure will reverse the abnormalities that have developed in the heart. I will also investigate whether a simple, non-invasive procedure – an MRI of the heart – can predict which patients living with obesity will develop heart failure. My work will inform treatment guidelines for patients with obesity and heart failure, to improve their health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033569</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Lacy-Nichols</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Strengthening evidence on harmful industries and their influence on public health policy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$661,609.86</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | human society | policy and administration | health policy | human society | political science | australian government and politics | </Fields_of_Research>
        <Res_KW1>public health policy</Res_KW1>
        <Res_KW2>chronic diseases</Res_KW2>
        <Res_KW3>policy analysis</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>social determinants of health</Res_KW5>
        <Plain_Description>Government policies to reduce consumption of harmful products like alcohol, tobacco and sugary drinks face strong opposition from industries selling those products. We know little about these opposition strategies. This research program will generate evidence about the political activities of alcohol, tobacco and sugary drink industries and develop a tool to monitor political activities. This will help public health organisations to protect public health policies from industry interference.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033589</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Asha Bowen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Strong Skin means Strong Health</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | clinical sciences | infectious diseases | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | </Fields_of_Research>
        <Res_KW1>impetigo</Res_KW1>
        <Res_KW2>rheumatic fever</Res_KW2>
        <Res_KW3>staphylococcus aureus</Res_KW3>
        <Res_KW4>group a streptococcal disease</Res_KW4>
        <Res_KW5>indigenous health</Res_KW5>
        <Plain_Description>The skin is the largest and only visible organ, and is a protective barrier. Skin infections are itchy, and embarrassing, and when ignored, have deathly consequences including sepsis, rheumatic fever, and bone infections. My research focusses on telling the healthy skin and rheumatic fever prevention stories to healthcare workers and families, through guidelines, hip hop videos, and storybooks in local Aboriginal languages. I also design and lead clinical trials to improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033596</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Philippa Karoly</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Stress in Epilepsy: Relating multiday cycles of seizure risk and the autonomic nervous system to deliver novel epilepsy management.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | neurosciences | autonomic nervous system  | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>autonomic nervous system</Res_KW2>
        <Res_KW3>neuroscience</Res_KW3>
        <Res_KW4>seizures</Res_KW4>
        <Res_KW5>cortical excitability</Res_KW5>
        <Plain_Description>I recently developed a world-first mobile and wearable app to forecast the risk of epileptic seizures. Tracking seizure risk enables people with epilepsy to better manage their seizures, improving quality of life and safety. Moving forward, this project will explore how seizure risk relates to stress and multiday rhythms in the autonomic nervous system and will then link risk forecasts to a novel targeted, mobile intervention to reduce the chance of having a seizure.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033600</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Maria Tanzer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Investigating macrophage programming during dead cell clearance</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | biological sciences | biochemistry and cell biology | systems biology | </Fields_of_Research>
        <Res_KW1>cell death</Res_KW1>
        <Res_KW2>cytokine biology</Res_KW2>
        <Res_KW3>proteomics</Res_KW3>
        <Res_KW4>cell signalling</Res_KW4>
        <Res_KW5>phagocytosis</Res_KW5>
        <Plain_Description>Dying cells release inflammatory molecules. Therefore, other cells must rapidly eat dead cells to avoid inflammatory disease. This project investigates the mechanisms regulating the eating process and its effect on neighbouring cells. The identified mechanisms will provide novel treatment approaches for inflammatory disease and wound healing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033610</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Valsamma Eapen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Improving the outcomes for children with Tourette Syndrome and co-morbid mental health conditions</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,788,978.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>tourette syndrome</Res_KW1>
        <Res_KW2>child health</Res_KW2>
        <Res_KW3>mental health</Res_KW3>
        <Res_KW4>comorbidity</Res_KW4>
        <Res_KW5>health inequalities</Res_KW5>
        <Plain_Description>Children with Tourette Syndrome (TS) and associated mental health needs experience barriers in health service access and this is much more significant for those from disadvantaged backgrounds. This grant will improve timely and equitable access to comprehensive assessment, and apply models of integrated person-centred care. This Australian first program co-designed with consumers and stakeholders will improve the holistic health and quality of life of ˜50,000 Australian children living with TS.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033626</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Amanda Gwee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>TReatment Equity and AccessibiliTy for kids (TREATkids)</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,422,642.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>antibiotics</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>staphylococcus aureus</Res_KW4>
        <Res_KW5>dose optimisation</Res_KW5>
        <Plain_Description>Many children with serious infections do not get the treatment they need because we do not know how much medicine to give them or whether the drug is safe to use in children. My research includes five projects that will find better dosing strategies, new treatment approaches, and prevent harms from medicines used for the most common and serious childhood infections. This research aims to ensure that every child can get the very best and safest treatment for their infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033643</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Laurence Luu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Targeting essential colonisation factors of bacterial pathogens for vaccine development</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>pertussis</Res_KW1>
        <Res_KW2>bacterial pathogenesis</Res_KW2>
        <Res_KW3>vaccine</Res_KW3>
        <Res_KW4>functional genomics</Res_KW4>
        <Res_KW5>molecular microbiology</Res_KW5>
        <Plain_Description>Whooping cough caused by Bordetella pertussis has adapted to current vaccines and re-emerged worldwide. My project will develop new mRNA vaccines against whooping cough by first determining what genes does this bacteria need to cause infection and how they escaped current vaccines. A better understanding of pertussis infection and a new mRNA vaccine will allow us to better control whooping cough. I will leverage this information to find new antigens to develop and test in an mRNA vaccine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033661</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Amanda Leach</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Tackling the evidence-policy-practice gap in ear and hearing health of First Nations children, particularly in the Northern Territory</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | rural and remote health services | health sciences | public health | community child health  | </Fields_of_Research>
        <Res_KW1>rural and remote health services</Res_KW1>
        <Res_KW2>aboriginal child</Res_KW2>
        <Res_KW3>rural workforce</Res_KW3>
        <Res_KW4>otitis media</Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>My vision is to contribute to evidence-based policy and practice that leads to eradication of chronic ear disease and disabling hearing loss and change in the trajectory of disadvantage.     My 5-year objectives are to co-design high-quality trials of innovative strategies that sustain local Ear Health Facilitators in service and research, increase GP diagnostic skills and guideline adherence, and improve effectiveness of hearing aids and grommets, for which there is no evidence to date.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033679</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Eva Alisic</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Homicide at home: Minimising the impact on young survivors</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | community child health  | </Fields_of_Research>
        <Res_KW1>domestic violence</Res_KW1>
        <Res_KW2>qualitative research</Res_KW2>
        <Res_KW3>childhood</Res_KW3>
        <Res_KW4>mental health</Res_KW4>
        <Res_KW5>community</Res_KW5>
        <Plain_Description>When a sibling, parent or caregiver is killed through family violence, it turns a young person's life entirely upside down and deeply affects their broader family and community. This research program builds towards evidence-based support for young people affected by such homicides and the people around them. It will listen to the stories of people with lived experience, work with professionals to develop guidance, and collaborate with the broader community to transform stigma into support.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033680</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Karlheinz Peter</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Innovative Biotechnological Approaches for Prevention and Therapy of Myocardial Infarction</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>myocardial infarction</Res_KW1>
        <Res_KW2>nanotechnology</Res_KW2>
        <Res_KW3>atherosclerosis</Res_KW3>
        <Res_KW4>plaque rupture</Res_KW4>
        <Res_KW5>messenger rna (mrna)</Res_KW5>
        <Plain_Description>Heart attack is the most common single cause of death. Even if survived, there is often substantial damage to the heart causing its weakening. Using cutting-edge technologies, I aim to improve treatment and prevention of heart attacks. This requires a better understanding of the causes of heart attacks, identification and treatment of the heart vessel areas that are at risk of blocking off and causing heart attacks, and the development of novel medication that can prevent damage to the heart.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033683</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Valerie Sung</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Population approaches for prevention, diagnosis and management of childhood deafness</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,422,642.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | neurosciences | sensory systems | </Fields_of_Research>
        <Res_KW1>hearing loss</Res_KW1>
        <Res_KW2>cytomegalovirus (cmv) infection</Res_KW2>
        <Res_KW3>child development</Res_KW3>
        <Res_KW4>medical genomics</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>Deaf and hard of hearing children experience many life challenges and unanswered questions about their future despite early diagnosis and medical advances. My fellowship aims to improve prevention, diagnosis and management of hearing loss for all Australian children, using a national child hearing registry that links routinely collected data from different hearing services and large research studies, together with collaborations with families with lived experience.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033694</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Alicia Spittle</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Optimising developmental outcomes for children born preterm using digital health solutions</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>very preterm birth</Res_KW1>
        <Res_KW2>physiotherapy management</Res_KW2>
        <Res_KW3>cerebral palsy</Res_KW3>
        <Res_KW4>physiotherapy assessment</Res_KW4>
        <Res_KW5>infant development</Res_KW5>
        <Plain_Description>Every year 15 million babies worldwide are born preterm. Despite improved survival rates, developmental impairments are on the increase. My program is directly focused on addressing current knowledge gaps in access to early intervention to improve developmental outcomes. My program involves trialling digital health solutions to enable early detection of specific developmental impairments and delivery of targeted interventions, thereby improving developmental outcomes for children born preterm.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033705</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Cavan Bennett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Defining Inflammation in Myeloproliferative Neoplasms</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>haematological malignancy</Res_KW1>
        <Res_KW2>novel therapies</Res_KW2>
        <Res_KW3>chronic inflammation</Res_KW3>
        <Res_KW4>iron metabolism</Res_KW4>
        <Res_KW5>survivorship</Res_KW5>
        <Plain_Description>Myeloproliferative neoplasms (MPNs) are blood cancers that cause chronic inflammation. Inflammatory changes in MPNs are poorly documented. I will document these inflammatory changes and explore whether targeted therapies against inflammatory molecules can be useful in MPNs.     Further, inflammation regulates iron metabolism, which may influence MPN disease. In MPNs non-classical inflammatory pathways have a role in iron regulation. I will define these other inflammatory pathways in iron regulation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033718</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Sumaira Hasnain</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Unlocking the Therapeutic Potential of Interleukin-22</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>immune-mediated inflammation</Res_KW1>
        <Res_KW2>chronic inflammation</Res_KW2>
        <Res_KW3>oxidative stress</Res_KW3>
        <Res_KW4>obesity</Res_KW4>
        <Res_KW5>metabolic disease</Res_KW5>
        <Plain_Description>I discovered that a factor released by our white blood cells, Interleukin-22, can suppress stress in cells. I designed a pancreas and liver targeted Interleukin-22 and applied it to models of metabolic disease. I have laid the groundwork to show that Interleukin-22 significantly improves liver health. This fellowship aims to build on this work and will allow me to gain key understanding of how Interleukin-22 suppresses stress and benchmark the therapy before we progress it into clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033747</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Day</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Establishment of a Translational Myositis Research Program</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | rheumatology and arthritis  | </Fields_of_Research>
        <Res_KW1>inflammatory myopathy</Res_KW1>
        <Res_KW2>autoimmune disease</Res_KW2>
        <Res_KW3>muscle damage</Res_KW3>
        <Res_KW4>chronic inflammatory disease</Res_KW4>
        <Res_KW5>myopathy</Res_KW5>
        <Plain_Description>Myositis occurs when the immune system inappropriately attacks muscles. Diagnosis and treatment are often delayed, resulting in permanent muscle damage and disability. I aim to develop better diagnostic tests using cutting-edge technologies. I will also investigate the causes of muscle damage and how these may be prevented. This research program will pave the way for better treatments and outcomes for myositis patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033771</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Cameron Turtle</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Identifying and overcoming mechanisms of failure of CD19 CAR-T cell immunotherapy for large B cell lymphoma</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biomedical and clinical sciences | immunology | tumour immunology  | </Fields_of_Research>
        <Res_KW1>t cell immunotherapy</Res_KW1>
        <Res_KW2>non-hodgkin lymphoma</Res_KW2>
        <Res_KW3>human malignant b-cell lymphoma</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>t cells</Res_KW5>
        <Plain_Description>Immune system T cells that can kill a cancer called large B cell lymphoma can be made in the lab. These engineered cells are known as chimeric antigen receptor modified T cells (CAR-Ts). CAR-Ts have revolutionised lymphoma treatment. However, most patients (~60%) can’t be cured by CAR-Ts. This proposal will study the qualities of CAR-Ts and the factors that block their function in lymphoma tumours. We will then develop new methods to engineer and improve CAR-Ts and test them in clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033783</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Katherine Kedzierska</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Harnessing optimal immunity for protection from life-threatening respiratory virus infections</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biological sciences | biochemistry and cell biology | receptors and membrane biology | </Fields_of_Research>
        <Res_KW1>immunology</Res_KW1>
        <Res_KW2>influenza</Res_KW2>
        <Res_KW3>cellular immunity</Res_KW3>
        <Res_KW4>viral immunology</Res_KW4>
        <Res_KW5>covid-19</Res_KW5>
        <Plain_Description>Respiratory viruses such as influenza and SARS-CoV-2 are constant threats to global health. Based on our pioneering studies, cutting-edge technologies and powerful clinical cohorts, this project will define optimal immunity against respiratory viruses, with a focus on protective killer T cells. We will identify key factors in life-threatening disease and decipher susceptibility in high-risk populations. This work will inform designs of new vaccines and therapies against severe viral infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033787</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Ebony Monson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Lipid droplets as novel antiviral extracellular communicators</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>lipid</Res_KW1>
        <Res_KW2>antiviral</Res_KW2>
        <Res_KW3>antiviral immunity</Res_KW3>
        <Res_KW4>innate immunity</Res_KW4>
        <Res_KW5>cell-cell communication</Res_KW5>
        <Plain_Description>Viral infections represent a significant global health issue and for many viruses, we still don’t have effective therapeutics. We showed that lipid droplets (LDs), produced by the host during viral infection underpin a successful innate immune response. This research program aims to better understand how LDs are secreted and how we can use them to combat viral infections. This will lead to the development of more effective antiviral treatments, relieving the rising burden of infectious diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033799</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Kirstine Bell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Paving the Way Towards a New National Screening Program for Type 1 Diabetes and Coeliac Disease for all Australian Children</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</Res_KW1>
        <Res_KW2>autoimmunity</Res_KW2>
        <Res_KW3>population screening</Res_KW3>
        <Res_KW4>paediatric</Res_KW4>
        <Res_KW5>coeliac disease</Res_KW5>
        <Plain_Description>Screening will be transformative for type 1 diabetes (T1D) and coeliac disease (CD), improving immediate and lifelong health outcomes and creating the opportunity for early treatment and ultimately prevention of these autoimmune conditions. This project aims to support a new national screening program for all Australian children, by 1) engaging with diverse Australians, 2) screening 10,000 children aged 2-13 years for T1D &amp; CD and 3) following-up children to understand long-term health impacts.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033803</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Norelle Sherry</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Harnessing pathogen genomics to understand and control antimicrobial resistance</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$504,640.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical bacteriology  | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>antimicrobial resistance</Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>clinical microbiology</Res_KW3>
        <Res_KW4>bacterial infection</Res_KW4>
        <Res_KW5>disease transmission</Res_KW5>
        <Plain_Description>Antibiotic-resistant bacteria are increasing globally, and cause significant illness and deaths. Genomic sequencing can help identify outbreaks and choose the best antibiotic treatments for patients, but new methods must be optimised for use in hospitals and communities. My research will harness these innovations to tackle antibiotic resistance, detecting outbreaks more efficiently, finding resistance in hospital wastewater, and better predicting antibiotic resistance from genomic data.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033811</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Uday Yadav</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Social referral initiatives: A transformative approach to improve the health and well-being of Aboriginal and Torres Strait Islander people with chronic conditions</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social, emotional, cultural and spiritual wellbeing | health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>chronic diseases</Res_KW2>
        <Res_KW3>primary care</Res_KW3>
        <Res_KW4>social determinants of health</Res_KW4>
        <Res_KW5>culturally appropriate methodology</Res_KW5>
        <Plain_Description>‘Social referral initiatives’ are a transformative approach for linking Aboriginal and Torres Strait Islander people with chronic conditions to a range of various services and supports. Connecting people from primary care to services and supports will address people’s unmet holistic needs. In the proposed research, I will evaluate how people with chronic conditions can be best supported to access services and participate in activities to manage their conditions and improve their quality of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033815</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr James Whittle</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Longitudinal analysis of glioma: identifying new biomarkers of treatment response</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,422,642.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | </Fields_of_Research>
        <Res_KW1>glioblastoma</Res_KW1>
        <Res_KW2>drug resistance</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>longitudinal study</Res_KW5>
        <Plain_Description>Glioblastoma (GBM) is an aggressive brain cancer with a dismal 5-year survival rate of 5%. Our collaborative research program GLIMMER (Glioma Liquid biopsy and Multi-omic Monitoring Enabled Research platform) will address the lack of effective treatment options with a pipeline of early to late translational science. The impact of this program will improve survival outcomes, quality of life and avoid unnecessary health burdens for this devastating disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033823</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Marina Naval Sanchez</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Deciphering the gene regulatory code of ageing to set the stage for therapeutic intervention</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | biological sciences | bioinformatics and computational biology | bioinformatics and computational biology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>gene regulation</Res_KW1>
        <Res_KW2>ageing</Res_KW2>
        <Res_KW3>transcription factor</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>As one in four Australians will be over 65 by 2056 (The Treasury, Australian Government), the frequency of age-related diseases, including degenerative diseases, will drastically increase. This program aims to elucidate the epigenetic and gene regulatory mechanisms driving ageing, which is critical to develop new therapeutic strategies that reduce age-onset disease and meet the growing healthcare needs of the ageing Australian population.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033832</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Cele Richardson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Developing Better Sleep and Circadian Interventions to Improve Sleep in Young People</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | applied and developmental psychology | child and adolescent development  | </Fields_of_Research>
        <Res_KW1>clinical psychology</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>sleep disturbance</Res_KW3>
        <Res_KW4>psychological treatment</Res_KW4>
        <Res_KW5>adolescent</Res_KW5>
        <Plain_Description>Sleep and circadian treatments are effective at improving both sleep and mental health problems, but current treatments do not meet the needs and priorities of adolescents and young adults. This research program will address this challenge by co-designing and evaluating i) a digital sleep and circadian intervention for young people and ii) a peer-led sleep intervention for young adults at university.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033834</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Yun Shi</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Molecular characterisation of NMNAT2 activity and regulation for neuroprotection</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biological sciences | biochemistry and cell biology | enzymes | chemical sciences | medicinal and biomolecular chemistry | biologically active molecules | </Fields_of_Research>
        <Res_KW1>protein structure</Res_KW1>
        <Res_KW2>drug discovery</Res_KW2>
        <Res_KW3>enzyme activity</Res_KW3>
        <Res_KW4>protein-protein interaction</Res_KW4>
        <Res_KW5>neuroprotection</Res_KW5>
        <Plain_Description>My project aims to study a brain biomolecule that protects nerve cells in the context of neurodegenerative disorders. With an interdisciplinary approach developed in my biochemistry program, I will determine the molecular and structural basis underlying the activity and regulation of this biomolecule and design chemicals to preserve its neuroprotective activities. This project will lay a fundamental framework to target this biomolecule to treat neurodegenerative diseases such as Alzheimer's.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033850</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Amy Freeman-Sanderson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Developing high-quality, clinically relevant and person-centred interventions to optimise communication function for adults with critical illness</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | speech pathology | </Fields_of_Research>
        <Res_KW1>intensive care</Res_KW1>
        <Res_KW2>intensive care medicine</Res_KW2>
        <Res_KW3>critical care</Res_KW3>
        <Res_KW4>critical illness</Res_KW4>
        <Res_KW5>speech pathology</Res_KW5>
        <Plain_Description>Critically ill patients admitted to ICUs often experience communication problems that persist during their stay and after discharge, adversely affecting their treatment experience, state of mind, and health and social outcomes. This project will involve patients, carers and health staff in designing interventions aimed at tackling these problems. The interventions will be tested and will inform future research that can then be put into practice in ICUs, addressing patients’ communication needs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033851</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Patrick Harris</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>New diagnostic strategies for antibiotic-resistant infections</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,362,265.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>genomics</Res_KW1>
        <Res_KW2>clinical microbiology</Res_KW2>
        <Res_KW3>molecular diagnostics</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Patients who develop bloodstream infections with drug-resistant bacteria are at increased risk of major complications and death. Conventional diagnostic methods are often slow and delay initiation of effective treatment.  My research aims to clinically evaluate novel molecular and genomics-based diagnostics in patients with life-threatening infections. The expected outcomes will lead to the development and application of new molecular and genomics-based methods, improving outcomes for patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033891</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Benjamin Solomon</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Advancing Precision Medicine for Lung Cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,739,264.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>non-small cell lung cancer</Res_KW1>
        <Res_KW2>translational research</Res_KW2>
        <Res_KW3>targeted therapy</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>anticancer drug</Res_KW5>
        <Plain_Description>Outcomes for patients diagnosed with lung cancer, the most deadly cancer in Australia and worldwide, remain poor. Through an integrated program of clinical trials with novel therapies and translational research to understand and overcome treatment resistance, we will develop new treatment strategies and understand how to match patients with the best treatments at all stages in their disease using an approach called precision medicine to improve outcomes for people with lung cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033906</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Laura Downie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Saving Sight in Uveitis: The cornea as a novel window to the ocular immune system</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | ophthalmology and optometry not elsewhere classified | biomedical and clinical sciences | ophthalmology and optometry | optical technology  | </Fields_of_Research>
        <Res_KW1>eye disease</Res_KW1>
        <Res_KW2>cornea</Res_KW2>
        <Res_KW3>optical imaging</Res_KW3>
        <Res_KW4>uveitis</Res_KW4>
        <Res_KW5>immune response</Res_KW5>
        <Plain_Description>My vision is to advance health outcomes for people living with uveitis, a condition that causes blindness from inflammation inside the eye. My program will address priority clinical needs for new, non-invasive ways to examine uveitis and optimise its treatment. My research focuses on analysing the immune cells in the eye using advanced techniques, including innovative imaging of corneal immune cells in patients, to improve the clinical diagnosis and treatment of this sight-threatening condition.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033915</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof William Heath</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Harnessing T cell immunity in the liver</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cd8 t cells</Res_KW1>
        <Res_KW2>vaccination</Res_KW2>
        <Res_KW3>immunologic memory</Res_KW3>
        <Res_KW4>malaria</Res_KW4>
        <Res_KW5>dendritic cell</Res_KW5>
        <Plain_Description>In 2021, malaria killed 619K people, largely because current vaccines are poorly effective. My vision is to characterize immunity to malaria and use this knowledge to design more effective vaccines. This work has identified previously unknown key immune cells that can fight malaria (not engaged by traditional vaccination approaches) and key parts of the parasite to attack. I will now develop pre-clinical studies advancing effective vaccines against malaria, including novel mRNA vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033917</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Matthew Page</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Novel approaches to enhance the quality of systematic reviews that underpin public health and policy decisions</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,503,775.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | mathematical sciences | statistics | biostatistics | </Fields_of_Research>
        <Res_KW1>evidence-based health care</Res_KW1>
        <Res_KW2>biostatistics</Res_KW2>
        <Res_KW3>meta-analysis</Res_KW3>
        <Res_KW4>methodology</Res_KW4>
        <Res_KW5>clinical practice guidelines</Res_KW5>
        <Plain_Description>Systematic reviews capture, and attempt to distil, all available evidence on a given question, and routinely underpin healthcare decision making. However, weaknesses in their quality mean that systematic reviews can mislead patients, health care providers and policy makers, leading to suboptimal care. My program will develop and evaluate novel technologies and tools to improve the quality of systematic reviews of health evidence, hence improving health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033919</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Yannick Alexandre</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Modulating stem-like T cells to resolve chronic infections and cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>fibroblasts</Res_KW1>
        <Res_KW2>chronic infection</Res_KW2>
        <Res_KW3>stromal cells</Res_KW3>
        <Res_KW4>cd8 t cells</Res_KW4>
        <Res_KW5>immune response</Res_KW5>
        <Plain_Description>Chronic viral infections and cancer remain a global health problem, affecting millions of people with limited treatment options. Specialised white blood cells called T cells are responsible for killing infected and cancer cells but become non-responsive during chronic infection or cancer, failing to control the disease. This program will explore new ways to target and reinvigorate T cells and aid in the design of new and improved treatments for chronic infections and cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033921</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Garnish</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Cell death at the host-pathogen interface</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | bacteriology  | biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>microbiology</Res_KW1>
        <Res_KW2>host/pathogen interaction</Res_KW2>
        <Res_KW3>intracellular bacterial infections</Res_KW3>
        <Res_KW4>cell death</Res_KW4>
        <Res_KW5>cell signalling</Res_KW5>
        <Plain_Description>Bacterial infections impose a significant health burden on the population worldwide. Programmed cell death is a crucial defense mechanism against bacterial pathogens however, many have developed weaponry to evade or delay cell death. This project will investigate how the bacterial pathogen, Coxiella burnetii, manipulates host cells during infection and inhibits cell death. Interrogating the evasion mechanisms deployed by Coxiella will assist in the development of novel therapeautic strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033928</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Bryant</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Improving Posttraumatic Mental Health</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander biomedical and clinical sciences | </Fields_of_Research>
        <Res_KW1>posttraumatic stress disorder (ptsd)</Res_KW1>
        <Res_KW2>aboriginal mental health</Res_KW2>
        <Res_KW3>cognitive behaviour therapy</Res_KW3>
        <Res_KW4>clinical psychology</Res_KW4>
        <Res_KW5>diagnostic algorithms</Res_KW5>
        <Plain_Description>Trauma is a major cause of psychiatric disorders worldwide. However, most people affected by trauma do not benefit from our best treatments. Further, most socially disadvantaged people do not receive proper care. This research program addresses both these problems by advancing how we treat posttraumatic mental health, reducing the barriers to mental health programs in Indigenous communities, and developing scalable interventions in low-and-middle-income countries.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033935</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Beth Temple</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Supporting reduced-dose pneumococcal conjugate vaccine use in low- and middle-income countries through reduced-dose schedules and opportunistic vaccination approaches</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$589,520.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | biomedical and clinical sciences | paediatrics | infant and child health | health sciences | epidemiology | major global burdens of disease | </Fields_of_Research>
        <Res_KW1>pneumococcal vaccination</Res_KW1>
        <Res_KW2>immunogenicity</Res_KW2>
        <Res_KW3>alternative vaccination strategies</Res_KW3>
        <Res_KW4>child health</Res_KW4>
        <Res_KW5>microbiology</Res_KW5>
        <Plain_Description>Pneumococcal conjugate vaccines (PCVs) protect against diseases like pneumonia and meningitis but are expensive for countries to provide and often don’t reach those most in need. My research aims to find more cost-effective ways for countries to use PCVs and to find new ways for people to receive these life-saving vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033943</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Daniel Poppe</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Mature neuronal cell culture systems for the study of human disease</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | biological sciences | biochemistry and cell biology | cell development, proliferation and death | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | </Fields_of_Research>
        <Res_KW1>stem cells</Res_KW1>
        <Res_KW2>brain cell cultures</Res_KW2>
        <Res_KW3>brain development</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>neuroscience</Res_KW5>
        <Plain_Description>Diseases affecting the brain are often studied using cells cultured in a laboratory, but drugs discovered this way often fail when given to patients. This happens because most cells generated outside the body remain in a young state, which may not be suitable for studying diseases that affect older adults. This project seeks to identify how cell cultured neurons are different to neurons found in a human brain and uses that knowledge to improve their maturation and similarity to real neurons.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033949</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Haruo Usuda</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Artificial Placenta Development -A New Life Support System for Premature Babies</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | paediatrics | infant and child health | biomedical and clinical sciences | reproductive medicine | foetal development and medicine | </Fields_of_Research>
        <Res_KW1>neonatology</Res_KW1>
        <Res_KW2>premature infant</Res_KW2>
        <Res_KW3>neonatal intensive care (nicu)</Res_KW3>
        <Res_KW4>very low birth weight infant</Res_KW4>
        <Res_KW5>fetal development</Res_KW5>
        <Plain_Description>Preterm birth is the leading cause of perinatal death and disease in Australia; extremely preterm infants (EPIs) are at the highest risk. The underdeveloped lung makes current ventilation therapies of limited use to EPIs. My program will develop artificial placenta technology for EPIs, obviating the need for pulmonary ventilation. I will simultaneously leverage this unique placental-knockout system to optimize fetal assessments and generate new knowledge for healthy fetal growth and development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033951</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Kirill Alexandrov</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Artificial protein circuits and the next generation diagnostics</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | synthetic biology | biomedical and clinical sciences | medical biotechnology | medical molecular engineering of nucleic acids and proteins | biomedical and clinical sciences | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | </Fields_of_Research>
        <Res_KW1>biochemistry</Res_KW1>
        <Res_KW2>protein biochemistry</Res_KW2>
        <Res_KW3>biosensor</Res_KW3>
        <Res_KW4>diagnostic</Res_KW4>
        <Res_KW5>biomedical engineering</Res_KW5>
        <Plain_Description>To ensure high-quality healthcare we need advancements in disease diagnostics. I will use synthetic biology to develop technologies for detecting and monitoring diseases. These technologies can be used by both doctors and patients through simple devices. By doing so, the costs associated with disease detection will decrease, patients will be able to monitor their conditions on their own, and medical care will become more effective with computational prediction of health status.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033958</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Matthias Ernst</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Improving the response to anti-cancer therapy</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>gastrointestinal tumourigenesis</Res_KW1>
        <Res_KW2>macrophages</Res_KW2>
        <Res_KW3>src-family tyrosine kinases</Res_KW3>
        <Res_KW4>cytokine biology</Res_KW4>
        <Res_KW5>epithelial cells</Res_KW5>
        <Plain_Description>While immunotherapy has transformed treatment for some cancer patients, most remain resistant to these drugs. I therefore will investigate how the response to immunotherapy can be improved through a better understanding of mechanisms that limit the response.  I will investigate how the the normal cell surrounding the tumour cells protect the latter from being killed by immune cells and develop novel therapeutics that can reverse the immune protective aspects conferred by these normal cells.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033961</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Julie McMullen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Targeting the protective properties of exercise to prevent and treat heart failure, atrial fibrillation and cardiometabolic disease in males and females</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,324,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>animal model</Res_KW1>
        <Res_KW2>molecular basis of disease</Res_KW2>
        <Res_KW3>cardiomyocytes</Res_KW3>
        <Res_KW4>cardioprotection</Res_KW4>
        <Res_KW5>therapeutic agents</Res_KW5>
        <Plain_Description>The prevalence of heart failure, atrial fibrillation, and metabolic disorders is increasing. The aim of this research is to identify new therapeutic approaches &amp; risk prediction markers of heart disease by understanding the differences between a healthy heart and failing heart in both males and females. The expected outcomes are the development of new therapies, and the identification of blood markers which aid in the earlier detection of people at risk of heart disease.    </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033963</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Chris Maher</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>ENSURING AUSTRALIANS WITH BACK PAIN RECEIVE THE RIGHT CARE</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | health sciences | health services and systems | health systems | </Fields_of_Research>
        <Res_KW1>low back pain</Res_KW1>
        <Res_KW2>health services</Res_KW2>
        <Res_KW3>musculoskeletal disorders</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>clinical effectiveness</Res_KW5>
        <Plain_Description>An Investigator Fellowship would support me to complete a program of research comprising (i) clinical trials evaluating therapies for low back pain and (ii) research to improve health service delivery for low back pain. The goal is to ensure that Australians with back pain receive the right care</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033976</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jeggan Tiego</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Understanding the structure and genetic and neurobiological mechanisms of adult psychopathology</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical and health psychology not elsewhere classified | psychology | other psychology  | other psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>psychopathology</Res_KW1>
        <Res_KW2>behaviour genetics</Res_KW2>
        <Res_KW3>neuroimaging</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>psychiatry</Res_KW5>
        <Plain_Description>Mental illness affects 2 in 5 (43.7% or 8.6 million) Australians aged 16 – 85 years over the course of their lifetime. Existing systems for classifying and researching mental illness have failed to provide insights into underlying mechanisms with clear therapeutic implications. Using a novel framework, I will characterise all the major dimensions of adult psychopathology and their mechanisms, facilitating the development of more effective prevention strategies and therapeutic interventions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033989</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Dargaville</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Safer oxygen therapy for preterm infants through automated oxygen titration</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$2,462,040.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | engineering | biomedical engineering | medical devices | </Fields_of_Research>
        <Res_KW1>premature birth</Res_KW1>
        <Res_KW2>oxygen toxicity</Res_KW2>
        <Res_KW3>neonatal respiratory distress syndrome</Res_KW3>
        <Res_KW4>oxygen therapy</Res_KW4>
        <Res_KW5>biomedical engineering</Res_KW5>
        <Plain_Description>Preterm infants frequently require breathing support and oxygen therapy, and are at risk of adverse effects arising from low blood oxygen levels, but are also uniquely vulnerable to oxygen toxicity. Innovative technology to automatically adjust delivered oxygen concentration stabilises oxygen levels. This research will apply this novel technology throughout the patient journey for preterm infants in both high- and low-resource settings, leading to improved oxygenation and clinical outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033999</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Camelia Quek</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Dissecting the cancer ecosystem as a precision medicine approach towards improving patient outcomes with high-risk melanoma</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | sequence analysis | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | clinical sciences | pathology (excl. oral pathology) | </Fields_of_Research>
        <Res_KW1>melanoma</Res_KW1>
        <Res_KW2>expression profiling</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>Melanoma is a significant health problem and the commonest cancer in young Australians, accounting for 75% of all skin cancer deaths. Although modern medicine is used to harness the body’s immune system to fight cancer, most patients recur or develop resistant after initial treatment. This research program investigates how tumour immune microenvironment helps cancer cells evade treatment and uncovers cancer vulnerabilities for each individual patient to advance precision medicine strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034000</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr James Pang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Next-generation techniques for mapping and modelling brain changes in clinical disorders</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | cognitive neuroscience | </Fields_of_Research>
        <Res_KW1>magnetic resonance imaging (mri)</Res_KW1>
        <Res_KW2>neuroimaging</Res_KW2>
        <Res_KW3>brain disorders</Res_KW3>
        <Res_KW4>neuropsychiatric disorders</Res_KW4>
        <Res_KW5>brain mapping</Res_KW5>
        <Plain_Description>Psychiatric and neurological conditions are among the world’s leading causes of disease burden. This Fellowship will deliver next-generation techniques to map and model how these conditions affect the brain, advancing our understanding of their causes and informing strategies for future clinical interventions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034002</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Jason Grebely</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Enhancing hepatitis C testing, treatment, and prevention to facilitate elimination</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>hepatitis c infection</Res_KW1>
        <Res_KW2>treatment outcomes</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>diagnostic</Res_KW4>
        <Res_KW5>clinical epidemiology</Res_KW5>
        <Plain_Description>The World Health Organization has set a goal to eliminate hepatitis C as a major global public health threat by 2030. However, globally, only 20% of people have been diagnosed and 1% have received treatment. My research program will evaluate interventions to enhance hepatitis C testing, treatment, and prevention to facilitate disease elimination. This research will improve clinical management, transform health service delivery, and inform policy, placing Australia at the global forefront.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034008</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Priscila Pereira Machado</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Responding to the burden of chronic diseases attributable to ultra-processed foods in Australia</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | nutrition and dietetics | public health nutrition | biomedical and clinical sciences | nutrition and dietetics | nutrition and dietetics not elsewhere classified | </Fields_of_Research>
        <Res_KW1>nutrition</Res_KW1>
        <Res_KW2>public health policy</Res_KW2>
        <Res_KW3>diet</Res_KW3>
        <Res_KW4>obesity</Res_KW4>
        <Res_KW5>disease prevention</Res_KW5>
        <Plain_Description>Almost half of Australians’ diet comprises ultra-processed foods (UPFs). UPFs have been linked to poor diets, obesity, diabetes, cancer and other diseases in many countries. People are eating more UPFs each year, many without being aware of their harms. This research program will create new knowledge on UPF consumption trends and health impacts, develop a framework to increase consumer awareness of UPFs, and create and test a warning label to help UPFs identification in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034017</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Conor Kearney</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Systematic Identification of Novel Immunotherapy Targets </Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,278,300.66</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | oncology and carcinogenesis not elsewhere classified | </Fields_of_Research>
        <Res_KW1>anticancer drug</Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>cancer immunology</Res_KW3>
        <Res_KW4>cancer immunotherapy</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>The human immune system is capable of recognising and eliminating cells that have become cancerous. Cancer Immunotherapies have revolutionized medical oncology and are now recognised as one of the core pillars of cancer treatment.Despite the success of immunotherapies, responses are limited to a subgroup of patients in particular cancer types and patients frequently relapse. This project aims to identify new druggable targets that improve current immunotherapies.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034034</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Bei Bei</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Healthy sleep: Advancing the treatment and prevention of insomnia</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,403,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | clinical and health psychology | health psychology | </Fields_of_Research>
        <Res_KW1>insomnia</Res_KW1>
        <Res_KW2>sleep disorders</Res_KW2>
        <Res_KW3>cognitive behaviour therapy</Res_KW3>
        <Res_KW4>sleep onset insomnia</Res_KW4>
        <Res_KW5>sleep</Res_KW5>
        <Plain_Description>Insomnia is the most common sleep disorder, causing significant distress, impairment, and societal burden. The first-line treatment for insomnia is effective but is largely not accessible to the community. Further, there are no current insomnia prevention programs in Australia. This proposal will (1) create new knowledge to inform the treatment and prevention of insomnia, and (2) co-design evidence-based treatment and prevention with stakeholders and community involvement.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034044</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Christopher Horne</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Illuminating mechanisms of calcium signalling and their role in human disease</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>protein kinases</Res_KW1>
        <Res_KW2>protein biochemistry</Res_KW2>
        <Res_KW3>cell signalling</Res_KW3>
        <Res_KW4>calcium binding proteins</Res_KW4>
        <Res_KW5>structural biology</Res_KW5>
        <Plain_Description>Calcium ions are important molecules that help cells to carry out their functions properly. Our bodies perform this role using calcium-binding proteins, but if this process doesn't work correctly, it can lead to human disease. My research has found new ways that calcium and calcium-binding proteins interact. Using advanced techniques, this project will determine how these interactions function in our body, and how we can therapeutically target these interactions to treat human disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034047</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Caitlin Hitchcock</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Harnessing digital technologies to scale trauma-focussed mental healthcare</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | psychology | cognitive and computational psychology | cognitive and computational psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>posttraumatic stress disorder (ptsd)</Res_KW1>
        <Res_KW2>rural and remote health</Res_KW2>
        <Res_KW3>episodic memory</Res_KW3>
        <Res_KW4>cognitive therapy</Res_KW4>
        <Res_KW5>clinical psychology</Res_KW5>
        <Plain_Description>Up to 75% of people experience trauma in their lifetime, but many people with trauma-related mental health problems never receive any treatment. We urgently need to improve access to psychological treatment, especially in rural Australia. I will roll-out a new, online, psychological support program which fulfils this need, and deliver new technology to allow large-scale identification of those who need support, alleviating the growing global crises of climate-related natural disasters and war.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034064</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Celina Jin</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Investigating host immunity against Cryptosporidium infection to accelerate vaccine development.</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical microbiology | medical parasitology  | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cryptosporidium</Res_KW1>
        <Res_KW2>vaccine design</Res_KW2>
        <Res_KW3>host/pathogen interaction</Res_KW3>
        <Res_KW4>cellular immunity</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Cryptosporidium parasites are a leading cause of diarrhoea in children. My goal is to fast-track the development of vaccines targeting Cryptosporidium. Using a challenge model, which involves deliberately infecting healthy volunteers, I will study protective responses to infection. I will combine this with animal studies to identify which parasite components trigger these protective responses. This will lead to new understandings of how best to develop vaccines against Cryptosporidium infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034082</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Anthony Cunningham</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Complementary studies of HIV and Herpes Simplex Viral infection of genital mucosa and the mechanism of action of systemically delivered vaccines</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv)</Res_KW1>
        <Res_KW2>vaccines</Res_KW2>
        <Res_KW3>herpes simplex virus (hsv)</Res_KW3>
        <Res_KW4>mucosal immunology</Res_KW4>
        <Res_KW5>interferon (ifn)</Res_KW5>
        <Plain_Description>We will study the infection of human genital skin by the sexually transmitted viruses HIV and Herpes simplex virus (HSV)  which share similarities, differences and interactions: prior genital HSV infection predisposes to HIV acquisition. Mapping the spread of HIV and HSV viruses in skin to nerves or immune cells and subsequent effects will help guide vaccine development. We will compare these studies with immune responses to delivery of highly effective vaccines into lymph nodes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034092</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Yvonne Clark</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Investing in the early years to improve social and emotional wellbeing (SEWB) of Aboriginal parents and young people. </Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute Limited</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,614,775.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander child health and wellbeing | psychology | applied and developmental psychology | applied and developmental psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>aboriginal mental health</Res_KW1>
        <Res_KW2>childhood</Res_KW2>
        <Res_KW3>trauma</Res_KW3>
        <Res_KW4>wellbeing</Res_KW4>
        <Res_KW5>strength</Res_KW5>
        <Plain_Description>This research focuses on strengthening social and emotional wellbeing (SEWB) and empowering Aboriginal adolescents and post pregnant mothers and their support people including dads. Adolescence and post pregnancy are two life phases which may be stressful, particularly if there is underlying trauma. Empowering Aboriginal adolescents and new parents in designing ways to strengthen SEWB to reduce stress from lateral violence and trauma and propose improved culturally safe family focused services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034104</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof James Murphy</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Killing zombies: the emergence of dead enzymes as therapeutic targets in inflammatory disease</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | signal transduction | biological sciences | biochemistry and cell biology | enzymes | biological sciences | biochemistry and cell biology | proteomics and intermolecular interactions (excl. medical proteomics) | </Fields_of_Research>
        <Res_KW1>kinases</Res_KW1>
        <Res_KW2>protein interactions</Res_KW2>
        <Res_KW3>cell signalling</Res_KW3>
        <Res_KW4>cell death</Res_KW4>
        <Res_KW5>necrosis</Res_KW5>
        <Plain_Description>Every day, millions of our cells undergo an orchestrated cell death. How these cells die can encode additional information, such as to prompt an immune reaction to an invading virus. When one such pathway - necroptosis - is dysregulated, inflammatory diseases, such as inflammatory bowel disease, can arise. Here, we will perform detailed studies to understand how the pathway works on the molecular, cellular and organ scale. Such knowledge will inform ways to drug the pathway therapeutically.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034108</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Miles Davenport</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Translational Analytics: Integrating experimental and clinical data to understand vaccination and immunity</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | mathematical sciences | statistics | biostatistics | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>medical virology</Res_KW1>
        <Res_KW2>mathematical modelling</Res_KW2>
        <Res_KW3>human immunodeficiency virus (hiv)</Res_KW3>
        <Res_KW4>clinical microbiology</Res_KW4>
        <Res_KW5>biostatistics</Res_KW5>
        <Plain_Description>Experimental methods have advanced rapidly to improve our understanding of infection and immunity. However, we need novel analytical approaches to incorporate pre-clinical studies to provide evidence-based guidance for the development and clinical use of vaccines and therapeutics. Translational analytics uses quantitative, interdisciplinary, collaborative approaches to harness the power of experimental data to inform policy and practice in treatment and control of infectious diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034122</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Yue Wang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Advanced nanoplatform for modulated macrophage phenotype and enhanced gene delivery against bacterial infection</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | biomedical engineering not elsewhere classified | chemical sciences | macromolecular and materials chemistry | inorganic materials (incl. nanomaterials) | biological sciences | industrial biotechnology | nanobiotechnology | </Fields_of_Research>
        <Res_KW1>nanotechnology</Res_KW1>
        <Res_KW2>messenger rna (mrna)</Res_KW2>
        <Res_KW3>drug delivery systems</Res_KW3>
        <Res_KW4>biomaterials</Res_KW4>
        <Res_KW5>biomedical engineering</Res_KW5>
        <Plain_Description>Bacterial infection, particularly antibiotic resistant bacteria, poses a major health burden in Australia, calling for new antibiotic-free therapeutic strategies. This project aims to develop an advanced nanoplatform technology to educate the immune system to kill bacteria. Outcomes include a new nanoplatform with enhanced efficacy and clinical application potential, which will significantly benefit healthcare and advance Australia's leadership in the global gene technology market.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034130</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Whitehouse</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Developing effective, efficient and scalable clinical pathways for autistic children</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | community child health  | </Fields_of_Research>
        <Res_KW1>autism spectrum disorders</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>community child health</Res_KW3>
        <Res_KW4>neurodevelopmental disorders</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Autism is a lifelong neurodevelopmental disability that is diagnosed in 3% of Australians. This research program will address three of the most urgent challenges affecting clinical care for autistic children. By combining expertise from various fields, this program will seek to discover more effective ways to support babies with early delays, new methods to diagnose children more efficiently, and critical knowledge about how to deliver personalised interventions that reduce lifelong disability.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034141</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Dharmesh Bhuva</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Studying the topology of cancer tissue and its microenvironment to identify topological biomarkers.</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | bioinformatic methods development | biological sciences | bioinformatics and computational biology | biological network analysis | information and computing sciences | computer vision and multimedia computation | pattern recognition | </Fields_of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>applied statistics</Res_KW2>
        <Res_KW3>image analysis</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>gene expression</Res_KW5>
        <Plain_Description>Just as blueprints are essential in understanding and repairing a damaged building, our tissues have a specific organization that gets disrupted in cancers. Using advanced tools, akin to a "biological magnifying glass", I will develop software to closely examine and map damages, helping doctors predict how a cancer might respond to treatment or progress, much like predicting a building's stability from its blueprint.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034148</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Allison Carter</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Reaching Global Targets for HPV Vaccination in Australia: Toward Equity for People with Disability</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>human papillomavirus (hpv)</Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>disability</Res_KW3>
        <Res_KW4>adolescent health</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Adolescents with disability face persistent barriers to vaccination against human papillomavirus (HPV). This research program aims to develop, implement and evaluate a specialised school-based intervention to increase HPV and routine vaccine uptake in this group, through co-design with consumers and providers. Outcomes are expected to inform practice and policy to optimise the delivery of programs in all jurisdictions and advance health equity for people the disability in Australia and globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034150</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Kristiana Ludlow</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving frailty knowledge and empowering behaviour change via a co-designed Frailty Hub for healthcare consumers and caregivers</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | public health | health promotion | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>participatory action research</Res_KW1>
        <Res_KW2>behaviour change</Res_KW2>
        <Res_KW3>frailty</Res_KW3>
        <Res_KW4>health education</Res_KW4>
        <Res_KW5>consumer participation</Res_KW5>
        <Plain_Description>Frailty refers to declines in cognitive and physical capacity leading to poor health outcomes. Frailty is modifiable, meaning that it can be prevented, reduced or even reversed. This research aims to co-design a digital platform called “The Frailty Hub” that contains education modules, resources, and goal-setting activities. It is expected that the Frailty Hub will improve consumers’ knowledge of frailty and provide them with the skills and resources to prevent and manage frailty.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034174</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas Hunt</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Nanocarriers for oral biologic delivery</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical delivery technologies | </Fields_of_Research>
        <Res_KW1>drug delivery</Res_KW1>
        <Res_KW2>targeted gene delivery</Res_KW2>
        <Res_KW3>pharmaceutics</Res_KW3>
        <Res_KW4>immunological intervention</Res_KW4>
        <Res_KW5>nanotechnology</Res_KW5>
        <Plain_Description>My research program will spearhead the development of next generation nanomedicine therapies for oral biologic delivery. Over the last 5 years I have led a nanotechnology-focused drug discovery pipeline from technology conception to pre-trial development. During this fellowship I will further develop this technology for delivery of immuno- and gene- therapies and support the clinical translation of our oral insulin and immune prevention treatment for type 1 diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034194</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Elliot Long</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Transforming clinical care for children with sepsis</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$589,520.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | epidemiology | disease surveillance | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>sepsis</Res_KW1>
        <Res_KW2>clinical epidemiology</Res_KW2>
        <Res_KW3>paediatric</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>clinical guidelines</Res_KW5>
        <Plain_Description>Sepsis refers to any life-threatening infection, and is of national importance due to its burden on children, families, and healthcare systems. Early treatment saves lives. This program will develop methods to identify children with sepsis early and establish the most effective treatments. The goal is to reduce preventable deaths from this devastating disease globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034195</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Miles Andrews</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Androgen disruption as a novel treatment approach in hormone 'insensitive' cancers</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>sex differences</Res_KW1>
        <Res_KW2>cancer immunotherapy</Res_KW2>
        <Res_KW3>androgen-response</Res_KW3>
        <Res_KW4>solid tumours</Res_KW4>
        <Res_KW5>targeted therapy</Res_KW5>
        <Plain_Description>Females and males experience cancer differently, ultimately having unequal treatment outcomes and survivals, but it remains poorly understood why. Emerging evidence shows striking effects on cancer therapy responses attributable to adverse effects of androgens, the group of male sex hormones. This research aims to tease apart the mechanisms by which androgens negatively impact melanoma and lung cancer outcomes and use this knowledge to develop better cancer treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034202</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Julee McDonagh</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>FRAIL-CVD: a co-designed multi-component intervention to improve frailty and health-related quality-of-life in adults with cardiovascular disease</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | health sciences | nursing | nursing not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>cardiovascular disease</Res_KW1>
        <Res_KW2>nursing care</Res_KW2>
        <Res_KW3>frailty</Res_KW3>
        <Res_KW4>gerontology</Res_KW4>
        <Res_KW5>multidisciplinary</Res_KW5>
        <Plain_Description>This program will explore strategies to improve frailty in adults with cardiovascular disease (CVD). CVD is extremely common in Australia. Around half of those with CVD will also develop frailty, a devastating syndrome of ‘accelerated aging’, resulting in more hospital visits and health system strain and poorer quality-of-life. This program aims to develop, test and evaluate a novel co-designed intervention to reduce hospital visits and improve frailty and quality-of-life in adults with CVD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034209</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Laura Mackay</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Unravelling the Diversity and Function of Tissue-Resident Lymphocytes</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>t cell memory</Res_KW1>
        <Res_KW2>cellular immunity</Res_KW2>
        <Res_KW3>t cell immunity</Res_KW3>
        <Res_KW4>t cells</Res_KW4>
        <Res_KW5>immunotherapy</Res_KW5>
        <Plain_Description>Whilst some T cells patrol the blood, a unique subset called tissue-resident memory T cells (TRM) exists within tissues of the body. These cells provide critical immune protection against infection and cancer, and are associated with improved survival rates in patients with various cancers. This project will advance our understanding of how TRM can be generated and controlled, with a view to harness these cells for enhanced immune protection against disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034225</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Melissa Sharpe</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Discovery of a novel dopamine circuit that uniquely contributes to methamphetamine use disorder</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | biological psychology  | behavioural neuroscience | </Fields_of_Research>
        <Res_KW1>dopamine</Res_KW1>
        <Res_KW2>drug addiction</Res_KW2>
        <Res_KW3>hypothalamus</Res_KW3>
        <Res_KW4>learning</Res_KW4>
        <Res_KW5>behaviour</Res_KW5>
        <Plain_Description>Methamphetamine dependence is an increasing problem in Australia. It is not easy to treat methamphetamine dependence with psychological therapies. Finding a drug treatment is critical. Our new data in this proposal point to a new circuit in the brain that contributes to a fundamental cognitive process that is changed in addiction and drives future drug seeking and relapse. This research will reveal if this new circuit is a viable target for drug development to treat methamphetamine addiction.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034232</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Cassandra Wannan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Multi-Axial Profile Scores (MAPS): A Personalised Fingerprinting Framework for Improving Diagnosis and Treatment of Psychiatric Disorders</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | psychology | applied and developmental psychology | applied and developmental psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>child behaviour</Res_KW1>
        <Res_KW2>youth</Res_KW2>
        <Res_KW3>mental health</Res_KW3>
        <Res_KW4>individualising management</Res_KW4>
        <Res_KW5>clinical diagnosis</Res_KW5>
        <Plain_Description>Mental illness is a leading cause of disability in people aged &lt;25. While early diagnosis and intervention are critical for reducing disability and improving outcomes, there are currently no clinical decision support tools available for use in child and youth mental health settings. I will optimise and translate a novel biopsychosocial "fingerprinting" framework to improve early diagnosis of mental illness and assist clinicians to develop intervention strategies personalised to each patient.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034258</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Terence O'Brien</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Applying innovative approaches to developing transformational treatments for people with drug resistant epilepsy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>adult stem cells</Res_KW2>
        <Res_KW3>epilepsy surgery</Res_KW3>
        <Res_KW4>antiepileptic drugs</Res_KW4>
        <Res_KW5>biomedical engineering</Res_KW5>
        <Plain_Description>The goal of my research program is to develop life-changing new treatments approaches for people with epilepsy. I will achieve this by harnessing advances in technology and multidisciplinary collaborations to identify treatments that reduce seizures, disability and risk of death or other adverse outcomes in a sustained manner, and innovative ways to predict the outcomes of treatments to enable “precision therapy” targeting of treatments to people who are most likely to benefit from them.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034261</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Stephanie Topp</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Revolutionising equitable health workforce policy and planning in Australia </Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,483,020.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems | human society | policy and administration | health policy | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>health policy evaluation</Res_KW1>
        <Res_KW2>equity</Res_KW2>
        <Res_KW3>workforce policy</Res_KW3>
        <Res_KW4>rural workforce</Res_KW4>
        <Res_KW5>health service accessibility</Res_KW5>
        <Plain_Description>Developing a strong health workforce is a national priority. This proposal outlines a novel research program to examine the design and implementation of health workforce policy at federal, state and territory levels. It will map existing policies, identify policy gaps, and examine the influence and impacts of different stakeholders in policy design and implementation. Findings will clarify priority policy targets and  effective approaches to achieving equitable and efficient workforce policy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034266</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Lazzarini</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Better feet, better lives: Next generation care for people with diabetes foot disease</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | podiatry | biomedical and clinical sciences | clinical sciences | endocrinology | health sciences | health services and systems | health systems | </Fields_of_Research>
        <Res_KW1>chronic leg or foot ulcers</Res_KW1>
        <Res_KW2>clinical studies</Res_KW2>
        <Res_KW3>wound healing</Res_KW3>
        <Res_KW4>diabetic complications</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>One in 40 people live with diabetes foot disease and often can’t feel pain, ulcers or infections until hospitalised or amputated. Best care prevents half of all hospitalisations and amputations, yet few people get this care. My research will test a number of next generation tools and treatments designed to empower people with diabetes foot disease to better detect, self-care and access best care, for better feet, better lives and a better world with half the hospitalisations and amputations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034281</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Jane Visvader</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Deciphering mechanisms underlying breast cancer to improve patient outcomes</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer cell biology | </Fields_of_Research>
        <Res_KW1>breast cancer</Res_KW1>
        <Res_KW2>mouse models</Res_KW2>
        <Res_KW3>mammary gland cancer</Res_KW3>
        <Res_KW4>stem cell biology</Res_KW4>
        <Res_KW5>developmental biology</Res_KW5>
        <Plain_Description>My team has discovered breast stem and progenitor cells that generate the ductal system and provided a single cell breast 'roadmap'. These provide a key framework for identifying regulators of normal development and the earliest changes that occur when a cell becomes cancerous. This research program will provide insights into mechanisms that lead to cancer initiation, progression and drug resistance, using cutting-edge technologies and preclinical models to enable translation to the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034282</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Eva Stadler</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Protecting the immunosuppressed from COVID-19</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | mathematical sciences | applied mathematics | biological mathematics  | biomedical and clinical sciences | immunology | immunology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>mathematical modelling</Res_KW1>
        <Res_KW2>antiviral therapy</Res_KW2>
        <Res_KW3>sars-cov-2</Res_KW3>
        <Res_KW4>monoclonal antibody</Res_KW4>
        <Res_KW5>data analysis</Res_KW5>
        <Plain_Description>Through either vaccination or infection, most people now possess some degree of immune protection from COVID-19. However, nearly 2 in 10 people in Australia have some degree of immunosuppression which can leave them susceptible to severe COVID-19. This project aims to link clinical and laboratory data to identify at-risk individuals, develop strategies for the optimal use of vaccines and treatments to protect them from COVID-19, and to inform treatment guidelines to protect the most vulnerable.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034290</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Bronwyn Griffin</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>A new implementable early burn care intervention strategy for children across Australia</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | rural clinical health | biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified | biomedical and clinical sciences | clinical sciences | emergency medicine | </Fields_of_Research>
        <Res_KW1>burn injury</Res_KW1>
        <Res_KW2>acute pain</Res_KW2>
        <Res_KW3>child health</Res_KW3>
        <Res_KW4>emergency medicine</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Children with burns require special, often complex treatments within 24 hours of injury to effectively reduce the impact of injury and minimise chronic physical and emotional scars. Unfortunately, treatments are often not implemented (e.g. first aid), are too complex (emerging technologies), or patients are too far away (e.g. in regional and remote areas of Australia). My research aims to test simple new technologies to make sure every child, no matter where they live, gets the best care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034292</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Glenda Halliday</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Cell type and organelle specific identification of molecular mechanisms initiating and propagating neurodegenerative diseases</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | biomedical and clinical sciences | neurosciences | central nervous system  | biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>neurodegeneration</Res_KW1>
        <Res_KW2>alpha-synuclein</Res_KW2>
        <Res_KW3>frontotemporal dementia</Res_KW3>
        <Res_KW4>parkinson disease</Res_KW4>
        <Res_KW5>neuroglia</Res_KW5>
        <Plain_Description>Degeneration starts in the brain long before any clinical symptoms are obvious. This research aims to identify the different organelles within brain cells that become dysfunctional before and after a diagnosis of frontotemporal and Lewy body dementias (more lethal than Alzheimer’s intself) and Parkinson's disease. Analysis of samples from brain donors at different disease stages will determine which organelles are affected before obvious pathology to indicate new treatment opportunities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034293</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Boris Martinac</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Molecular basis of cardiac mechanotransduction: Focus on Piezo ion channels </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,581,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | receptors and membrane biology | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biological sciences | biochemistry and cell biology | signal transduction | </Fields_of_Research>
        <Res_KW1>biophysics</Res_KW1>
        <Res_KW2>molecular basis of disease</Res_KW2>
        <Res_KW3>patch clamp</Res_KW3>
        <Res_KW4>fluorescence spectroscopy</Res_KW4>
        <Res_KW5>molecular biology</Res_KW5>
        <Plain_Description>Mechanical force is increasingly recognised as a major regulator of both cell structure and function with a significant role in pathology of disease. This is especially true for heart and lungs as both are mechanically very active organs. This research will study cellular membrane proteins that convert mechanical force into biological signals, which promises to make significant contribution to our understanding of their role in human health and disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034294</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Roberts</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Enhancing the activity of BH3 mimetic drugs in blood cancers</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,588,978.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | </Fields_of_Research>
        <Res_KW1>bcl-2</Res_KW1>
        <Res_KW2>apoptosis</Res_KW2>
        <Res_KW3>leukaemia</Res_KW3>
        <Res_KW4>lymphoma</Res_KW4>
        <Res_KW5>multiple myeloma</Res_KW5>
        <Plain_Description>To significantly improve outcomes for patients with currently incurable blood cancers (leukaemias, lymphomas, myeloma), new types of anti-cancer therapy are required. We will build on our past research with venetoclax, the first of a new class of anti-cancer drug, which has recently improved outcomes for people with some leukaemias. Over the next five years, my team will work in the lab and in clinic trials to find ways to enhance the activity of venetoclax and new drugs that work similarly.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034308</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jodie Ingles</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Using genomics to diagnose and manage patients with inherited cardiac disorders</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>genetic testing</Res_KW1>
        <Res_KW2>sudden cardiac death</Res_KW2>
        <Res_KW3>genetic counselling</Res_KW3>
        <Res_KW4>familial hypertrophic cardiomyopathy</Res_KW4>
        <Res_KW5>genetic variation</Res_KW5>
        <Plain_Description>Cardiovascular diseases affecting children, adolescents and young adults are often genetic and can have significant burden including risk of sudden cardiac death. Genetic testing is a key part of management, however, only 40% have a genetic cause identified impacting on care of the family. My vision is to apply genomics and genetic counselling equitably, to improve care for all, to clarify diagnosis and refine risk for families with inherited cardiac diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034321</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Aleksandra Petrovic Fabijan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Phage therapy: translating research evidence into clinical application</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$632,308.82</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biological sciences | microbiology | bacteriology  | biomedical and clinical sciences | medical microbiology | medical bacteriology  | </Fields_of_Research>
        <Res_KW1>bacteriophage</Res_KW1>
        <Res_KW2>antimicrobial therapy</Res_KW2>
        <Res_KW3>medical bacteriology</Res_KW3>
        <Res_KW4>antibiotic resistance</Res_KW4>
        <Res_KW5>bacterial infection</Res_KW5>
        <Plain_Description>Phage therapy is promising solution for antibiotic-resistant infections but can sometimes be ineffective in patients. Research suggests that commonly used phages cannot kill certain forms of bacteria called "L-forms", often present in infections for which phage therapy is recommended. To address this challenge, this project will use advanced technologies to study the complex interactions between bacteria and phages and develop a new generation of phage therapeutics to prevent treatment failure.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034386</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Ms Shania Liu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Reducing the harms associated with inappropriate opioid use before spine surgery</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | pain | </Fields_of_Research>
        <Res_KW1>opioid analgesia</Res_KW1>
        <Res_KW2>pharmacy</Res_KW2>
        <Res_KW3>acute pain</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>musculoskeletal</Res_KW5>
        <Plain_Description>My research aims to reduce harms caused by the inappropriate use of unnecessary pain medicines. This will be achieved by supporting people undergoing spine surgery for back pain to safely and effectively reduce or stop pain medicines that may be causing more harm than benefit. I will collaborate with people with lived experience, health professionals, and international organisations to ensure my findings are translated into practice to improve the quality of care for Australians with back pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034392</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr David Skerrett-Byrne</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Balancing the burden and responsibility of fertility between women and men</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | reproduction  | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - proteins and peptides (incl. medical proteomics) | biomedical and clinical sciences | reproductive medicine | foetal development and medicine | </Fields_of_Research>
        <Res_KW1>male reproduction</Res_KW1>
        <Res_KW2>contraception in male</Res_KW2>
        <Res_KW3>fertility</Res_KW3>
        <Res_KW4>environmental influences</Res_KW4>
        <Res_KW5>placental function</Res_KW5>
        <Plain_Description>For too long the burden of infertility has been placed on women, despite > 50% of infertility cases involving a male factor. In fact, male infertility is now considered a global public health issue, and yet our understanding of its causes remains limited. I will address these knowledge gaps by identifying what regulates a healthy fertilisation competent sperm cell, development of new male contraceptive and how exposures throughout a man’s life might affect the health of the next generation</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034395</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Gemma Kelly</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Understanding the molecular basis of therapy resistance to improve outcomes for lymphoma </Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | haematological tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>non-hodgkin lymphoma</Res_KW1>
        <Res_KW2>bcl-2</Res_KW2>
        <Res_KW3>apoptosis</Res_KW3>
        <Res_KW4>p53</Res_KW4>
        <Res_KW5>epstein-barr virus (ebv)</Res_KW5>
        <Plain_Description>Non-Hodgkin lymphoma (NHL) is the 6th most common cancer in Australia. Whilst overall survival rates are good for NHL, there are features of certain NHL cancers that are associated with poor therapy responses and poor patient outcomes. I will use innovative pre-clinical models and methodologies to investigate how three poor prognostic features contribute to therapy resistance. Using this information, I will test new anti-cancer therapies that could improve patient survival rates.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034399</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Lauren Aoude</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Enabling precision medicine for oesophageal cancer patients</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>oesophageal cancer</Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>cancer genetics</Res_KW3>
        <Res_KW4>medical genomics</Res_KW4>
        <Res_KW5>sequence analysis</Res_KW5>
        <Plain_Description>Oesophageal adenocarcinoma is a deadly, poor-outcome cancer. We currently do not understand the genetic drivers of disease and lack biomarkers to aid clinical decisions. This program will identify genetic defects that increase disease risk. Molecular analysis and 3D tumour models will assess how these features relate to therapy response and how they can be used to improve outcomes. Deep learning will enhance the interpretation of medical scans and identify new markers related to patient care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034405</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Juergen Goetz</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Complementary strategies to increase the utility of low-intensity ultrasound as a therapeutic modality for Alzheimer’s disease </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biomedical and clinical sciences | neurosciences | central nervous system  | </Fields_of_Research>
        <Res_KW1>ultrasound</Res_KW1>
        <Res_KW2>antibody therapy</Res_KW2>
        <Res_KW3>blood-brain barrier</Res_KW3>
        <Res_KW4>brain</Res_KW4>
        <Res_KW5>neuron</Res_KW5>
        <Plain_Description>Low-intensity ultrasound will revolutionise the way how we treat brain diseases. Grounded in our work in preclinical Alzheimer models and our recent initiation of a clinical safety trial using a custom-built medical device, the proposed research will provide a better understanding of how different ultrasound parameters differentially affect brain cells and functional outcomes, explore novel ways of gene delivery using ultrasound, and improve therapeutic antibody efficacy using ultrasound.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034406</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Julia Brotherton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Implementation and evaluation of single dose human papillomavirus vaccination to achieve equitable cervical cancer elimination</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | epidemiology | disease surveillance | </Fields_of_Research>
        <Res_KW1>cervical cancer</Res_KW1>
        <Res_KW2>implementation</Res_KW2>
        <Res_KW3>human papillomavirus (hpv)</Res_KW3>
        <Res_KW4>immunisation</Res_KW4>
        <Res_KW5>cancer prevention</Res_KW5>
        <Plain_Description>Cervical cancer is preventable but remains the fourth commonest cause of cancer in women globally.  Remarkably it now appears that just a single dose of human papillomavirus (HPV) vaccine can prevent it, with Australia moving to one dose in 2023. My research will show that one dose of vaccine is enough, that it can more equitably reach those who are currently under-immunised and co-design and trial an education/communication tool that results in more young people being vaccinated and screened.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034414</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Anagha Killedar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Making equitable decisions: Embedding appropriate and robust methods for exploring equity impacts in health decision-making processes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>economics | applied economics | health economics  | </Fields_of_Research>
        <Res_KW1>health economics</Res_KW1>
        <Res_KW2>decision making</Res_KW2>
        <Res_KW3>equity</Res_KW3>
        <Res_KW4>economic evaluation</Res_KW4>
        <Res_KW5>resource allocation</Res_KW5>
        <Plain_Description>Government funding of a new medicine, health service or public health program may perpetuate or mitigate unfair inequalities in health (i.e. health inequities) but these impacts are not always accounted for in funding decisions. This project will canvas Australian decision-maker and community views on equity and probe Big Data to find a way to comprehensively embed equity in health decision-making. By making equitable decisions, progress towards health for all Australians will be made.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034418</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Marianne Martinello</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Improving infectious diseases outcomes among people who inject drugs</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,301,887.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>injecting drug use</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>hepatitis c infection</Res_KW3>
        <Res_KW4>bacterial infection</Res_KW4>
        <Res_KW5>cohort study</Res_KW5>
        <Plain_Description>People who inject drugs (PWID) are more likely to acquire infectious diseases, including bloodborne viruses (such as hepatitis C) and bacterial and fungal injecting-related infections (such as endocarditis). To improve health outcomes, we need to increase hepatitis C diagnosis and treatment, and optimize management of injecting-related infections. I will explore novel diagnostic and treatment strategies among PWID, addressing preventable infections associated with vulnerability and disadvantage.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034420</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Helen Reddel</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Paradigm-changing strategies to reduce global asthma mortality and morbidity</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,785,304.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>asthma</Res_KW1>
        <Res_KW2>clinical practice guidelines</Res_KW2>
        <Res_KW3>population health</Res_KW3>
        <Res_KW4>breathlessness</Res_KW4>
        <Res_KW5>qualitative research</Res_KW5>
        <Plain_Description>This program of work aims to reduce the global burden of death and disability due to asthma, which is largely preventable. It will provide evidence for a simple new way of diagnosing and treating asthma. The new therapy both relieves patients’ symptoms and reduces the risk of severe asthma attacks. The research aims to improve how we assess asthma and respond to patients’ treatment needs, with good quality innovations that are valued by patients and easy to implement in a range of countries.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034422</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Monika Janda</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Evidence generation for a national melanoma prevention and early detection strategy</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>behaviour change</Res_KW1>
        <Res_KW2>digital imaging</Res_KW2>
        <Res_KW3>skin cancer</Res_KW3>
        <Res_KW4>self-management</Res_KW4>
        <Res_KW5>cancer prevention</Res_KW5>
        <Plain_Description>Melanoma and skin cancer diagnoses place a heavy physical, emotional, and financial toll on many Australians and their families. This program of research will provide the evidence for how Australia can move toward a targeted melanoma screening program for those at highest risk, and improve the reach and relevance of personalised skin cancer prevention. Together this will lead to a significant reduction in melanoma incidence, morbidity and mortality.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034424</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Emily See</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving kidney outcomes for critically ill patients with vasodilatory shock</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$547,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care  | biomedical and clinical sciences | clinical sciences | nephrology and urology  | </Fields_of_Research>
        <Res_KW1>angiotensin ii</Res_KW1>
        <Res_KW2>acute renal failure</Res_KW2>
        <Res_KW3>noradrenaline</Res_KW3>
        <Res_KW4>shock</Res_KW4>
        <Res_KW5>death</Res_KW5>
        <Plain_Description>‘Vasodilatory shock’ is a life-threatening medical emergency characterised by low blood pressure and impaired oxygen delivery to tissues. Kidney failure is a common and serious complication of vasodilatory shock that is highly burdensome to patients. This research program will test whether a new medication (‘angiotensin II’) improves kidney outcomes in patients with vasodilatory shock. Its findings could change management globally, transforming the lives of this highly vulnerable patient group.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034431</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Susan Christo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Exploiting the diversity of tissue-resident memory T cells for novel therapies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | </Fields_of_Research>
        <Res_KW1>cd8 t cells</Res_KW1>
        <Res_KW2>t cell memory</Res_KW2>
        <Res_KW3>t cell immunity</Res_KW3>
        <Res_KW4>t cell response</Res_KW4>
        <Res_KW5>adaptive immunity</Res_KW5>
        <Plain_Description>Diseases mostly originate in organs not blood, therefore therapies should focus on boosting immune cells in these sites. Specifically, tissue-resident memory T cells (TRM) in organs rapidly protect against infection &amp; cancer but may contribute to autoimmunity. Here, I will explore TRM diversity &amp; molecular cues that govern their behaviour in disease-specific contexts to uncover novel pathways that can precisely target ‘pathogenic’ TRM while preserving ‘protective’ TRM.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034433</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Richard Lobb</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Across the blood-brain barrier: digital profiling of circulating brain-derived extracellular vesicles to monitor primary brain cancer and brain metastases</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | liquid biopsies | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | </Fields_of_Research>
        <Res_KW1>glioblastoma</Res_KW1>
        <Res_KW2>lung cancer</Res_KW2>
        <Res_KW3>prognostic markers</Res_KW3>
        <Res_KW4>cell-cell communication</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Despite therapeutic advances, the global cancer burden is steadily rising, with 1 in 5 men and 1 in 6 women developing cancer in their lifetime. This makes cancer one of the leading causes of death worldwide. There is a clinical need to identify patients at early-stage risk of cancer metastases or progression. To achieve this, this project aims to develop a technology for cancer detection from the blood that is highly accurate and can be implemented in routine screening.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034450</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Brendan Nolan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Improving health outcomes for transgender women</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | human society | gender studies | transgender studies  | </Fields_of_Research>
        <Res_KW1>endocrinology</Res_KW1>
        <Res_KW2>gender differences</Res_KW2>
        <Res_KW3>estradiol</Res_KW3>
        <Res_KW4>gender</Res_KW4>
        <Res_KW5>sex steroids</Res_KW5>
        <Plain_Description>Transgender Australians are arguably among the most marginalised groups in our community. Despite a significant increase in the number of individuals seeking medical care, there is a profound lack of research to guide optimal gender-affirming hormone therapy interventions. This project will provide robust evidence to improve the health and well-being of the transgender community to improve the safety of gender-affirming therapy and guide treatment guidelines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034451</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Julie Marchant</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Improving the understanding and management of chronic wet cough and its associations in children</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | other biomedical and clinical sciences | other biomedical and clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cough</Res_KW1>
        <Res_KW2>wheeze</Res_KW2>
        <Res_KW3>bronchitis</Res_KW3>
        <Res_KW4>bronchiectasis</Res_KW4>
        <Res_KW5>child</Res_KW5>
        <Plain_Description>A large proportion of lung disease in adults begins in childhood and so early intervention is the key to reducing lung health burden. My research program aims to identify modifiable factors which will improve the understanding and management of chronic wet cough in preschool children. It will also look at associations with wheeze and asthma within this group of children with cough. I expect it to provide new clinical strategies for managing these common early childhood healthcare presentations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034453</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Gail Garvey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Beyond the Cancer Care Divide: achieving First Nations health equity</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health services | </Fields_of_Research>
        <Res_KW1>aboriginal health</Res_KW1>
        <Res_KW2>psycho-oncology</Res_KW2>
        <Res_KW3>cancer care</Res_KW3>
        <Res_KW4>cancer screening</Res_KW4>
        <Res_KW5>health services</Res_KW5>
        <Plain_Description>Indigenous Australians carry a significantly greater cancer burden than other Australians and are less likely to receive comprehensive cancer treatment and care. Working alongside Indigenous people affected by cancer, my program targets key gaps across the cancer continuum, from preventative screening programs to end-of-life care. My research aims to improve cancer experiences and outcomes for Indigenous patients and their carers, giving them the best chance to not just survive but to thrive.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034478</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Chung-Wei Christine Lin</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Management of musculoskeletal pain: testing treatment effectiveness and reducing medication-related harm</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | other biomedical and clinical sciences | other biomedical and clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>musculoskeletal disorders</Res_KW1>
        <Res_KW2>back pain</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>pain management</Res_KW4>
        <Res_KW5>opioids</Res_KW5>
        <Plain_Description>Pain of the muscle, bone and joint (musculoskeletal) system represents a major cause of disease burden. There is a lack of highly effective treatments while some treatments, such as opioids, are being used with no clear evidence of benefits but known harms.    I will lead a research program to address the enormous burden of musculoskeletal pain, by providing evidence for treatment effectiveness and for reducing unnecessary medication-related harm.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034480</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Calum Roberts</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Improving health outcomes for sick and premature infants</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,362,265.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>surfactant</Res_KW2>
        <Res_KW3>premature infant</Res_KW3>
        <Res_KW4>neonatal respiratory distress syndrome</Res_KW4>
        <Res_KW5>ventilatory support</Res_KW5>
        <Plain_Description>Asphyxia (lack of oxygen) and prematurity (being born early) are the most important health issues for newborn babies, affecting millions globally every year. These issues can have life-long consequences for babies and their families. My research will identify new ways to treat these babies in early life, whether they are born in large intensive care units in major cities, or smaller regional neonatal units. Improving early care can translate into better health in childhood and beyond.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034488</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Alain Wuethrich</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Immune Dashboard Chip (IDC): Single-molecule digital  nanotechnology for profiling trace immune dysregulations in Long COVID-19 and improving mRNA vaccines</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | nanomedicine | biological sciences | industrial biotechnology | industrial biotechnology diagnostics (incl. biosensors) | biological sciences | industrial biotechnology | nanobiotechnology | </Fields_of_Research>
        <Res_KW1>nanotechnology</Res_KW1>
        <Res_KW2>chronic inflammation</Res_KW2>
        <Res_KW3>covid-19</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>messenger rna (mrna)</Res_KW5>
        <Plain_Description>The immune system is a finely balanced process that builds our defence against diseases. Even low-level dysregulations of the immune system, such as those thought to drive long COVID, can cause severe suffering. This project develops a digital nanotechnology capable of detecting trace immune dysregulation from a pin-prick of blood. This will lead to a better understanding, diagnosis, and treatment of long COVID and the development of personalised vaccines with greatly reduced side effects.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034489</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jillian Lau</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Advancing clinical trials towards a cure for HIV</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>human immunodeficiency virus (hiv)</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>persistence</Res_KW3>
        <Res_KW4>virus eradication</Res_KW4>
        <Res_KW5>social research</Res_KW5>
        <Plain_Description>Human Immunodeficiency Virus (HIV) infection is a chronic disease that can't be cured, requiring life-long treatment. This research program aims to help identify people with HIV who are best suited to enrol in clinical trials to test drugs that may allow someone to keep HIV at very low levels in their blood without medications. This could lead to HIV remission or cure. I will do this by incorporating clinical and social science research projects to design safe and effective trials in this field.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034497</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Frederic Gachon</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>The critical role of circadian rhythms disruption on the pathophysiology of metabolic diseases</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | biological sciences | biochemistry and cell biology | systems biology | biological sciences | bioinformatics and computational biology | genomics and transcriptomics | </Fields_of_Research>
        <Res_KW1>circadian rhythms</Res_KW1>
        <Res_KW2>growth hormone</Res_KW2>
        <Res_KW3>hepatic fibrosis</Res_KW3>
        <Res_KW4>endocrine disorder</Res_KW4>
        <Res_KW5>cell signalling</Res_KW5>
        <Plain_Description>Our body clock orchestrates our physiology, including when we eat and sleep, synchronizing it with the daily changes in our environment and the alteration of day and night. Modern western lifestyles, technology and shift work disrupt our body clock. This disruption is associated with many diseases including obesity, liver diseases and cancer, but the mechanisms responsible are poorly understood. My research will decipher how disruption of the body clock leads to liver and metabolic diseases.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034498</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Jo Salmon</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Improving sustainability and equity of youth physical activity initiatives at scale</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | behavioural epidemiology | health sciences | public health | health promotion | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>physical activity</Res_KW1>
        <Res_KW2>adolescence</Res_KW2>
        <Res_KW3>sedentary behaviour</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>community intervention</Res_KW5>
        <Plain_Description>Just one in 10 young people in Australia meet national physical activity guidelines of an hour a day. Those who are socially disadvantaged are the most inactive. This research program will determine how to improve the uptake and delivery of youth physical activity programs nationally, so that they are more effective and sustainable in the long term and can reduce inequalities in participation. This new evidence will underpin large-scale initiatives to benefit all young people in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034513</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Susan Jordan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Addressing Critical Knowledge Gaps to Improve Outcomes in Ovarian, Endometrial and Thyroid Cancers</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cancer epidemiology</Res_KW1>
        <Res_KW2>longitudinal cohort study</Res_KW2>
        <Res_KW3>multiple risk factors</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>gynaecological cancers</Res_KW5>
        <Plain_Description>Cancer is the leading cause of disease burden in Australia, but this could be reduced with effective cancer prevention and ensuring patients receive the best evidence-based care. My research program focusses on three relatively common but understudied cancers: ovarian, endometrial and thyroid cancer. My research will identify new causes of these cancers to improve their prevention and will find ways that we can optimise the care patients receive and improve their outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034520</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Flora Wong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Personalising brain care in preterm babies</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,396,372.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | </Fields_of_Research>
        <Res_KW1>neonatal intensive care (nicu)</Res_KW1>
        <Res_KW2>neurodevelopment</Res_KW2>
        <Res_KW3>neurovascular mechanism</Res_KW3>
        <Res_KW4>premature infant</Res_KW4>
        <Res_KW5>cerebral blood flow</Res_KW5>
        <Plain_Description>Brain injury is common in infants born preterm, leading to serious, life-long neurodevelopmental problems with no cure currently available. My vision is the implementation of personalised and “brain-oriented” care. I have previously identified how preterm birth leads to low brain oxygen supply and brain injury. Now, my goals are to detect brain injury early in preterm infants and to personalise their hospital treatment, to reduce further brain injury and improve neurodevelopmental outcomes.          </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034533</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Pablo Canete</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Understanding how regulatory T cells control self-reactive B cells in autoimmune diseases</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$599,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | autoimmunity  | </Fields_of_Research>
        <Res_KW1>autoimmunity</Res_KW1>
        <Res_KW2>b cells</Res_KW2>
        <Res_KW3>regulatory t cells</Res_KW3>
        <Res_KW4>autoantibodies</Res_KW4>
        <Res_KW5>systemic lupus erythematosus (sle)</Res_KW5>
        <Plain_Description>In autoimmune diseases, a person's immune system attacks their own body. These debilitating, incurable conditions affect millions of people globally. Current treatments only offer temporary relief and can leave patients susceptible to infections. We have identified a new group of cells that are critical for preventing self-damage. This project aims to understand how these cells function to develop novel safer therapies for autoimmune disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034538</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Katrina Prior</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>The dangerous path of self-medicating postpartum stress and anxiety with alcohol: Intervening early to improve the health and wellbeing of both mother and child</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | psychology | clinical and health psychology | clinical and health psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>alcohol</Res_KW1>
        <Res_KW2>infant development</Res_KW2>
        <Res_KW3>anxiety</Res_KW3>
        <Res_KW4>maternal mental health</Res_KW4>
        <Res_KW5>maternal and child health</Res_KW5>
        <Plain_Description>Anxiety and alcohol use problems are both common and concerning among new mothers. Research shows that 1 in 4 mothers drink to cope with their anxiety, yet the impact of co-occurring postpartum anxiety and alcohol use is unknown. This research will generate new knowledge on the factors driving this comorbidity, and the impacts on both mother and child. It will develop &amp; evaluate a world-first online program designed to reduce anxiety, alcohol use and drinking to cope behaviours among new mothers</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034541</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jonathan Penm</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Opioid stewardship for patients undergoing hip and knee replacements</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacy and pharmacy practice | biomedical and clinical sciences | clinical sciences | pain | </Fields_of_Research>
        <Res_KW1>health services research</Res_KW1>
        <Res_KW2>acute pain</Res_KW2>
        <Res_KW3>pharmacy</Res_KW3>
        <Res_KW4>opioid analgesia</Res_KW4>
        <Res_KW5>musculoskeletal</Res_KW5>
        <Plain_Description>In Australia, 150 people are hospitalised and 3 people die every day from opioid-related events. Although opioids are commonly used to treat pain before and after hip or knee replacement, inappropriate use has been associated with inappropriate persistent opioid use, opioid-related harms and poorer post-operative pain and functional outcomes. This research program will identify the effectiveness of interventions to reduce persistent opioid use after patients undergo hip and knee replacements.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034556</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Joseph Powell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Bridging discovery and translation to target the genetic control of complex diseases at a cellular level</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biomedical and clinical sciences | medical biotechnology | gene and molecular therapy  | biological sciences | bioinformatics and computational biology | sequence analysis | </Fields_of_Research>
        <Res_KW1>genomics</Res_KW1>
        <Res_KW2>messenger rna (mrna)</Res_KW2>
        <Res_KW3>sequencing</Res_KW3>
        <Res_KW4>population genetics</Res_KW4>
        <Res_KW5>intracellular gene expression</Res_KW5>
        <Plain_Description>Over the past decade, genomics has accelerated drug development. This program combines population-scale cellular genomics, gene editing and cell painting technology, and machine learning to identify drug targets. They will collaborate with partners to develop diagnostics and RNA-based therapies for common diseases, such as autoimmune, cardiovascular, and neurodegenerative disorders, which often involve RNA-related genetic changes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034568</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Macgregor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Enabling genetics-based disease risk prediction in Australia</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | </Fields_of_Research>
        <Res_KW1>statistical genetics</Res_KW1>
        <Res_KW2>complex genetic disease</Res_KW2>
        <Res_KW3>glaucoma</Res_KW3>
        <Res_KW4>eye disease</Res_KW4>
        <Res_KW5>genetic association</Res_KW5>
        <Plain_Description>Almost 10% of Australians over the age of 55 are visually impaired. Many common eye diseases have a strong genetic component. My program of research will harness genetic information to predict who is at highest risk of eye disease, enabling sight saving interventions. My work will deliver the tools required for genetics-based risk prediction, resulting in fewer Australians going blind due to diseases such as glaucoma.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034583</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Zoe Bradfield</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Measuring what Matters to Australian Mothers: The MMAMs Study</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | midwifery | midwifery not elsewhere classified  | </Fields_of_Research>
        <Res_KW1>health outcomes</Res_KW1>
        <Res_KW2>maternal health</Res_KW2>
        <Res_KW3>consumer participation</Res_KW3>
        <Res_KW4>consumer preferences</Res_KW4>
        <Res_KW5>patient safety</Res_KW5>
        <Plain_Description>The aim of this study is to develop an evidence-based, consumer-informed tool to measure the experiences and outcomes of those accessing maternity care in Australia. By capturing and measuring what matters to Australian mothers, health services will be better placed to improve the safety and quality of maternity care; aligned to a key set of experience and outcome indicators, identified and developed in collaboration with Australian mothers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034591</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Pingping Han</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Harnessing Small Extracellular Vesicles for Precision Periodontics </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | biomedical engineering | biomechanical engineering | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | engineering | nanotechnology | nanomaterials | </Fields_of_Research>
        <Res_KW1>early prognosis</Res_KW1>
        <Res_KW2>tissue regeneration</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>adult stem cells</Res_KW5>
        <Plain_Description>Gum disease is ranked 6th by WHO, necessitating non-invasive diagnosis and functional tissue regeneration. This project explores salivary sEVs as non-invasive liquid biopsy to monitor PD treatment prognosis, as well as gum cell derived sEVs as cell-free nanomedicine for treatment. The goal is to advance sEVs' diagnostic and therapeutic applications, shaping future research for improved patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034592</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Iain Abbott</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Innovating diagnostics, antibiotic treatment, and prevention strategies for urinary tract infections</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | medical microbiology | medical bacteriology  | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </Fields_of_Research>
        <Res_KW1>urinary tract infection (uti)</Res_KW1>
        <Res_KW2>pharmacokinetics</Res_KW2>
        <Res_KW3>antibiotic therapy</Res_KW3>
        <Res_KW4>clinical microbiology</Res_KW4>
        <Res_KW5>pharmacodynamics</Res_KW5>
        <Plain_Description>Urinary tract infections (UTIs) are extremely common worldwide. We require better diagnostics and oral antibiotic therapies to improve patient care, reduce recurrence, suppress antimicrobial resistance, and prevent hospitalisations. This project will bridge the gap between in vitro modelling and clinical practice by taking patient factors into laboratory investigations to inform future drug development and optimise clinical practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034593</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Tangye</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Molecular and cellular requirements for generating long-lived adaptive humoral immunity in humans</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | humoural immunology and immunochemistry | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | </Fields_of_Research>
        <Res_KW1>b cells</Res_KW1>
        <Res_KW2>cytokine biology</Res_KW2>
        <Res_KW3>adaptive immunity</Res_KW3>
        <Res_KW4>t cell activation</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>Our immune system protects us against microbes &amp; some cancers. However, our immune can also cause significant diseases, such as chronic infections, autoimmunity &amp; allergy. Some of these diseases result from errors in single genes that disrupt the way our immune system works. My studies of rare cases of immune dysregulatory diseases will provide significant insight into exactly what is required to keep our immune system functioning properly, &amp; how to modulate its function in different diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034599</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Yuyi You</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>The Visual System: A Window into Glial Dynamics and Neuroinflammatory Pathways in Neurodegenerative Diseases</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,301,887.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | ophthalmology and optometry | ophthalmology | biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>optic nerve</Res_KW1>
        <Res_KW2>multiple sclerosis (ms)</Res_KW2>
        <Res_KW3>visual pathways</Res_KW3>
        <Res_KW4>glaucoma</Res_KW4>
        <Res_KW5>neurodegeneration</Res_KW5>
        <Plain_Description>The eye is a window to the brain. We're exploring eye issues from diseases like glaucoma and multiple sclerosis to grasp 'neurodegeneration'—the ongoing death of nerve cells. Our goal is to uncover how this damage begins, expands, and if we can halt it. Combining lab studies with real patient data, we're on a quest to craft protective treatments for these prevalent diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034602</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Simone Pettigrew</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>The right to know: Addressing health-related information deficits in online purchasing contexts</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,781,630.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>health promotion</Res_KW1>
        <Res_KW2>alcohol</Res_KW2>
        <Res_KW3>consumer information</Res_KW3>
        <Res_KW4>nutrition</Res_KW4>
        <Res_KW5>health policy</Res_KW5>
        <Plain_Description>There are growing trends towards shopping for foods and beverages online rather than instore. This includes the purchase of snacks, meals, groceries, and alcohol. Existing requirements for the provision of health-related information at the point of sale are being undermined in the way products are presented on online purchasing platforms. This project will develop processes to ensure consumers have access to important health-related information when buying foods and beverages online.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034615</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Ziad Nehme</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Advancing the evidence-base in cardiac arrest and resuscitation</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,483,020.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | biomedical and clinical sciences | clinical sciences | paramedicine | </Fields_of_Research>
        <Res_KW1>cardiac arrest</Res_KW1>
        <Res_KW2>defibrillation</Res_KW2>
        <Res_KW3>resuscitation</Res_KW3>
        <Res_KW4>emergency medical service</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Out-of-hospital cardiac arrest (OHCA) is the ultimate prehospital emergency. For every minute that passes without life-saving treatment, survival from OHCA decreases by approximately 10%. Shaped by key research priorities identified by the International Liaison Committee on Resuscitation (ILCOR), my vision is to improve survival from OHCA through a research program of innovative, world-first, randomised controlled trials that will comprehensively transform the evidence base in cardiac arrest.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034631</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Veronica Matthews</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Strengthening primary health systems through Australian Indigenous paradigms: self-governance for healthy Country and community wellbeing</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>environmental sciences | climate change impacts and adaptation | human impacts of climate change and human adaptation | health sciences | health services and systems | primary health care | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>environmental health</Res_KW2>
        <Res_KW3>primary care</Res_KW3>
        <Res_KW4>climate change adaption</Res_KW4>
        <Res_KW5>community</Res_KW5>
        <Plain_Description>Indigenous communities are currently experiencing severe environmental challenges related to climate change. This project aims to simultaneously build community self-governance and attend to priority climate concerns through multi-sector alliances between community-controlled primary health care and Traditonal Owner organisations. These alliances will enhance community negotiating power and decision-making authority to address complex issues for improved health of Country and community.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034633</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Emma Devenney</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>AT RISK – A Novel Neurophysiological Approach to Biomarkers in Neurodegeneration </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>frontotemporal dementia</Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>amyotrophic lateral sclerosis</Res_KW3>
        <Res_KW4>clinical diagnosis</Res_KW4>
        <Res_KW5>neurophysiology</Res_KW5>
        <Plain_Description>This project aims to identify the timepoint at which ALS-FTD begins. Previous work has already shown that behavioural and cognitive changes are the first signs of disease and will prove a useful target for drug trials where the aim is to stop the disease as early as possible. This project will leverage national links to develop a cohort of pre-symptomatic gene carriers that initially will be observed over time and will subsequently form a base for recruitment into clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034643</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Alan Cowman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Malaria and development of new antimalarials</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | virology  | </Fields_of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>drug development</Res_KW2>
        <Res_KW3>antimalarial</Res_KW3>
        <Res_KW4>malaria drug resistance</Res_KW4>
        <Res_KW5>falciparum malaria</Res_KW5>
        <Plain_Description>Malaria is a major disease of humans that kills >630,000 people each year. The treatment and control of malaria is being threatened by the ability of the infectious agent to develop resistance to current antimalarials. Overall, this program will develop new antimalarials with a high barrier for resistance and provide novel insights into the fundamental biology of ubiquitin in P. falciparum and adapt this knowledge for new therapies that mitigate emergence of drug resistance in malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034644</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Helen Marshall</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Novel strategies for global control of meningococcal disease and gonorrhoea </Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,554,448.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | biomedical and clinical sciences | medical microbiology | medical infection agents (incl. prions) | biomedical and clinical sciences | paediatrics | adolescent health | </Fields_of_Research>
        <Res_KW1>immunisation</Res_KW1>
        <Res_KW2>youth</Res_KW2>
        <Res_KW3>meningococcal disease</Res_KW3>
        <Res_KW4>gonorrhoea</Res_KW4>
        <Res_KW5>public health policy</Res_KW5>
        <Plain_Description>Meningococcal disease and gonorrhoea are 2 serious diseases that affect young people. The bacteria that cause these diseases are genetically closely related which provides an ideal opportunity to target them with one vaccine. My research aims to establish an effective, safe and cost-effective immunisation program to protect against these diseases. By working with young people, we will co-design approaches to increase vaccine uptake for optimal protection against these 2 devastating diseases.     </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034651</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Guochen Bao</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>New-generation superbright upconversion nanoprobes for ultrasensitive microRNA detection</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | nanotechnology | nanomaterials | biomedical and clinical sciences | medical biochemistry and metabolomics | medical biochemistry - nucleic acids | chemical sciences | analytical chemistry | instrumental methods (excl. immunological and bioassay methods) | </Fields_of_Research>
        <Res_KW1>nanotechnology</Res_KW1>
        <Res_KW2>fluorescence spectroscopy</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>kidney disease</Res_KW4>
        <Res_KW5>cancer detection</Res_KW5>
        <Plain_Description>This project aims to exploit nanotechnology for microRNA detection and diagnosis of kidney cancer. The project will create new superbright nanoprobes to superbright upconversion nanoprobes to achieve a single molecule sensitivity detection for microRNA. Expected outcomes include a new strategy to brighten luminescent materials, a better understanding of the relationship between microRNA-BARTs and kidney cancer, and a device that can detect multiple biomarkers, sensitively and efficiently.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034661</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof John Silke</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Cell death and inflammation</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | other biomedical and clinical sciences | other biomedical and clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>tumour necrosis factor (tnf)</Res_KW1>
        <Res_KW2>ubiquitination</Res_KW2>
        <Res_KW3>head and neck cancer</Res_KW3>
        <Res_KW4>acute inflammation</Res_KW4>
        <Res_KW5>apoptosis</Res_KW5>
        <Plain_Description>TNF is a very potent inflammatory cytokine and causes many inflammatory diseases, like psoriasis, IBD and rheumatoid arthritis. TNF can also kill cells. However, TNF signalling is complex and the link between cell death and inflammation is still unclear. Our aim is to discover how cellular and environmental context affects TNF signalling outcomes. We believe this will allow us to reduce TNF mediated inflammation or enhance TNF killing of cancer cells therapeutically.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034677</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephanie Gras</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>What tickles T cells? Understanding the drivers of T cell activation </Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,524,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biomedical and clinical sciences | immunology | cellular immunology | biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Fields_of_Research>
        <Res_KW1>t cell receptor</Res_KW1>
        <Res_KW2>structural immunology</Res_KW2>
        <Res_KW3>t cell response</Res_KW3>
        <Res_KW4>human leukocyte antigen (hla)</Res_KW4>
        <Res_KW5>epitopes</Res_KW5>
        <Plain_Description>My research focuses on understanding how the immune system, via T cells, recognises and responds to pathogens by identifying and killing infected cells. By elucidating the key drivers of T cell recognition and their association with the disease severity, I will provide valuable insights into T cell immunity. These discoveries could inform how therapeutically use T cells against immune-regulated conditions including infectious disease, cancer or autoimmunity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034686</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Bette Liu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Optimising adult vaccination programs</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>epidemiology</Res_KW1>
        <Res_KW2>record linkage</Res_KW2>
        <Res_KW3>vaccines</Res_KW3>
        <Res_KW4>population health</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>This proposal aims to reduce infectious diseases and their impacts on health in adults through generating evidence needed to inform adult vaccination programs. It will use large-scale linked electronic records to determine disease burden, identify high risk groups and examine the effectiveness and safety of current and alternate vaccine schedules.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034734</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Lee Fletcher</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Spatiotemporal patterning of dendritic computations and learning by cholinergic inputs in the neocortex</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | cellular nervous system | </Fields_of_Research>
        <Res_KW1>dendrites</Res_KW1>
        <Res_KW2>action potential</Res_KW2>
        <Res_KW3>neural coding</Res_KW3>
        <Res_KW4>acetylcholine</Res_KW4>
        <Res_KW5>synaptic plasticity</Res_KW5>
        <Plain_Description>My research aims to understand how the brain processes the world. In this project, I aim to find out how neural circuits highlight certain information in different contexts, such as during attention, and how this helps encode memories. This will help understand how our brains decline with age and go wrong in neurological disorders such as attention deficit and Alzheimer’s disease, and how we may adapt in a world increasingly bombarding us with information and capturing our attention.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034741</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jane Hawkey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Advancing diagnosis, management &amp; prevention of antimicrobial resistant bacterial infections with genomics</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | </Fields_of_Research>
        <Res_KW1>antimicrobial resistance</Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>plasmids</Res_KW4>
        <Res_KW5>microbiology</Res_KW5>
        <Plain_Description>Infections caused by antimicrobial resistant bacteria are a top global health priority due to limited therapeutic options. Genomics has the potential to be a powerful tool for control of antimicrobial resistant pathogens, improving detection, management and prevention of outbreaks. I will develop novel genomic methods that can bridge the gap between research and implementation of genomics in a clinical setting. This has the potential to improve patient outcomes and reduce healthcare costs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034743</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Zachary Gerring</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>From gene discovery to clinical drug development for neuropsychiatric disorders</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | neurogenetics | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | </Fields_of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>translational research</Res_KW2>
        <Res_KW3>genetics</Res_KW3>
        <Res_KW4>neuropsychiatric disorders</Res_KW4>
        <Res_KW5>drug targeting</Res_KW5>
        <Plain_Description>Drug repurposing, where existing drugs are used for a new indication, has the potential to identify new treatments for neuropsychiatric disorders faster than traditional drug development programs. My program identifies risk genes and mechanisms underlying neuropsychiatric disorders using genetic and molecular data. These results inform a novel drug repurposing analysis to identify drugs that target disease mechanisms. The candidate drugs are validated in cell models to inform follow-up studies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034754</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Hana Starobova</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title> Targeting cell adhesion molecules for the treatment of chemotherapy-induced neuropathy </Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | biological sciences | biochemistry and cell biology | systems biology | </Fields_of_Research>
        <Res_KW1>cellular interactions</Res_KW1>
        <Res_KW2>neuropathic pain</Res_KW2>
        <Res_KW3>cell adhesion molecule</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>immune-mediated inflammation</Res_KW5>
        <Plain_Description>Neuropathies that develop following cancer therapy, strongly correlate with inflammation. Cell adhesion molecules that tightly modulate immune/neuronal function and cancer progression show promising results in preventing neuropathies following cancer therapy and may serve as promising targets. I will use models of mono- and combination cancer therapy-induced neuropathy in cancer-bearing mice to characterise the role of cell adhesion molecules in molecular processes driving these neuropathies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034767</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Anoop Koshy</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Enhancing Cardiovascular Risk Prediction in Patients undergoing Liver Transplantation: Role of an Impaired Cardiac Reserve (ENVISION-LT)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$504,640.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | biomedical and clinical sciences | clinical sciences | anaesthesiology | </Fields_of_Research>
        <Res_KW1>liver transplantation</Res_KW1>
        <Res_KW2>coronary heart disease (chd)</Res_KW2>
        <Res_KW3>cardiovascular disease</Res_KW3>
        <Res_KW4>cardiomyopathy</Res_KW4>
        <Res_KW5>echocardiography</Res_KW5>
        <Plain_Description>Liver transplantation(LT) is the only curative treatment for patients with life-threatening liver disease. Heart disease is the leading cause of death after LT in Australia. We have shown that liver disease leads to structural changes in the heart - known as cirrhotic cardiomyopathy(CCM). We aim to evaluate whether CCM increases the risk of post-transplant cardiac events and whether LT can cure CCM. Early diagnosis and treatment of this condition could reduce the risk of cardiac events after LT.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034770</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Stone</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Systematic reviews of aetiology and risk factors of disease: a program of methodological research</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological methods | </Fields_of_Research>
        <Res_KW1>meta-analysis</Res_KW1>
        <Res_KW2>risk factors</Res_KW2>
        <Res_KW3>methodology</Res_KW3>
        <Res_KW4>clinical epidemiology</Res_KW4>
        <Res_KW5>aetiology</Res_KW5>
        <Plain_Description>Translating health research into practice relies on systematic reviews (SR). There is considerable guidance on the conduct of SRs of intervention effectiveness. Less attention has been given to addressing problems in SRs of aetiology and risk, which synthesise observational data for use in health promotion and prevention. This research involves an investigation into best conduct of SRs of aetiology and risk to deliver a unified framework for methods guidance, teaching and capacity building.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034779</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Sam Buckberry</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Precision Medicine for Indigenous Australians: Epigenetic biomarkers to improve cardiometabolic disease prediction, management and prevention</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander public health and wellbeing | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biological sciences | bioinformatics and computational biology | translational and applied bioinformatics | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>diabetes</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Metabolic and cardiac diseases, especially Type-2 Diabetes, are big concerns for Indigenous Australians, leading to serious health problems. Current prediction, monitoring and treatment methods aren't fully addressing this issue, and the gap in life expectancy and health outcomes continues to widen. This research aims to create biomarkers that can better predict and manage these diseases that are tailored for Indigenous communities, thus improving health outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034788</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Carla Treloar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Building the knowledge base for effective stigma reduction interventions in health care</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health equity | health sciences | public health | social determinants of health | human society | sociology | sociology of inequalities | </Fields_of_Research>
        <Res_KW1>health inequalities</Res_KW1>
        <Res_KW2>social determinants of health</Res_KW2>
        <Res_KW3>social health issues</Res_KW3>
        <Res_KW4>social research</Res_KW4>
        <Res_KW5>health promotion</Res_KW5>
        <Plain_Description>Stigma reduction is a priority for all health systems to deliver more effective health care and better outcomes for individuals. This program will develop new evidence, tools and pathways to reform approaches to stigma reduction in health systems. A sustainability framework will be developed to provide a blueprint for driving and achieving stigma reduction, training the next generation of scholars and workforce development.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034809</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Megan Ferguson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Co-designing innovative healthy food retail policies with remote Indigenous populations to improve nutrition</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | social determinants of health | biomedical and clinical sciences | nutrition and dietetics | public health nutrition | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>translational research</Res_KW2>
        <Res_KW3>food</Res_KW3>
        <Res_KW4>population</Res_KW4>
        <Res_KW5>policy analysis</Res_KW5>
        <Plain_Description>Diets are the lead cause of chronic disease. My research will work with Indigenous storeowners and retailers to translate new evidence into healthy food actions in stores and define systems and policy to ensure these are implemented in all 220 remote Australian stores. I will investigate how this approach could apply in international Indigenous retail. Healthy food actions will lead to the creation of stores that support consumers make healthier purchases and reduce burden of disease disparity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034812</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Anju Joham</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Improving understanding of natural history, refining diagnosis and optimising health outcomes in women with polycystic ovary syndrome – a prevalent, yet underserved population</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,362,265.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | major global burdens of disease | health sciences | other health sciences | other health sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>polycystic ovarian syndrome (pcos)</Res_KW1>
        <Res_KW2>clinical diagnosis</Res_KW2>
        <Res_KW3>clinical epidemiology</Res_KW3>
        <Res_KW4>overweight/obesity</Res_KW4>
        <Res_KW5>statistics</Res_KW5>
        <Plain_Description>As an active clinician, academic and rapidly emerging leader, I bring an exemplary track record at my career stage and a research and translation program that addresses key priorities, linked to international guidelines, to directly improve the diagnosis, understanding of natural history and improvement in prevention and treatment of Polycystic   Ovary Syndrome, one of the most common conditions affecting a striking 13% of women.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034827</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Benn Sartorius</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>SPIDERMAP: Harnessing Spatial Epidemiology for Infectious Disease Estimation, Research and Mapping to Enhance Public Health Action in Australia and the Pacific</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological modelling | mathematical sciences | statistics | time series and spatial modelling | environmental sciences | climate change impacts and adaptation | ecological impacts of climate change and ecological adaptation | </Fields_of_Research>
        <Res_KW1>infectious diseases</Res_KW1>
        <Res_KW2>climate variability</Res_KW2>
        <Res_KW3>modelling</Res_KW3>
        <Res_KW4>geographic variations</Res_KW4>
        <Res_KW5>environmental epidemiology</Res_KW5>
        <Plain_Description>Space-time analysis of infectious diseases helps us understand disease patterns, and optimally and more efficiently guide control and prevention strategies. However, a gap remains between this research and translation into real-world use/impact, especially in resource-poor countries. SPIDERMAP aims to bridge this gap through innovative spatial research on priority IDs in Australia and Pacific Islands, helping optimise decision-making and thereby improving health in high-risk sub-populations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034837</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Yeda Wu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Genetic Insights into Gastrointestinal Disorders and their Comorbidity with Neuropsychiatric Conditions: Advancing Treatment and Prevention Strategies</Grant_Title>
        <Admin_Institution>The Council of the Queensland Institute of Medical Research</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | bioinformatics and computational biology | statistical and quantitative genetics | </Fields_of_Research>
        <Res_KW1>complex genetic disease</Res_KW1>
        <Res_KW2>genetic epidemiology</Res_KW2>
        <Res_KW3>genetic analysis</Res_KW3>
        <Res_KW4>genetic susceptibility</Res_KW4>
        <Res_KW5>genetic predisposition</Res_KW5>
        <Plain_Description>Gastrointestinal (GI) disorders burden patients and society. They often co-occur with neuropsychiatric (NP) conditions, suggesting a hidden connection. Investigating the genetic origins of GI disorders and their connection to NP conditions is essential for advancing prevention and treatment. This project delves into the genetics of GI disorders and their relationship with NP conditions, offering potential for more personalized and effective treatments that can make a life-changing difference.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034857</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Guangze Yang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Innovative Chemoimmunotherapy for Metastatic Castration-Resistant Prostate Cancer</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | nanotechnology | nanomaterials | engineering | biomedical engineering | biomaterials  | biomedical and clinical sciences | medical biotechnology | nanomedicine | </Fields_of_Research>
        <Res_KW1>drug delivery systems</Res_KW1>
        <Res_KW2>tumour targeting</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>biomaterials</Res_KW4>
        <Res_KW5>drug delivery</Res_KW5>
        <Plain_Description>Prostate cancer is a significant health concern both in Australia and globally. Many individuals undergoing hormone therapy eventually develop advanced prostate cancer that resists treatment. To tackle this issue, this project aims to create innovative nanomedicines for a combined chemoimmunotherapy approach, integrating chemotherapy and immunotherapy. The goal is to enhance the effectiveness of treatment for advanced prostate cancer while reducing unwanted side effects.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034904</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Sandersan Onie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Using internet searches and digital advertising to intervene during suicidal ideation</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$649,400.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical and health psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>suicide prevention</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>suicide</Res_KW3>
        <Res_KW4>internet</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>Suicide is a leading cause of death in Australia, but most people will not seek help prior; thus, we need to find new ways to reach them. I will utilise internet search ads to reach out to those contemplating suicide by showing an ad to individuals searching for suicide related keywords.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034925</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Zachary Munn</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Advancing the science of evidence synthesis: developing standards, guidance and resources for better evidence for better health decisions </Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | epidemiology | epidemiology not elsewhere classified | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>epidemiology</Res_KW1>
        <Res_KW2>synthesis</Res_KW2>
        <Res_KW3>clinical decision making</Res_KW3>
        <Res_KW4>epidemiological research methods</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>People who make decisions regarding the health of individuals or society need trustworthy information to support these decisions, whether they be about the effectiveness of a strategy, the burden of a disease, the accuracy of a medical test or the preferences and values of a population. To produce trustworthy evidence, we need to collate and synthesise all of the information available. This work will improve the science behind evidence synthesis and the quality of evidence synthesis efforts.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034943</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Dominic Dwyer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Preventing Psychotic Disorders Using Artificial Intelligence</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>early intervention</Res_KW1>
        <Res_KW2>biological risk factors</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>early psychosis</Res_KW4>
        <Res_KW5>magnetic resonance imaging (mri)</Res_KW5>
        <Plain_Description>Psychosis is a life-threatening mental illness that needs to be prevented. Australia has world-class preventative clinics, yet our therapies only work 50% of the time. We desperately need to improve this statistic by understanding why young people are at-risk of psychosis and how to better prevent their first-episode of illness. Cutting-edge artificial intelligence techniques will be used with a vision to reform care by personalizing preventative therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034945</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Hao Song</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Harnessing Nanotechnology to Develop Next-Generation mRNA Oral Vaccines</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>engineering | nanotechnology | nanomaterials | biomedical and clinical sciences | medical biotechnology | nanomedicine | engineering | biomedical engineering | biomaterials  | </Fields_of_Research>
        <Res_KW1>nanotechnology</Res_KW1>
        <Res_KW2>oral vaccine</Res_KW2>
        <Res_KW3>biomedical engineering</Res_KW3>
        <Res_KW4>messenger rna (mrna)</Res_KW4>
        <Res_KW5>biomaterials</Res_KW5>
        <Plain_Description>This project aims to develop a thermal stable oral-vaccine delivery platform through materials innovation and formulation engineering, with the ultimate goal of converting vaccine jabs into oral tablets. It is anticipated that a patient-friendly, market-ready oral vaccine nanotechnology with business advantages will be generated to improve the reach and acceptability of emerging vaccines to treat infectious and chronic diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034960</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof David Beard</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Strategic Development of a Trial Culture for Surgical Innovation and Evaluation: A Node Catalyst Model</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,054,863.70</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | surgery | biomedical and clinical sciences | clinical sciences | orthopaedics  | biomedical and clinical sciences | clinical sciences | rural clinical health | </Fields_of_Research>
        <Res_KW1>orthopaedic surgery</Res_KW1>
        <Res_KW2>abdominal surgery</Res_KW2>
        <Res_KW3>evaluation</Res_KW3>
        <Res_KW4>biotechnology</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Surgery is an important and common area of medicine, yet it has developed without strong safety, benefit and value assessment, particularly with regard to new implanted devices and innovative practice.  This shortcoming will be addressed by setting up pockets of surgical trial research and expertise in four focused areas; orthopaedic, plastic, liver and vascular surgery. These specialty areas will act as examples for others to follow. The result will be an increase in surgical trials in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034965</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Hanif Haidari</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Development of a dissolvable antibacterial microneedle patch for deep wound biofilms</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | nanomedicine | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>drug delivery systems</Res_KW1>
        <Res_KW2>antimicrobial therapy</Res_KW2>
        <Res_KW3>bacterial biofilm</Res_KW3>
        <Res_KW4>controlled release</Res_KW4>
        <Res_KW5>wound infection</Res_KW5>
        <Plain_Description>The treatment of chronic wound-resistant infections remains a substantial clinical challenge primarily stemming from the absence of new antimicrobial breakthroughs. I am addressing this challenge by developing a patient-compliant, self-administrable antibacterial microneedle that can precisely access biofilm infections to eliminate them while initiating mechanisms to support wound healing. This technology will provide targeted, safe, and effective solution for all forms of resistant infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034976</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Victoria Mar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Data driven approaches to outsmart skin cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,362,265.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | dermatology | biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | information and computing sciences | computer vision and multimedia computation | multimodal analysis and synthesis | </Fields_of_Research>
        <Res_KW1>cutaneous melanoma</Res_KW1>
        <Res_KW2>early diagnosis</Res_KW2>
        <Res_KW3>non-melanoma skin cancer</Res_KW3>
        <Res_KW4>cancer prevention</Res_KW4>
        <Res_KW5>artificial intelligence</Res_KW5>
        <Plain_Description>Early detection and accurate diagnosis of melanoma improves survival, however a standardised approach to diagnosis does not currently exist, nor is it possible to monitor quality of care.  My research will enable development and validation of cutting-edge technologies to standardise diagnosis and optimise care. Emerging technologies will be used to identify significant variations in care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034989</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Katherine Anders</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Optimsing the scale-up of evidence-based tools for control and local elimination of dengue</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | disease surveillance | biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>vector-borne disease</Res_KW1>
        <Res_KW2>climate change</Res_KW2>
        <Res_KW3>dengue</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>Dengue is a viral disease spread by mosquitoes. Regular large outbreaks in tropical settings place a strain on communities and health systems, and conventional approaches for controlling mosquitoes have been ineffective. My research will examine the real-world impact of two new effective tools for dengue control - Wolbachia mosquito releases and a vaccine - in Indonesia and Fiji, and generate evidence to support their scale-up to protect communities from dengue and other mosquito-borne diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035021</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Jose Polo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Exploring the Boundaries of Nuclear Reprogramming</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | oncology and carcinogenesis | cancer genetics | </Fields_of_Research>
        <Res_KW1>stem cell biology</Res_KW1>
        <Res_KW2>cell differentiation</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>cell biology</Res_KW5>
        <Plain_Description>This research aims to understand "nuclear reprogramming" - a process that can change a cell’s identity. I hope to find new ways to treat diseases and health problems. I am especially interested in how cells keep their identity and how amenable they can be in changing it. This knowledge can help us improve cell-based treatments and even fight cancer by reverting harmful cells into harmless ones. In short, this work could transform how we approach treatments in regenerative medicine and cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035037</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Ira Deveson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 (L1)</Sub_Type>
        <Grant_Title>Long-read sequencing methods and resources for genomic medicine</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,792,745.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | genomics | biological sciences | bioinformatics and computational biology | bioinformatic methods development | biomedical and clinical sciences | clinical sciences | medical genetics (excl. cancer genetics) | </Fields_of_Research>
        <Res_KW1>dna sequencing</Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>medical genomics</Res_KW3>
        <Res_KW4>biotechnology</Res_KW4>
        <Res_KW5>molecular diagnostics</Res_KW5>
        <Plain_Description>Cutting-edge long-read sequencing (LRS) technologies provide a more complete picture of the human genome than previously possible. There are countless opportunities to streamline, improve or reimagine disease diagnosis using LRS. I will develop a collaborative research program that will lead LRS innovation and impact in Australia. My program will deliver new knowledge, resources and tools for genomic medicine, and support the biomedical community with access to the latest LRS advances.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035040</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Melissa Wake</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Faster health solutions for today's children and adults</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | community child health  | health sciences | epidemiology | major global burdens of disease | health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>child</Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>outcome evaluation</Res_KW4>
        <Res_KW5>transformation</Res_KW5>
        <Plain_Description>Many children are not thriving and life expectancy is falling. For long and healthy lives, we need new strategies to help children and midlife adults to flourish, prevent illness and effectively manage complex 21st century problems. Leveraging >$90 million of establishment and research funding, my program will harness the power of Australia’s new Generation Victoria cohort (final expected n ~150,000) into a discovery and intervention pipeline to improve the health and wellbeing of our nation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035042</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Ryan Lister</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 (L2)</Sub_Type>
        <Grant_Title>Exploiting epigenetic memory and manipulation to advance cell biotechnologies and disease treatment</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,924,080.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | epigenetics (incl. genome methylation and epigenomics) | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>epigenetics</Res_KW1>
        <Res_KW2>regenerative medicine</Res_KW2>
        <Res_KW3>gene regulation</Res_KW3>
        <Res_KW4>stem cell biology</Res_KW4>
        <Res_KW5>cell differentiation</Res_KW5>
        <Plain_Description>The epigenome is essential for cell function, is disrupted in disease, and can store memories of a cell's past. This project will determine how cells remember their past and how to erase this memory to better engineer them; create new tools for adjusting gene activity to improve disease treatments; and investigate epigenome disruption during development in neurological disorders. This will unlock improved cell therapy tools and better understanding of diseases, underpinning future therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035090</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Prof Glenn King</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 (L3)</Sub_Type>
        <Grant_Title>Venoms to drugs: translating venom peptides into human therapeutics</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,981,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>chemical sciences | medicinal and biomolecular chemistry | proteins and peptides | </Fields_of_Research>
        <Res_KW1>novel therapeutic agents</Res_KW1>
        <Res_KW2>chronic pain</Res_KW2>
        <Res_KW3>peptides</Res_KW3>
        <Res_KW4>ion channels</Res_KW4>
        <Res_KW5>epilepsy</Res_KW5>
        <Plain_Description>Many disorders of the nervous system, including intractable chronic pain and epilepsy, result from the aberrant activity of ion channels that ferry sodium and potassium ions across neuronal cell membranes. There are very few drugs available for treating some of these disorders and they often have debilitating side-effects. We are using animal venoms to develop potent and selective modulators of these ion channels as the next-generation of safe and effective pain killers and anti-epileptic drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035111</App_ID>
        <Date_Announced>2024-05-02T00:00:00</Date_Announced>
        <CIA_Name>Dr Amy Dennett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 (EL1)</Sub_Type>
        <Grant_Title>Connecting Patients to Cancer Rehabilitation: Delivering CaRe  at the right place and time using the Cancer Rehabilitation to Recreation  (CaReR) Framework</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$674,400.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | </Fields_of_Research>
        <Res_KW1>rehabilitation</Res_KW1>
        <Res_KW2>physiotherapy</Res_KW2>
        <Res_KW3>exercise</Res_KW3>
        <Res_KW4>service provision</Res_KW4>
        <Res_KW5>supportive care</Res_KW5>
        <Plain_Description>Exercise-based rehabilitation essential to cancer treatment and recovery. However, just 1 in 200 people can access exercise-based cancer rehabilitation. People struggle to return to their previous function which negatively affects their quality of life. My research program leverages my previous work to identify the needs of patients and doctors to access services and evaluate a framework to connect more patients to cancer rehabilitation that can be adapted to cancer centres nationwide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032153</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Craig Olsson</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Extending lifespan and healthspan: A 40-year prospective cohort study of early life determinants of leading causes of mental disorder and chronic disease burden in populations.</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,227,913.40</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>psychology | applied and developmental psychology | psychology of ageing | health sciences | epidemiology | social epidemiology | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>psychology</Res_KW1>
        <Res_KW2>psychiatric epidemiology</Res_KW2>
        <Res_KW3>longitudinal cohort study</Res_KW3>
        <Res_KW4>older people</Res_KW4>
        <Res_KW5>childhood</Res_KW5>
        <Plain_Description>Life expectancies worldwide have increased substantially over the past century; however, extended lifespans have not translated to extended healthspans. The ATP is one of Australia’s longest running cohorts. Next year, Generation 1 will enter their 70s, Generation 2 will enter their 40s, and Generation 3 will turn 10. This provides a rare opportunity examine the earlier life determinants of mental disorders and physical disease in middle and later life as well as across generations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032163</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Dr Katherine Gibney</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>ISAAC - Invasive Streptococcus A: a randomised control trial of antibiotic prophylaxis for contact management </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,960,351.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>group a streptococcal disease</Res_KW1>
        <Res_KW2>prophylaxis</Res_KW2>
        <Res_KW3>public health policy</Res_KW3>
        <Res_KW4>streptococcal invasive diseases</Res_KW4>
        <Res_KW5>antibiotic use</Res_KW5>
        <Plain_Description>Invasive group A streptococcal disease (iGAS) causes more deaths in Australia than meningococcal disease. iGAS is becoming more common in Australia and overseas. Household contacts of a case have a 2000-times increased risk of developing iGAS themselves. Unlike meningococcal disease, a national approach to preventing iGAS among household contacts is lacking. Findings from this trial will clarify when household contacts need antibiotics to prevent further iGAS cases, and which antibiotics to use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032210</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Parsons</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Atrial Myopathy and Embolic Stroke (AMES) trial</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,743,489.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>post-stroke dementia</Res_KW1>
        <Res_KW2>ischaemic stroke</Res_KW2>
        <Res_KW3>neuroinflammation</Res_KW3>
        <Res_KW4>magnetic resonance imaging (mri)</Res_KW4>
        <Res_KW5>cognition</Res_KW5>
        <Plain_Description>This unique world-first project targets a significant area of unmet need by identifying a relatively new but common cause of stroke, atrial myopathy, that is a harbinger of recurrent stroke and cognitive decline. This project will deliver major knowledge gain in understanding stroke pathophysiology, facilitating earlier detection and treatment. There will substantial health impact should our trial show that anticoagulation in atrial myopathy reduces stroke recurrence and cognitive decline.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032228</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Boon Chua</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,128,247.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | radiation therapy | </Fields_of_Research>
        <Res_KW1>breast neoplasms</Res_KW1>
        <Res_KW2>breast cancer</Res_KW2>
        <Res_KW3>radiation oncology</Res_KW3>
        <Res_KW4>radiation therapy</Res_KW4>
        <Res_KW5>quality of life</Res_KW5>
        <Plain_Description>DCIS within milk ducts may turn into invasive breast cancer if untreated. The 5-year results of our study of 1608 women shows that after surgery, higher radiation doses to the part of the breast where DCIS was in addition to whole breast radiotherapy (RT) significantly reduced recurrence. The more convenient 3 weeks of RT is as safe and effective as 5 weeks of RT. Our proposal aims to assess their 10-year outcomes, and explore their lived experiences to support shared treatment decision-making.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032302</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof David Simmons</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Treatment Of early gestational diabetes Mellitus: THe follow-Up of Mothers and Babies future cardio-metabolic risk and neurodevelopment (TOMTHUMB)</Grant_Title>
        <Admin_Institution>Western Sydney University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,492,610.26</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | endocrinology | health sciences | epidemiology | major global burdens of disease | biomedical and clinical sciences | medical biochemistry and metabolomics | metabolic medicine | </Fields_of_Research>
        <Res_KW1>glucose</Res_KW1>
        <Res_KW2>diagnosis</Res_KW2>
        <Res_KW3>gestational diabetes</Res_KW3>
        <Res_KW4>early pregnancy</Res_KW4>
        <Res_KW5>prospective cohort study</Res_KW5>
        <Plain_Description>Treatment of gestational diabetes mellitus (GDM) identified in early pregnancy prevents birth complications. This research will discover if it also reduces long-term risks of diabetes and obesity in mother or baby. We will take metabolic measurements in mothers and offspring over 5-7 years to determine the benefits or harms of treating early GDM and to compare immediate versus deferred treatment. This definitive study will inform GDM screening, diagnostic and practice policies globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032328</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Emmanuel Stamatakis</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The 24-hour physical behaviour spectrum for cancer prevention: associations with cancer incidence and mortality in the ProPASS consortium of prospective wearables-based cohorts </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,989,419.50</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | behavioural epidemiology | </Fields_of_Research>
        <Res_KW1>physical activity</Res_KW1>
        <Res_KW2>cancer prevention</Res_KW2>
        <Res_KW3>applied statistics</Res_KW3>
        <Res_KW4>health promotion</Res_KW4>
        <Res_KW5>guidelines</Res_KW5>
        <Plain_Description>Physical activity, sitting and sleep - termed “physical behaviours” - are major determinants of risk for many cancers, although we do not know what the minimal and optimal amounts for cancer prevention are. This project will use the wearable device data derived from the ProPASS consortium to examine the combined associations of physical activity, sitting and sleep with cancer risk. The aim is to provide precise evidence that will contribute to future cancer prevention guidelines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032361</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Nadine Ezard</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Randomised double blind placebo controlled trial of oral lisdexamfetamine for methamphetamine withdrawal</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,175,568.98</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </Fields_of_Research>
        <Res_KW1>substance use disorders</Res_KW1>
        <Res_KW2>amphetamine</Res_KW2>
        <Res_KW3>addiction treatment</Res_KW3>
        <Res_KW4>stimulant medication</Res_KW4>
        <Res_KW5>illicit drug use</Res_KW5>
        <Plain_Description>Australia has the highest rate of methamphetamine (MA) dependence globally. Cessation of regular MA use leads to symptoms of withdrawal, which perpetuate drug use and can prevent help-seeking. There is no treatment for MA withdrawal. We will conduct a clinical trial using a stimulant medication already used to treat attention-deficit/hyperactivity disorder in Australia. Lisdexamfetamine has the potential reduce withdrawal symptoms and become the first treatment for MA withdrawal in the world.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032362</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Ms Karen Glover</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The Aboriginal Families Study (Wave 3) grounded in Aboriginal knowledge and culture: Exploring Aboriginal and Torres Strait Islander young people’s social and emotional wellbeing</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$3,666,252.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health equity | health sciences | public health | social determinants of health | </Fields_of_Research>
        <Res_KW1>adolescent health</Res_KW1>
        <Res_KW2>indigenous health</Res_KW2>
        <Res_KW3>aboriginal mental health</Res_KW3>
        <Res_KW4>social determinants</Res_KW4>
        <Res_KW5>maternal and child health</Res_KW5>
        <Plain_Description>This project aims to strengthen Aboriginal and Torres Strait Islander young people’s social and emotional wellbeing and translate knowledge into action across primary health care, mental health, housing, education and social care sectors to benefit Aboriginal and Torres Strait Islander young people and families.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032384</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Dr Clare Whitehead</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>PROMOAT: An Adaptive Platform Trial of Antibiotic Therapy to Improve Outcomes from Preterm Prelabour Rupture of Membranes</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$4,388,940.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>very preterm birth</Res_KW1>
        <Res_KW2>pregnancy complications</Res_KW2>
        <Res_KW3>neonatal survival</Res_KW3>
        <Res_KW4>sepsis</Res_KW4>
        <Res_KW5>maternal infection</Res_KW5>
        <Plain_Description>Preterm birth can lead to death and life-long disability. In nearly half of preterm births, the mother "breaks her waters" before the onset of labour, which increases the risk of infection for the mother and baby. PROMOAT is an innovative clinical trial that will assess what is the best antibiotic to give mothers with "preterm broken waters" or "PPROM" to improve outcomes for preterm babies and their mothers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032407</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Jacob George</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Precision Medicine in Liver Cancer a National Consortium for Spatial and molecular Phenotyping of HCC</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,947,688.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>liver cancer</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>immunotherapy</Res_KW3>
        <Res_KW4>patient outcomes</Res_KW4>
        <Res_KW5>cohort study</Res_KW5>
        <Plain_Description>This project aims to bring precision medicine, a treatment approach tailored to individual patients, to liver cancer care. We will use cellular and spatial genomics to understand liver cancer at the molecular level and build a national cohort for in-depth study, hoping to improve treatment and patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032420</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Thanh Phan</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Randomized controlled trial of thrombectomy versus standard medical therapy for stroke with medium sized vessel occlusion: Frontier-AP</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,249,615.44</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiovascular medicine and haematology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>acute stroke</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>outcome assessment</Res_KW3>
        <Res_KW4>cardiovascular</Res_KW4>
        <Res_KW5>thrombolysis treatment</Res_KW5>
        <Plain_Description>Ischaemic stroke is due to clot blocking vessels of the brain. Thrombectomy or mechanical removal of clot is the best treatment for clot obstructing large vessel compared to clot busting drug or best medical therapy. However, the best treatment (clot busting or extraction) of clot obstructing medium sized vessel is yet to be determined. The aim of this trial is to determine the best treatment strategy for blood clot blocking medium sized vessels of the brain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032421</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Kirsten Perrett</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Testing an implementable strategy to modulate immune function and reduce inflammation to prevent asthma and preserve lung function: 6-year follow-up of the existing VITALITY RCT. </Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,617,205.05</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>vitamin d</Res_KW2>
        <Res_KW3>lung function</Res_KW3>
        <Res_KW4>asthma</Res_KW4>
        <Res_KW5>allergic airways disease</Res_KW5>
        <Plain_Description>We will test if a simple and well tolerated intervention, daily vitamin D drops in the first year of life, can prevent asthma and lung function deficits. This trial may change global infant nutrition recommendations and reduce the lifelong effects of respiratory disease. This is an age 6 years follow-up study of our large NHMRC funded trial, VITALITY, which recruited 2739 children, and is testing if this intervention (vitamin D) can prevent food allergy and eczema at age 1.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032441</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Grimison</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours - An Australian-Led, International Randomised Trial</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,362,000.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | </Fields_of_Research>
        <Res_KW1>cancer</Res_KW1>
        <Res_KW2>germ cell tumours</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>testicular cancer</Res_KW4>
        <Res_KW5>relapse prevention</Res_KW5>
        <Plain_Description>Advanced germ cell tumours such as testicular cancer typically affect young people, and more than half of those with the worst prognosis features die with standard treatment. The purpose of this trial is to determine whether giving the same dose of a chemotherapy combination called BEP, Bleomycin, Etoposide Cisplatin, on a 2-weekly schedule will be more effective than a 3-weekly schedule. This Australian led international trial could improve cure rates and reduce the duration of side effects.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032444</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Dr Ameneh Khatami</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Staphylococcus aureus bacteraemia treated with phage therapy to improve outcomes (SABRE-Phi trial)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$4,342,730.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biomedical and clinical sciences | clinical sciences | clinical microbiology | biomedical and clinical sciences | clinical sciences | intensive care  | </Fields_of_Research>
        <Res_KW1>bacteriophage</Res_KW1>
        <Res_KW2>bacteraemia</Res_KW2>
        <Res_KW3>staphylococcus aureus</Res_KW3>
        <Res_KW4>bacterial infection</Res_KW4>
        <Res_KW5>intensive care</Res_KW5>
        <Plain_Description>Staph aureus (golden staph) bloodstream infections are common and deadly, despite antibiotics. Phages are viruses that infect and kill bacteria. We have been treating patients with severe infections using phages produced by our team since 2022. This trial will investigate use of a locally produced 2-phage combination (cocktail) that targets the golden staph bacteria to see if it provides an advantage in addition to antibiotics in treating patients with severe golden staph bloodstream infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032454</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Dr Robin Cash</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Next Generation Therapeutic Brain Stimulation for Depression</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,464,141.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | psychiatry (incl. psychotherapy)  | </Fields_of_Research>
        <Res_KW1>major depressive disorder</Res_KW1>
        <Res_KW2>neuroscience</Res_KW2>
        <Res_KW3>neuroimaging</Res_KW3>
        <Res_KW4>transcranial magnetic stimulation (tms)</Res_KW4>
        <Res_KW5>neuropsychiatry</Res_KW5>
        <Plain_Description>Non-invasive brain stimulation offers new hope to individuals suffering from depression who do not respond to standard therapy. Recent work demonstrates brain stimulation clinical outcomes might be substantially improved by adjusting the exact position, at which brain stimulation is applied, to directly modulate a brain circuit involved in depression. We aim to test this in a large clinical trial comparing this new targeted brain stimulation approach with a conventional brain stimulation therapy</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032492</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Odette Pearson</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>South Australian Aboriginal Cancer Cohort Study to Improve Cancer Management and Outcomes</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute Limited</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,060,772.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health and wellbeing not elsewhere classified | health sciences | epidemiology | epidemiological methods | health sciences | public health | social determinants of health | </Fields_of_Research>
        <Res_KW1>cancer epidemiology</Res_KW1>
        <Res_KW2>data linkage</Res_KW2>
        <Res_KW3>social determinants of health</Res_KW3>
        <Res_KW4>capacity building</Res_KW4>
        <Res_KW5>evidence-based health care</Res_KW5>
        <Plain_Description>Cancer in the Indigenous population is increasing. Led by Indigenous researchers and informed by the community, an Aboriginal cancer cohort will be established by creating a unique state-wide dataset to identify the most important priority areas for addressing disparities that will have greatest impact on reducing inequalities and improving outcomes for Aboriginal people with cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032498</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Dr Alyna Turner</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Enhancing work participation after stroke: supporting regional and rural Australians</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,928,425.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>rural and remote health services</Res_KW3>
        <Res_KW4>stroke</Res_KW4>
        <Res_KW5>return to work</Res_KW5>
        <Plain_Description>Working after a stroke is associated with better physical and mental health outcomes. In Australia, people who have had a stroke can often miss out on targeted support to help them return to and stay at work, particularly those in rural areas. We plan to evaluate a telehealth service designed to improve work ability after a stroke. This service ensures recovery as well as work-related needs are met, and has the potential to increase work participation and productivity long term after stroke.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032516</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Sam Adie</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Early Pain Intervention after total Knee replacement (EPIK): a registry-nested trial</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,154,577.23</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | pain | biomedical and clinical sciences | clinical sciences | orthopaedics  | health sciences | allied health and rehabilitation science | physiotherapy | </Fields_of_Research>
        <Res_KW1>knee replacement</Res_KW1>
        <Res_KW2>orthopaedic surgery</Res_KW2>
        <Res_KW3>chronic pain</Res_KW3>
        <Res_KW4>physiotherapy assessment</Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>Total Knee replacement (TKR) is a common surgical procedure that aims to improve pain and quality of life in people with severe arthritis of the knee. However, one in four people have persistent, pain after TKR. We have developed a model of cae (EPIK) to improve outcomes for people with persistent pain after TKR, which will be evaluated in a rigorous, high-quality randomised controlled trial.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032525</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Craig Anderson</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>ACT-GLOBAL platform trial to resolve uncertainty over thrombolysis treatment in acute ischaemic stroke</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,191,922.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | major global burdens of disease | health sciences | health services and systems | people with disability | biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | </Fields_of_Research>
        <Res_KW1>acute stroke</Res_KW1>
        <Res_KW2>ischaemic stroke</Res_KW2>
        <Res_KW3>thrombolysis treatment</Res_KW3>
        <Res_KW4>clinical effectiveness</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>Opening up blocked blood vessels with intravenous thrombolysis is a proven treatment for acute ischaemic stroke. However, there are still knowledge gaps over the balance of benefits and risks of this treatment in certain types of patients. The goal of our newly developed ACT-GLOBAL platform is to efficiently undertake a series of randomised investigations to optimise thrombolysis treatment for patients across the world.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032534</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Shyamali Dharmage</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Does inhaled triple therapy in individuals with pre-COPD arrest progression to full-blown COPD? A double-blind randomised placebo-controlled trial (PRE-TREAT)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,026,874.19</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | health sciences | public health | preventative health care | </Fields_of_Research>
        <Res_KW1>chronic obstructive pulmonary disease (copd)</Res_KW1>
        <Res_KW2>early prevention</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>secondary prevention</Res_KW4>
        <Res_KW5>therapeutic agents</Res_KW5>
        <Plain_Description>Chronic Obstructive Pulmonary Disease (COPD) is usually diagnosed far too late, when lung damage cannot be recovered and treatment cannot prevent further decline. Aiming to prevent 3.2 million premature deaths, we will conduct a world first trial of Triple Therapy (3 safe medicines in one inhaler) to stop progression of early lung damage to full-blown COPD. We will also identify if particular groups of people are more likely to benefit from this treatment and evaluate its cost-effectiveness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032553</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Debra Palmer</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Developing infant tolerance to peanut via breastmilk: a randomised controlled trial.</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,290,114.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | biomedical and clinical sciences | immunology | allergy | </Fields_of_Research>
        <Res_KW1>food allergy</Res_KW1>
        <Res_KW2>breast milk</Res_KW2>
        <Res_KW3>allergy prevention</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>maternal nutrition</Res_KW5>
        <Plain_Description>This study aims to determine the ideal amount of peanuts in breastfeeding mothers’ diets to prevent peanut allergies in their babies. A new finding from our pilot trial suggests that a high-peanut diet during breastfeeding may reduce babies developing peanut allergies. To make maternal diet during breastfeeding for food allergy prevention guidelines, we now need to include more women and babies. This research has been co-designed with consumers who will be involved in all stages of this project.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032603</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Raymond Lovett</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Counting what counts: using a national cohort study to develop, validate and apply an Indigenous Quality of Wellbeing Utility Index and quantifying key determinants of health</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,789,516.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander epidemiology | </Fields_of_Research>
        <Res_KW1>psychometrics</Res_KW1>
        <Res_KW2>quality of life</Res_KW2>
        <Res_KW3>wellbeing</Res_KW3>
        <Res_KW4>indigenous health</Res_KW4>
        <Res_KW5>measurement</Res_KW5>
        <Plain_Description>Health and wellbeing are influenced by many factors, yet globally, Western-developed Quality of Life measurements focus almost exclusively on physical health. For Indigenous peoples, social, emotional and cultural wellbeing of community, and health of country impact quality of life. This project will create a world-first Indigenous wellbeing index to inform policy, services and programs that meet Aboriginal and Torres Strait Islanders’ wellbeing needs - a model that could be adapted globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032605</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jennifer Koplin</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>Improving Food Allergy Outcomes in Adolescents</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,117,916.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | allergy | biomedical and clinical sciences | paediatrics | adolescent health | </Fields_of_Research>
        <Res_KW1>food allergy</Res_KW1>
        <Res_KW2>adolescent</Res_KW2>
        <Res_KW3>quality of life</Res_KW3>
        <Res_KW4>clinical patient management</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>Food allergy affects 1 in 10 Australian children. Adolescents are at highest risk of life-threatening allergic reactions, however, much less is known about food allergy in adolescents compared to young children. This study will investigate how food allergy affects adolescents and their families; find out how often childhood food allergy resolves by adolescence; develop better tests to determine if food allergy has resolved and improve clinical management of food allergy in this age group.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032610</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anthony Delaney</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>PRophylaxis against VENTilator-associated infections in NEUROlogically injured ICU patients (PReVENT-NEURO) trial</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$6,339,906.70</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care  | biomedical and clinical sciences | neurosciences | neurosciences not elsewhere classified | biomedical and clinical sciences | cardiovascular medicine and haematology | respiratory diseases  | </Fields_of_Research>
        <Res_KW1>intensive care medicine</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>pneumonia</Res_KW3>
        <Res_KW4>neurological disorders</Res_KW4>
        <Res_KW5>mechanical ventilation</Res_KW5>
        <Plain_Description>Patients with severe acute brain injury who require treatments to support their breathing in an intensive care unit are at high risk of developing lung infection. Those that do develop lung infections have a higher risk of dying, and may not recover as well as they could from the brain injury. We plan to conduct a clinical trial to assess whether the use of antibiotics at the time of commencing intensive care interventions will lead to reduced risk of death and improved recovery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032628</App_ID>
        <Date_Announced>2024-05-10T00:00:00</Date_Announced>
        <CIA_Name>Prof Steven Tong</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies</Grant_Type>
        <Sub_Type>2023 Clinical Trials and Cohort Studies</Sub_Type>
        <Grant_Title>The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$6,952,426.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | biological sciences | microbiology | bacteriology  | biomedical and clinical sciences | clinical sciences | intensive care  | </Fields_of_Research>
        <Res_KW1>staphylococcus aureus</Res_KW1>
        <Res_KW2>multiply-resistant staphylococci</Res_KW2>
        <Res_KW3>antibiotic therapy</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>Staphylococcus aureus bloodstream infections causes 300,000 deaths per year. The SNAP trial is an Australian led international clinical trial addressing priority treatment questions. Despite delays in starting SNAP due to the COVID-19 pandemic, SNAP is now the largest S. aureus bloodstream infection trial ever. Through ongoing funding, we aim to involve more countries, ensure sufficient participants to address current and new questions, and understand long-term patient impacts of the infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2033880</App_ID>
        <Date_Announced>2024-06-27T00:00:00</Date_Announced>
        <CIA_Name>Dr Carolien van de Sandt</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 (EL2)</Sub_Type>
        <Grant_Title>Restoring immunity across the human lifespan and in high-risk groups</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,603,775.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | cellular immunology | biological sciences | microbiology | virology  | biomedical and clinical sciences | immunology | immunogenetics (incl. genetic immunology) | </Fields_of_Research>
        <Res_KW1>viral immunology</Res_KW1>
        <Res_KW2>influenza virus</Res_KW2>
        <Res_KW3>healthy ageing</Res_KW3>
        <Res_KW4>cd8 t lymphocytes</Res_KW4>
        <Res_KW5>sars-cov-2</Res_KW5>
        <Plain_Description>My research aims to understand why the same virus causes mild infections in one person and has devastating-outcomes in another. 1-in-5 people have weak immunity resulting in severe infections. Traditional vaccines boost healthy immunity rather than repair immune function, providing suboptimal protection in high-risk populations. Understanding how immunity is generated, why it fails and how immunity can be repaired will aid development of novel vaccines/interventions for high-risk populations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035274</App_ID>
        <Date_Announced>2024-07-19T00:00:00</Date_Announced>
        <CIA_Name>Prof Yin Paradies</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Commercial Determinants of Aboriginal and Torres Strait Islander Health</Sub_Type>
        <Grant_Title>Addressing Commercial Health-determinants: Indigenous Empowerment and Voices for Equity (ACHIEVE)</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,566,842.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social determinants of health | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>social determinants of health</Res_KW2>
        <Res_KW3>public health</Res_KW3>
        <Res_KW4>equity</Res_KW4>
        <Res_KW5>health promotion</Res_KW5>
        <Plain_Description>ACHIEVE aims to understand and address how commercial factors impact Indigenous health. Working closely with Indigenous communities the project will explore Indigenous views on the commercial determinants of health (CDoH); evaluate the effectiveness of existing marketing regulations; assess how specific commercial entities affect Indigenous health, and collaborate with Indigenous organisations to co-create solutions to the CDoH. The key outcome will be an Indigenous-led CDoH policy agenda.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035347</App_ID>
        <Date_Announced>2024-07-19T00:00:00</Date_Announced>
        <CIA_Name>Prof Sandra Eades</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Commercial Determinants of Aboriginal and Torres Strait Islander Health</Sub_Type>
        <Grant_Title>Living the commercial determinants of health: A remote Aboriginal and Torres Strait Islander experience.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,273,513.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health policy | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>qualitative research</Res_KW2>
        <Res_KW3>determinants</Res_KW3>
        <Res_KW4>remote communities</Res_KW4>
        <Res_KW5>wellbeing</Res_KW5>
        <Plain_Description>This project seeks to understand how the commercial determinants of health (CDoH) impact the everyday lives of people living in the remote NT community of Ngukurr. Supporting Indigenous knowledge systems and methdologies, the project will  employ community based researchers to work with community members to develop models and frameworks for understanding the pathways and networks between health and the commercial determinants and to propose solutions for advocacy and community planning.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035564</App_ID>
        <Date_Announced>2024-07-19T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mark Wenitong</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Commercial Determinants of Aboriginal and Torres Strait Islander Health</Sub_Type>
        <Grant_Title>A co-designed framework to drive action to promote health and equity in remote Aboriginal and Torres Strait Islander community stores</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,408,201.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | social determinants of health | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social determinants of health | </Fields_of_Research>
        <Res_KW1>indigenous australians</Res_KW1>
        <Res_KW2>indigenous health</Res_KW2>
        <Res_KW3>social determinants of health</Res_KW3>
        <Res_KW4>translational research</Res_KW4>
        <Res_KW5>policy development</Res_KW5>
        <Plain_Description>Community stores servicing people in remote Indigenous communities across Australia are adopting practices that challenge the profit-at-any-cost approach to implement stores driven by social values. We aim to build a deeper understanding of facilitators and obstacles that promote the health of people and planet, and co-design a framework to support decision-making for action that promotes health in stores. Scaled-up, this approach could be adopted by other industries and contexts in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035577</App_ID>
        <Date_Announced>2024-07-19T00:00:00</Date_Announced>
        <CIA_Name>Prof Raymond Lovett</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Commercial Determinants of Aboriginal and Torres Strait Islander Health</Sub_Type>
        <Grant_Title>Developing an Indigenous Commercial Determinants of Health index and community implementation framework</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$977,532.40</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | social determinants of health | health sciences | epidemiology | social epidemiology | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander cultural determinants of health | </Fields_of_Research>
        <Res_KW1>indigenous health</Res_KW1>
        <Res_KW2>indigenous australians</Res_KW2>
        <Res_KW3>social determinants of health</Res_KW3>
        <Res_KW4>validation</Res_KW4>
        <Res_KW5>community development</Res_KW5>
        <Plain_Description>The commercial determinants of health for Indigenous peoples are not defined, which presents a significant knowledge gap; knowledge that is critical to address persistent health inequity. This proposal will create the first comprehensive Indigenous Commercial Determinants Index to equip policymakers to strengthen systems and services to improve health outcomes; and create a tool to empower communities to make decisions about local commercial activities that will bring benefit, and reduce harm.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035579</App_ID>
        <Date_Announced>2024-07-19T00:00:00</Date_Announced>
        <CIA_Name>Ms Carol-Lynne Christophersen</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Commercial Determinants of Aboriginal and Torres Strait Islander Health</Sub_Type>
        <Grant_Title>Project White-ant: co-creating knowledge with Aboriginal and Torres Strait Islander communities about mobilising to protect against commercial determinants of health</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,034,231.80</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander peoples, society and community | aboriginal and torres strait islander community-based research | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander social determinants of health | indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health policy | </Fields_of_Research>
        <Res_KW1>aboriginal</Res_KW1>
        <Res_KW2>culturally appropriate methodology</Res_KW2>
        <Res_KW3>community-based</Res_KW3>
        <Res_KW4>equity</Res_KW4>
        <Res_KW5>alcohol</Res_KW5>
        <Plain_Description>Project White-Ant will generate knowledge that can support Aboriginal and Torres Strait Islander communities to protect against harms caused by commercial systems. The project proposes tangible knowledge and skill-building which enables communities to influence which, and how, products and services are sold to their peoples, generating collective action to improve public policy in a context where effective policy and programs and different conversations are so sorely needed.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032909</App_ID>
        <Date_Announced>2024-08-08T00:00:00</Date_Announced>
        <CIA_Name>Dr Joanne Tropea</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Improving Infection Prevention and Control in Residential Aged Care Homes</Sub_Type>
        <Grant_Title>IMMERSE-2 IMpleMenting Effective infection prevention and control in ReSidential aged carE: Communities of Practice for IPC Leads</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$990,731.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | residential client care | </Fields_of_Research>
        <Res_KW1>aged care</Res_KW1>
        <Res_KW2>infection control</Res_KW2>
        <Res_KW3>nursing practice</Res_KW3>
        <Res_KW4>residential care</Res_KW4>
        <Res_KW5>evidence-based</Res_KW5>
        <Plain_Description>Older people living in residential care are at risk of infections like influenza and COVID. Staff are responsible for actions that prevent these infections and deliver quality care. They need ongoing training and support to do this. We will study how a group learning approach works (Community of Practice, CoP). Building on our current research, we will work with staff and consumers to test CoPs and explore how to share this approach across Australia. We aim to improve care and reduce infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034723</App_ID>
        <Date_Announced>2024-08-08T00:00:00</Date_Announced>
        <CIA_Name>Prof Ramon Shaban</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Improving Infection Prevention and Control in Residential Aged Care Homes</Sub_Type>
        <Grant_Title>Establishing Standards for the Governance, Program Elements and Practice of Infection Prevention and Control in Residential Aged Care in Australia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$745,287.20</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | health sciences | nursing | aged care nursing | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>aged care</Res_KW1>
        <Res_KW2>nursing practice</Res_KW2>
        <Res_KW3>residential care</Res_KW3>
        <Res_KW4>health professionals</Res_KW4>
        <Res_KW5>nosocomial infections</Res_KW5>
        <Plain_Description>Incoming aged care standards will require all residential aged care homes (RACHs) to appoint a designated infection control professional (ICP). This research will support these mandates by developing an evidence base for infection control in RACHs and by establishing a set of standards for: 1) the essential elements and governance arrangements for IPC programs in RACHs, and 2) the practice and competency for ICPs in RACHs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035155</App_ID>
        <Date_Announced>2024-08-08T00:00:00</Date_Announced>
        <CIA_Name>Dr Su-yin Hor</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Improving Infection Prevention and Control in Residential Aged Care Homes</Sub_Type>
        <Grant_Title>Partnering with residents, families and carers for person-centred infection prevention and control in residential aged care: developing strategies that are compassionate, appropriate and safe.</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$991,077.60</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>infection control</Res_KW1>
        <Res_KW2>aged care</Res_KW2>
        <Res_KW3>consumer participation</Res_KW3>
        <Res_KW4>evaluation</Res_KW4>
        <Res_KW5>health promotion</Res_KW5>
        <Plain_Description>This project will investigate how we can keep residents, staff, and the community safe from infectious diseases, without compromising the rights, and health and wellbeing needs of older people in care. Researchers will partner with people in care, their families and carers, residential aged care providers and infection control experts, to develop and evaluate resources to support infection prevention programs that are compassionate, appropriate and safe for people in residential aged care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035342</App_ID>
        <Date_Announced>2024-08-08T00:00:00</Date_Announced>
        <CIA_Name>Prof Anton Peleg</CIA_Name>
        <Grant_Type>Targeted Research</Grant_Type>
        <Sub_Type>2023 TCR Improving Infection Prevention and Control in Residential Aged Care Homes</Sub_Type>
        <Grant_Title>Optimised Infection Prevention and Control Study in Residential Aged Care Homes (OPTICS) </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$998,995.90</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | </Fields_of_Research>
        <Res_KW1>infection control</Res_KW1>
        <Res_KW2>aged care</Res_KW2>
        <Res_KW3>pneumonia</Res_KW3>
        <Res_KW4>cross-infection</Res_KW4>
        <Res_KW5>surveillance</Res_KW5>
        <Plain_Description>This research program will develop optimised models and approaches for infection prevention and control in residential aged care homes through a highly engaged co-design process with people with lived experience and end users to improve the lives of people living in aged care homes by reducing their risk of infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032385</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Steven McPhail</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Engendering agency in Aboriginal and Torres Strait Islander community health through responsive practice</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,332,594.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | primary health care | </Fields_of_Research>
        <Res_KW1>self-efficacy</Res_KW1>
        <Res_KW2>community care</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>doctor-patient relationships</Res_KW4>
        <Res_KW5>health care delivery</Res_KW5>
        <Plain_Description>This research originated (from inception) and is fundamentally led by the Aboriginal and Torres Strait Islander Community Health Service (ATSICHS), Brisbane which started searching for a means for their people to play a more direct role in their own wellbeing over half a century ago, which this project will build on.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032720</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Carlos Salomon</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>The Early study: Evaluating the Specificity and feasibility of the EARLY Test for Ovarian Cancer Detection</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,461,194.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer diagnosis | </Fields_of_Research>
        <Res_KW1>ovarian cancer</Res_KW1>
        <Res_KW2>clinical diagnosis</Res_KW2>
        <Res_KW3>disease susceptibility</Res_KW3>
        <Res_KW4>early detection</Res_KW4>
        <Res_KW5>cancer prognosis</Res_KW5>
        <Plain_Description>We have developed a new type of test (OCRF-7) for the earlier detection of ovarian cancer. The EARLY study will establish the disease specificity, analytical validation and feasibility of implementation of the OCRF-7 assay by performing a comparison analysis of the performance of OCRF-7 to identify women with ovarian cancer versus other types of cancer and relevant clinical conditions. This information is required to make progress in the pathway to making the test available for clinical use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032751</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Christina Aggar</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>A novel approach to partnering with family carers in the prevention of delirium</Grant_Title>
        <Admin_Institution>Southern Cross University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,334,456.37</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | nursing | acute care | </Fields_of_Research>
        <Res_KW1>delirium</Res_KW1>
        <Res_KW2>older people</Res_KW2>
        <Res_KW3>family support</Res_KW3>
        <Res_KW4>dementia care</Res_KW4>
        <Res_KW5>caregiver health</Res_KW5>
        <Plain_Description>Delirium is a common, frightening and costly hospital complication that causes confusion and negative outcomes for older Australian adults and their family carers. Despite being preventable, delirium assessment and recognition in clinical practice is poor. We aim to focus on the nurse-carer partnership, supported by a Prevention &amp; Early Delirium Identification Carer Toolkit (PREDICT) to reduce delirium incidence and associated hospital costs, and drive systemic change in delirium management.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032859</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Fabricio da Silva Costa</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Optimising maternal and perinatal outcomes through a digital clinical decision tool in maternity care</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,475,910.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | reproductive medicine | obstetrics and gynaecology  | health sciences | midwifery | clinical midwifery | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>pregnancy complications</Res_KW1>
        <Res_KW2>risk prediction</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>fetal development</Res_KW4>
        <Res_KW5>artificial intelligence</Res_KW5>
        <Plain_Description>Each year in Australia more than 9,000 pregnancies are impacted by pre-eclampsia, 27,000 babies are born preterm and 2,200 babies are stillborn. Many of these outcomes are preventable. Our initiative will implement a digital medical device developed with significant consumer and clinician engagement to provide pregnant women with personalised risk assessment, enabling effective care. Adoption of this device will dramatically improve outcomes, reduce variation in care and reduce healthcare costs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2032912</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Lazzarini</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Queensland Diabetes Footcare Hubs (Q DFootHubs)</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,363,466.75</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems | biomedical and clinical sciences | clinical sciences | endocrinology | health sciences | allied health and rehabilitation science | podiatry | </Fields_of_Research>
        <Res_KW1>chronic leg or foot ulcers</Res_KW1>
        <Res_KW2>wound healing</Res_KW2>
        <Res_KW3>diabetic complications</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>This project aims to robustly evaluate the implementation of co-designed, evidence-based, hub-spoke DFD models of care (“DFootHubs”) to determine if they do improve access to services, quality of services, effectiveness of services, are sustainable and scalable to other regions of Australia and potentially Internationally. The project will be guided by best practice implementation science frameworks to sequentially evaluate each stage of the implementation of each DFootHUB model.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2034917</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Naomi Hammond</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Consumer and clinician partnership to develop post sepsis follow-up models of care across the lifespan</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,478,026.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | intensive care  | biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>sepsis</Res_KW1>
        <Res_KW2>follow-up</Res_KW2>
        <Res_KW3>critical illness</Res_KW3>
        <Res_KW4>nursing</Res_KW4>
        <Res_KW5>paediatric</Res_KW5>
        <Plain_Description>Sepsis survivors across the lifespan have unmet chronic and complex health needs requiring comprehensive support after hospital discharge. These patients frequently fall through the cracks of the health system with as many as 70% being readmitted to hospital within 1 year. This program will provide critical information to develop and evaluate effective post sepsis follow-up models of care across the lifespan, to improve long-term outcomes of those experiencing sepsis and their families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035243</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Lara Farrell</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Bridging the science-service treatment gap for children and young people with obsessive compulsive disorder (OCD):  Implementation of evidence-based care in community mental health services</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,475,616.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | mental health services | psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>obsessive-compulsive disorder (ocd)</Res_KW1>
        <Res_KW2>implementation</Res_KW2>
        <Res_KW3>cognitive behaviour therapy</Res_KW3>
        <Res_KW4>assessment</Res_KW4>
        <Res_KW5>evidence-based clinical practice</Res_KW5>
        <Plain_Description>This proposal aims to bridge the science-to-service gap for Australian children and young people (CYP) suffering from obsessive-compulsive disorder (OCD). This partnership will transform mental health service delivery and policy via the implementation, evaluation, and dissemination of an evidence-based model of care (MoC) for young people with OCD in NSW and QLD.  Our MoC includes evidence-based screening; best-practice assessment; flexible delivery of CBT-ERP; and routine outcome assessments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035258</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Katherine Harding</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>WaitLESS: Applying data driven evidence based principles to reduce waiting lists in specialist clinics</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,469,063.30</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems | health sciences | health services and systems | implementation science and evaluation | health sciences | health services and systems | health management | </Fields_of_Research>
        <Res_KW1>waiting lists</Res_KW1>
        <Res_KW2>health service accessibility</Res_KW2>
        <Res_KW3>health services research</Res_KW3>
        <Res_KW4>health systems</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Waiting lists for specialist clinics are one the most intractable problems in our health system, despite a large body of evidence showing waiting lists can be reduced. This project will apply this evidence in 8 outpatient clinics, evaluating the impact on waiting times using a rigorous method for health services research. We will evaluate the economic costs and benefits, and work with staff and consumers to explore the "how and why" of our results to inform future translation to practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035321</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Janet Anderson</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Comprehensive geriatric assessment (CGA) to improve perioperative care for Older PeoplE (COPE) </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,449,962.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | aged health care | health sciences | health services and systems | health systems | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>geriatric assessment</Res_KW1>
        <Res_KW2>joint replacement</Res_KW2>
        <Res_KW3>outcome evaluation</Res_KW3>
        <Res_KW4>cost-effectiveness</Res_KW4>
        <Res_KW5>quality improvement</Res_KW5>
        <Plain_Description>Hip and knee replacement surgery is common in older people, but they often have multiple health conditions and poorer outcomes. One reason is the lack of routine expert geriatric assessment in their pre and post-surgical care despite international evidence of its benefits. This study will evaluate the effectiveness of Comprehensive Geriatric Assessment and produce a road map for introducing it to Australian hospitals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035358</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Leanne Hides</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>Implementation, Effectiveness and Sustainability of a Co-designed Value-based Brief Intervention Model of Healthcare in Alcohol and Other Drug Services</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,475,506.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | implementation science and evaluation | psychology | clinical and health psychology | clinical and health psychology not elsewhere classified | </Fields_of_Research>
        <Res_KW1>substance use disorders</Res_KW1>
        <Res_KW2>addiction treatment</Res_KW2>
        <Res_KW3>outcome measures</Res_KW3>
        <Res_KW4>information systems/decision support systems</Res_KW4>
        <Res_KW5>brief intervention</Res_KW5>
        <Plain_Description>We are currently only meeting half of the demand for alcohol and drug (AOD) treatment. This project will utilise our strong partnerships with AOD treatment and policy experts to examine the efficacy of the First Step brief intervention model of care, which places a brief intervention at the beginning of treatment. We will examine the cost-effectiveness and co-design implementation strategies to enhance and sustain the delivery of this brief intervention in AOD services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035393</App_ID>
        <Date_Announced>2024-08-18T00:00:00</Date_Announced>
        <CIA_Name>Prof Nigel Lovell</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2023 Partnership Projects PRC2</Sub_Type>
        <Grant_Title>A virtual health approach to provide value-based care for those with chronic comorbidities</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,446,108.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biomedical and clinical sciences | clinical sciences | geriatrics and gerontology  | engineering | biomedical engineering | biomedical engineering not elsewhere classified | </Fields_of_Research>
        <Res_KW1>telemedicine</Res_KW1>
        <Res_KW2>chronic diseases</Res_KW2>
        <Res_KW3>healthy ageing</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>machine learning</Res_KW5>
        <Plain_Description>Through partnering and co-design we will build and implement a telehealth platform for managing patients with complex chronic disease and integrate it into the virtual care and home-based care services run by our partner organisation. We will then evaluate the system to assess its effectiveness from patient and organisation perspectives. We will use these findings to guide the design of future systems aimed at providing safe, scalable and cost-effective holistic care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035789</App_ID>
        <Date_Announced>2024-08-21T00:00:00</Date_Announced>
        <CIA_Name>Dr Myles Murphy</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2024 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Co-designing and implementing a sustainable injury prevention program for Police Force recruits </Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,170,290.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | injury prevention | health sciences | epidemiology | occupational epidemiology  | </Fields_of_Research>
        <Res_KW1>injury prevention</Res_KW1>
        <Res_KW2>occupational injury</Res_KW2>
        <Res_KW3>musculoskeletal</Res_KW3>
        <Res_KW4>primary prevention</Res_KW4>
        <Res_KW5>exercise</Res_KW5>
        <Plain_Description>Our research will involve co-designing a Western Australia Police Force injury prevention program. This prevention program will be implemented as standard practice in Police Force recruit training. We will assess the effect of our program on injury rates, when compared to the past 10 years of injury data. This project will create a sustainable injury prevention program for the Police Force, increasing the health of their workforce and reducing the healthcare costs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036255</App_ID>
        <Date_Announced>2024-08-21T00:00:00</Date_Announced>
        <CIA_Name>Prof Valsamma Eapen</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2024 Partnership Projects PRC1</Sub_Type>
        <Grant_Title>Integrated Kids Connect program: Addressing inequities in service access in the early years by "going to where the children go"</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$698,393.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | health sciences | public health | health equity | </Fields_of_Research>
        <Res_KW1>mental health</Res_KW1>
        <Res_KW2>child development</Res_KW2>
        <Res_KW3>access to health care</Res_KW3>
        <Res_KW4>health inequalities</Res_KW4>
        <Res_KW5>health promotion</Res_KW5>
        <Plain_Description>The Kids Connect program aims to create a blended (digital/in-person) strengths-based integrated approach embedded within routine child and family service system across three priority communities to 1) Identify children with developmental needs early and 2) provide early intervention and supports through the co-production of equitable strengths-based models of care; 3) Evaluate the impact and implementation outcomes of the Kids Connect program and integrate new knowledge to address service gaps.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035240</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Natalie Bradford</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence for Paediatric Palliative Care</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health systems | biomedical and clinical sciences | clinical sciences | clinical sciences not elsewhere classified | biomedical and clinical sciences | paediatrics | infant and child health | </Fields_of_Research>
        <Res_KW1>paediatric</Res_KW1>
        <Res_KW2>palliative care</Res_KW2>
        <Res_KW3>health services research</Res_KW3>
        <Res_KW4>patient/professional communication</Res_KW4>
        <Res_KW5>priority setting</Res_KW5>
        <Plain_Description>Palliative care for the 30,000 Australian children who may need such care lacks evidence. Our project partners with experts and consumers to improve care through research. Our four programs of research are informed by and aligned with the Paediatric Palliative Care National Action Plan. Each program of research uses gold standard research methods to address questions. Our goal is to translate evidence into better healthcare for children with life-limiting conditions and their families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035256</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Laura Tarzia</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>RESTORE Centre of Research Excellence: Transforming health systems to restore wellbeing and enhance access to healing after sexual violence in adulthood</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | mental health services | health sciences | health services and systems | health and community services | </Fields_of_Research>
        <Res_KW1>sexual abuse</Res_KW1>
        <Res_KW2>mental health services</Res_KW2>
        <Res_KW3>domestic violence</Res_KW3>
        <Res_KW4>health services research</Res_KW4>
        <Res_KW5>trauma</Res_KW5>
        <Plain_Description>Sexual violence severely damages victim/survivors' health. Our goal is to transform health services to support victim/survivors to restore wellbeing and enhance healing. We will generate new knowledge to strengthen health practice and policy and guide investment in new models of care. We will work with lived experience experts to enhance trauma-informed service delivery. We will support early and mid-career researchers by mentoring and an international network.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035259</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Janet Bray</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>Optimising the emergency response to save lives: An Aus-ROC Centre of Research Excellence (Aus-ROC CRE)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | emergency medicine | health sciences | health services and systems | health services and systems not elsewhere classified | </Fields_of_Research>
        <Res_KW1>cardiac arrest</Res_KW1>
        <Res_KW2>cardiac resuscitation</Res_KW2>
        <Res_KW3>emergency medical service</Res_KW3>
        <Res_KW4>health service utilisation</Res_KW4>
        <Res_KW5>defibrillation</Res_KW5>
        <Plain_Description>Every year, over 31,000 out-of-hospital cardiac arrests (OHCA) occur in Australia and New Zealand, but only 7% survive. Actions taken in the initial minutes are critical to survival, but these are sub-optimal in our region. A paradigm shift is needed to improve our OHCA survival. We propose a comprehensive solution that integrates innovative health strategies, including cutting-edge technology, to enhance the efficacy and sophistication of the emergency response for OHCA.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035278</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Dennis Petrie</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Achieving Health Equity for All People with Disabilities (AHEAD)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health equity | economics | applied economics | health economics  | human society | policy and administration | public policy | </Fields_of_Research>
        <Res_KW1>disability</Res_KW1>
        <Res_KW2>equity</Res_KW2>
        <Res_KW3>health economics</Res_KW3>
        <Res_KW4>epidemiology</Res_KW4>
        <Res_KW5>public health policy</Res_KW5>
        <Plain_Description>Australians with disabilities have poorer health due to avoidable disadvantages in various life areas, driven by factors like poverty and social exclusion. AHEAD aims to collaborate with a wide range of stakeholders to co-design sustainable solutions for these challenges, ensuring health equity for all.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035298</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Seth Masters</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Basic Science Research</Sub_Type>
        <Grant_Title>The Centre of Excellence in Autoinflammatory Disease Research</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | </Fields_of_Research>
        <Res_KW1>inflammation</Res_KW1>
        <Res_KW2>immune-mediated inflammation</Res_KW2>
        <Res_KW3>inflammatory diseases</Res_KW3>
        <Res_KW4>chronic inflammation</Res_KW4>
        <Res_KW5>inflammatory arthritis</Res_KW5>
        <Plain_Description>One part of the human immune system is hardwired and innate, responding immediately to invading pathogens. This requires a system of sensors that detect pathogens or the damage that pathogens cause to the host. Unfortunately, gene alterations can lead to increased activation of these pathways causing autoinflammatory diseases. In this Centre, we learn from these gene variants how our innate immune system works, and how to target these inflammatory pathways to prevent disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035302</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Kaylene Young</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Basic Science Research</Sub_Type>
        <Grant_Title>Centre of multiple sclerosis research translation</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | neurosciences | neurology and neuromuscular diseases | </Fields_of_Research>
        <Res_KW1>multiple sclerosis (ms)</Res_KW1>
        <Res_KW2>adult stem cells</Res_KW2>
        <Res_KW3>glial cells</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>genetics</Res_KW5>
        <Plain_Description>Multiple Sclerosis (MS) is a disease that causes inflammation in the brain. People with MS need treatments that will protect and repair the brain. In our MS Centre, people with MS, researchers, and doctors work together to find out how MS affects the brain. This gives us clues about the type/s of drugs that might help. We grow brain cells in the lab, add the potential drugs, and measure the effect. Drugs that protect brain cells are then tested in the clinic to see how they help people with MS.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035303</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Dr Freya Shearer</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Australian Centre for Epidemic Forecasting and Analytics </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | epidemiological modelling | health sciences | epidemiology | disease surveillance | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>infectious diseases</Res_KW1>
        <Res_KW2>decision support</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>mathematical modelling</Res_KW4>
        <Res_KW5>public health policy</Res_KW5>
        <Plain_Description>Our Vision is to reduce disease and deaths associated with epidemic diseases in Australia. The Centre aims to advance methods and software tools in epidemic forecasting and analytics, and improve the utility of data collected by disease surveillance systems. Centre-led national Forecasting and Scenario Modelling Hubs will coordinate the provision of timely and high-quality evidence to decision-makers, improving public health responses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035308</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Timothy Slade</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>PRevention of Mental Illness and Substance usE (PREMISE) Next Generation: New Targets, New Interventions</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | preventative health care | health sciences | epidemiology | major global burdens of disease | health sciences | health services and systems | mental health services | </Fields_of_Research>
        <Res_KW1>alcohol</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>disease prevention</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>The global landscape of youth mental health and substance use is rapidly changing. Precipitous rises in youth anxiety, depression and self-harm, coupled with major population shifts in risk factors and emerging challenges, call for urgent new approaches to prevent mental and substance use disorders. The PREMISE Next Generation CRE will identify new targets for prevention and develop new interventions to prevent the leading causes of disease burden in young Australians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035317</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Jeanie Cheong</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>EPIC - Extremely Preterm Infant CRE: Innovative methods to improve the health and development of our most immature infants</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | paediatrics | neonatology | biomedical and clinical sciences | paediatrics | paediatrics not elsewhere classified | </Fields_of_Research>
        <Res_KW1>very preterm birth</Res_KW1>
        <Res_KW2>bronchopulmonary dysplasia</Res_KW2>
        <Res_KW3>neurodevelopment</Res_KW3>
        <Res_KW4>respiratory distress syndrome (rds)</Res_KW4>
        <Res_KW5>clinical practice guidelines</Res_KW5>
        <Plain_Description>Extremely preterm birth is associated with lifelong health and developmental problems. This CRE proposes a research program to address pressing health and developmental issues identified by consumers and clinicians. We will use innovative research methods to improve outcomes in the newborn period, up to adulthood. Our strong record of training world research leaders will be expanded in this CRE. We will extend our collaborations for research and translation throughout Australia, and worldwide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035319</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Nicholas Talley</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Transforming Gut Health</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | gastroenterology and hepatology | </Fields_of_Research>
        <Res_KW1>irritable bowel syndrome (ibs)</Res_KW1>
        <Res_KW2>functional bowel disorder</Res_KW2>
        <Res_KW3>nonulcer dyspepsia</Res_KW3>
        <Res_KW4>microbiology</Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>This Centre of Research Excellence will transform the clinical approach to extremely common chronic unexplained conditions of the digestive tract affecting millions of Australians. Combining advanced techniques to identify disease markers and personalised treatments, capture unmet patient needs, and remove dietary and other triggers, this work will improve symptoms, quality of life and patient experiences, and reduce the health care system burden due to chronic digestive tract disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035343</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Monica Slavin</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>Transforming infection management in the era of emerging cancer therapies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | health sciences | health services and systems | digital health | health sciences | health services and systems | implementation science and evaluation | </Fields_of_Research>
        <Res_KW1>infectious diseases</Res_KW1>
        <Res_KW2>health care delivery</Res_KW2>
        <Res_KW3>electronic health information</Res_KW3>
        <Res_KW4>surveillance</Res_KW4>
        <Res_KW5>cancer care</Res_KW5>
        <Plain_Description>There has been an explosion in the use of new cancer therapies acting on the immune system, however, infection is still the leading cause of death in these patients.  Simultaneously there has been an increase in the use of digital health systems which has created an ideal opportunity to design better systems to support cancer patients. We will transform infection prevention and management in high risk cancer patient groups in this new age of cancer immunotherapies and digital health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035348</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Benjamin Hogan</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Basic Science Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Lymphoedema and  Lymphatic Regeneration</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | genetics | developmental genetics (incl. sex determination) | biomedical and clinical sciences | medical biotechnology | regenerative medicine (incl. stem cells) | biological sciences | genetics | gene expression (incl. microarray and other genome-wide approaches) | </Fields_of_Research>
        <Res_KW1>lymphangiogenesis</Res_KW1>
        <Res_KW2>lymphoedema</Res_KW2>
        <Res_KW3>cell biology</Res_KW3>
        <Res_KW4>vascular biology</Res_KW4>
        <Res_KW5>development</Res_KW5>
        <Plain_Description>Lymphatic diseases are a major but frequently overlooked clinical burden. Lymphoedema is a debilitating disease caused by reduced lymphatic vessel function. It impacts as many as 300,000 Australians at any one time and is common in cancer survivors. The Centre of Research Excellence (CRE) in lymphoedema and lymphatic regeneration will use cutting edge genetics, cell and molecular biology to generate paradigm shifting knowledge in lymphatic biology and develop new avenues to treat lymphoedema.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035367</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Karin Thursky</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Health Services Research</Sub_Type>
        <Grant_Title>Redesign of Antimicrobial Stewardship Programs in the Digital Era across One Health (RADAR – 1H)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | health services and systems | health informatics and information systems | agricultural, veterinary and food sciences | other agricultural, veterinary and food sciences | other agricultural, veterinary and food sciences not elsewhere classified | health sciences | health services and systems | digital health | </Fields_of_Research>
        <Res_KW1>antibiotic use</Res_KW1>
        <Res_KW2>antibiotic resistance</Res_KW2>
        <Res_KW3>surveillance</Res_KW3>
        <Res_KW4>information systems/decision support systems</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>This Centre of Excellence will bring together clinician researchers from human and animal health, implementation scientists, human factors and digital health experts. The goal of the centre is to optimise the use of antimicrobials using digital innovation in the community and in hospitals. Rational antimicrobial use not only essential for patient safety, but is a fundamental requirement to limit the emergence of antibiotic resistant infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035369</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Gregory Fox</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in tuberculosis elimination on both sides of the border</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | clinical sciences | infectious diseases | </Fields_of_Research>
        <Res_KW1>mycobacterium tuberculosis</Res_KW1>
        <Res_KW2>tuberculosis</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>disease transmission</Res_KW4>
        <Res_KW5>infectious diseases</Res_KW5>
        <Plain_Description>Tuberculosis (TB) is the commonest infectious cause of death and affects over 10 million people worldwide every year. Most people with TB in Australia were infected overseas. So, keeping Australians safe and seizing the opportunity for regional leadership requires solutions at home and abroad. The TB-CRE will focus on 3 research themes (detect, treat and prevent) guided by TB affected communities and committed to  develop the next generation of TB research leaders needed to end the TB pandemic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035386</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Andreas Obermair</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence to Improve the QuALIty of SurVival in Gynaecological Cancer PatiEnts (ALIVE WELL)</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | solid tumours | biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | biomedical and clinical sciences | other biomedical and clinical sciences | other biomedical and clinical sciences not elsewhere classified | </Fields_of_Research>
        <Res_KW1>gynaecological cancers</Res_KW1>
        <Res_KW2>fertility</Res_KW2>
        <Res_KW3>lymphoedema</Res_KW3>
        <Res_KW4>survivorship</Res_KW4>
        <Res_KW5>consumers</Res_KW5>
        <Plain_Description>As survival rates for gynaecological cancers rise, there is increasing demand for focus on quality of survival. This CRE will work with women as experts in their own health and treatment and will train CRE fellows to conduct research that values women's input in the design, development, and delivery of quality care during and after treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035417</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Kay Crossley</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Clinical Research</Sub_Type>
        <Grant_Title>HERknee CRE: Preventing knee injury and osteoarthritis burden for women and girls</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | allied health and rehabilitation science | physiotherapy | </Fields_of_Research>
        <Res_KW1>knee</Res_KW1>
        <Res_KW2>knee osteoarthritis</Res_KW2>
        <Res_KW3>injury prevention</Res_KW3>
        <Res_KW4>physiotherapy</Res_KW4>
        <Res_KW5>sports injury</Res_KW5>
        <Plain_Description>Women and girls suffer more sports-related knee injuries than men and boys, and one in two women will rapidly develop arthritis following injury. Women and girls also have worse outcomes following a knee injury or with knee arthritis. This CRE aims to reduce the risk of knee injury in women and girls, reduce the likelihood of developing knee arthritis in women and girls, and reduce pain and improve outcomes in women and girls who have suffered a knee injury and/or who have developed arthritis.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035456</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof John Kaldor</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Ending the Neglect through Greater Access and Greater Effectiveness (ENGAGE) - A new CRE dedicated to the control of Neglected Tropical Diseases in our region.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>tropical disease</Res_KW1>
        <Res_KW2>antiparasitic chemotherapy</Res_KW2>
        <Res_KW3>population health</Res_KW3>
        <Res_KW4>antimicrobial therapy</Res_KW4>
        <Res_KW5>health systems</Res_KW5>
        <Plain_Description>We propose a new CRE to help countries and communities in our region to confront a group of 10 health conditions known as neglected tropical diseases (NTDs), that primarily affect remote and low-income communities. We will  align our activities to support WHO’s 2030 NTD Road Map, by providing new evidence to improve uptake and effectiveness of interventions, enhance country and community ownership of policy and programs and accelerate progress towards the public health elimination of NTDs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035494</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Juergen Goetz</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Basic Science Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Mechanisms In NeuroDegeneration – Alzheimer’s Disease (MIND-AD CRE)</Grant_Title>
        <Admin_Institution>The University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified  | biological sciences | biochemistry and cell biology | cell neurochemistry | biological sciences | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Fields_of_Research>
        <Res_KW1>alzheimer disease</Res_KW1>
        <Res_KW2>novel therapeutic agents</Res_KW2>
        <Res_KW3>animal model</Res_KW3>
        <Res_KW4>mitochondria</Res_KW4>
        <Res_KW5>protein aggregation</Res_KW5>
        <Plain_Description>Developing an effective treatment for the currently incurable Alzheimer’s disease (AD) requires an understanding of its underlying causes and improvements in brain drug delivery methods. We will address both aspects by bringing together interdisciplinary preclinical and clinical researchers, developing novel delivery tools, and uncovering the interplay between molecular and cellular defects leading to cognitive impairments in AD, thus identifying novel therapeutic avenues.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035500</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Carl Walkley</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Basic Science Research</Sub_Type>
        <Grant_Title>The Centre of Excellence for Nucleic Acid Sensing</Grant_Title>
        <Admin_Institution>St Vincent's Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | innate immunity | biological sciences | biochemistry and cell biology | cell development, proliferation and death | </Fields_of_Research>
        <Res_KW1>innate immunity</Res_KW1>
        <Res_KW2>type i interferon</Res_KW2>
        <Res_KW3>autoimmune disease</Res_KW3>
        <Res_KW4>rna binding proteins</Res_KW4>
        <Res_KW5>neurodevelopmental disorders</Res_KW5>
        <Plain_Description>Our cells have sensors that scan the cell for foreign nucleic acid (DNA/RNA) and react when they encounter it. This is key to protecting us from virus infections. Mutations can cause the sensors to react to the cell’s own DNA and RNA, causing inflammatory disease. In this Centre, we will study how and what the sensors are detecting, if this can be modified, how the sensors co-ordinate a response and apply this knowledge to provide treatment strategies for a range of auto-inflammatory diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035525</App_ID>
        <Date_Announced>2024-08-30T00:00:00</Date_Announced>
        <CIA_Name>Prof Helen Marshall</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Public Health Research</Sub_Type>
        <Grant_Title>Centre for Research Excellence in Neisseria disease control</Grant_Title>
        <Admin_Institution>The University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>biological sciences | microbiology | infectious agents | </Fields_of_Research>
        <Res_KW1>meningococcal disease</Res_KW1>
        <Res_KW2>gonorrhoea</Res_KW2>
        <Res_KW3>vaccine</Res_KW3>
        <Res_KW4>vaccine efficacy</Res_KW4>
        <Res_KW5>neisseria</Res_KW5>
        <Plain_Description>Meningococcal disease and gonorrhoea are two serious diseases in young people that are genetically similar. Our research has shown the meningococcal vaccine may protect against gonorrhoea. Our Centre of Research Excellence aims to extend this work, uniting national and international experts, to translate the best immunisation program to prevent both diseases with one vaccine. This is expected to significantly drive down cases of meningococcal disease and gonorrhoea in Australia and globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035912</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Berk</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>SYNDICAT: Synergy for the Development of Innovative Clinical Treatments in Schizophrenia</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>psychology | clinical and health psychology | clinical psychology | </Fields_of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>adult stem cells</Res_KW2>
        <Res_KW3>schizophrenia and related disorders</Res_KW3>
        <Res_KW4>drug treatment</Res_KW4>
        <Res_KW5>psychotic disorders</Res_KW5>
        <Plain_Description>SYNDICAT’s vision is to discover treatments to reduce the individual, social and economic burden of schizophrenia, and position Australia as a world leader in psychiatric treatment discovery while fostering a new generation of mental health researchers. This will provide people with schizophrenia and their carers hope of improved quality of life and renewed ability to contribute to their families, workplaces, and society.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2035975</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Enzo Porrello</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>A functional phosphoproteomic platform to enable precision therapies for dilated cardiomyopathy.</Grant_Title>
        <Admin_Institution>Murdoch Children's Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | cardiology (incl. cardiovascular diseases) | biological sciences | biochemistry and cell biology | signal transduction | biological sciences | genetics | genomics | </Fields_of_Research>
        <Res_KW1>machine learning</Res_KW1>
        <Res_KW2>stem cell biology</Res_KW2>
        <Res_KW3>dilated cardiomyopathy</Res_KW3>
        <Res_KW4>functional genomics</Res_KW4>
        <Res_KW5>cell signalling</Res_KW5>
        <Plain_Description>Dilated Cardiomyopathy (DCM) is the leading cause of heart failure in children and the most common indication for heart transplantation worldwide. There are no specific therapies that can restore heart function in patients with DCM. Current therapies are non-specific and only offer symptotmatic relief. Our vision is to transform the treatment of DCM by targeting molecular pathways that are predictive of patient outcomes, so that the right treatment can be tailored to the right patient. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036017</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Luke Wolfenden</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>Transformative synergies: Using Learning Health Systems for Chronic Disease Prevention</Grant_Title>
        <Admin_Institution>The University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | public health | health promotion | </Fields_of_Research>
        <Res_KW1>chronic illness prevention</Res_KW1>
        <Res_KW2>population health</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>health promotion</Res_KW4>
        <Res_KW5>health systems</Res_KW5>
        <Plain_Description>Interventions to prevent chronic disease are not implemented well and reach too few people to improve public health. New ways of supporting health organisations to implement interventions are required. We bring together researchers from different scientific disciplines to address this. We will generate evidence that supports a prevention system in Australia that is continuously improving to maximise its impact on reducing chronic disease in this country.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036025</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Erica Wood</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>Making better use of blood: new knowledge to improve stewardship of Australia’s national blood supplies and outcomes for transfused patients </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | cardiovascular medicine and haematology | haematology | health sciences | health services and systems | health systems | </Fields_of_Research>
        <Res_KW1>trauma</Res_KW1>
        <Res_KW2>haematological malignancy</Res_KW2>
        <Res_KW3>blood transfusion</Res_KW3>
        <Res_KW4>intensive care</Res_KW4>
        <Res_KW5>haemorrhage</Res_KW5>
        <Plain_Description>Our research addresses national community and government priorities to improve the evidence base for how we use blood and to make its use safer, more appropriate, and more cost-effective. We will use the new National Transfusion Dataset to understand how blood is used in Australia, and establish a transfusion trials methodology centre to conduct innovative clinical trials to test novel blood products and new approaches to transfusion support in trauma, critical illness and blood disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036067</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Veronica Matthews</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>Stronger Together As Unified Nations for Community-led Health (STAUNCH)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Fields_of_Research>indigenous studies | aboriginal and torres strait islander health and wellbeing | aboriginal and torres strait islander health policy | health sciences | public health | health equity | indigenous studies | aboriginal and torres strait islander culture, language and history | aboriginal and torres strait islander research methods | </Fields_of_Research>
        <Res_KW1>health policy</Res_KW1>
        <Res_KW2>social determinants of health</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>primary care</Res_KW4>
        <Res_KW5>community development</Res_KW5>
        <Plain_Description>With the rejection of the Voice to Parliament, processes of Indigenous Nation Building are more important than ever to enable First Nation communities to organise and prepare for renegotiated power relationships with government. Governments also need to prepare for new ways of working with communities, to deeply listen and operate more holistically and inclusively. STAUNCH melds nation building and health in all policy approaches to realise self-determined community health and wellbeing plans.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036071</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Prof John Mariadason</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>Improving outcomes for BRAF and KRAS mutant colorectal cancer</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Fields_of_Research>
        <Res_KW1>biomarkers</Res_KW1>
        <Res_KW2>anticancer drug action</Res_KW2>
        <Res_KW3>colorectal cancer</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>cell signalling</Res_KW5>
        <Plain_Description>Bowel cancer is a major cause of cancer mortality and is often caused by mutations in the genes RAS and BRAF. While drugs that target these proteins have recently emerged, they only extend life by 3-6 months. New ways to improve their activity are needed. To achieve this, we have assembled a research team of experts in the biology and treatment of these tumours and will build upon our exciting preliminary discoveries for enhancing the activity of these drugs to improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036089</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Marie-Liesse Asselin-Labat</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>Identifying and overcoming mechanisms of immune evasion in cancer</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biomedical and clinical sciences | oncology and carcinogenesis | molecular targets | </Fields_of_Research>
        <Res_KW1>cd4</Res_KW1>
        <Res_KW2>cd8 t cells</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>control of tumour progression</Res_KW4>
        <Res_KW5>cancer vaccine</Res_KW5>
        <Plain_Description>Immunotherapies exploit an individual’s immune system to activate immune cells to kill cancer cells. These treatments are beneficial only for a small number of patients. Future cancer therapies will better utilise the immune system against cancer cells. These advances will only be possible through a deep understanding of tumour and immune cell behaviours in response to immunotherapies, including cancer vaccines. Our team will take this challenge to improve health outcomes for cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036149</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Shahneen Sandhu</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>Exploiting interactions between microbiota and T cells to improve melanoma immunotherapy </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | tumour immunology  | biological sciences | bioinformatics and computational biology | proteomics and metabolomics | biomedical and clinical sciences | oncology and carcinogenesis | predictive and prognostic markers  | </Fields_of_Research>
        <Res_KW1>biomarkers</Res_KW1>
        <Res_KW2>metabolomics</Res_KW2>
        <Res_KW3>cancer immunology</Res_KW3>
        <Res_KW4>melanoma</Res_KW4>
        <Res_KW5>immune response</Res_KW5>
        <Plain_Description>Australia and New Zealand have the highest rates of melanoma in the world. Recent treatment advances based on immune therapies are significantly reducing mortality. Nonetheless, death rates remain high and there are no robust biomarkers predicting response and toxicity from therapy. Our team will explore how microorganisms in the intestinal tract produce key factors involved in immune responses against melanoma and identify novel therapeutic approaches and biomarkers to improve patient outcome.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036191</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Joanna Groom</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>A mechanistic approach to next-generation vaccine design</Grant_Title>
        <Admin_Institution>The Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science Research</Broad_Research_Area>
        <Fields_of_Research>biomedical and clinical sciences | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | biomedical and clinical sciences | pharmacology and pharmaceutical sciences | pharmaceutical sciences | mathematical sciences | applied mathematics | mathematical methods and special functions | </Fields_of_Research>
        <Res_KW1>respiratory infection</Res_KW1>
        <Res_KW2>mathematical modelling</Res_KW2>
        <Res_KW3>vaccine design</Res_KW3>
        <Res_KW4>drug delivery</Res_KW4>
        <Res_KW5>immunology</Res_KW5>
        <Plain_Description>Vaccines are one of the most important advances in modern medicine. Despite decades of research, vaccines that consistently induce long-lasting protection remain elusive. This results in decreased protection, requiring boosters and impacts socio-economic cost and vaccine compliance. Our synergy team will re-think the current approach to vaccine design to reveal how to best promote long-term protection against emerging and mutagenic respiratory infections, such as Influenza and Coronaviruses. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <App_ID>2036206</App_ID>
        <Date_Announced>2024-10-01T00:00:00</Date_Announced>
        <CIA_Name>Prof Susana Nery</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>2024 Synergy Grants</Sub_Type>
        <Grant_Title>Can the new anti-parasitic agent moxidectin transform the public health control of globally important infectious diseases? A multi-disciplinary investigation</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health Research</Broad_Research_Area>
        <Fields_of_Research>health sciences | epidemiology | social epidemiology | health sciences | health services and systems | health services and systems not elsewhere classified | health sciences | public health | public health not elsewhere classified | </Fields_of_Research>
        <Res_KW1>disease modelling</Res_KW1>
        <Res_KW2>health systems</Res_KW2>
        <Res_KW3>tropical disease</Res_KW3>
        <Res_KW4>epidemiology</Res_KW4>
        <Res_KW5>community intervention study</Res_KW5>
        <Plain_Description>Moxidectin is a new drug approved for human use to treat river blindness, a disease affecting poor communities in low- and middle- income countries. It has pharmaceutical advantages over existing drugs used in public health programs to control this and other parasitic diseases common in such settings. We will conduct a program of research consisting of epidemiological studies, disease transmission modelling, health economics and health systems to establish the public health role of moxidectin.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
</root>